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Rheumatoid Arthritis 
 
Rheumatoid arthritis (RA) is a systemic, chronic, autoimmune disease that targets 
the synovial joints 1;2. RA occurs in about 1% of the population and is associated with 
swelling and pain in multiple joints and destruction of cartilage and bone, which 
causes significant joint deformity and disability. Other implications due to the 
systemic nature of the disease include subcutaneous nodules, pleuritis, pericarditis 
and vasculitis, which contribute to morbidity and mortality in long-standing disease. 
The current gold standard for disease classification are the 1987 revised American 
College of Rheumatology Classification Criteria. Based on patient history, physical 
examination, and laboratory and radiographic findings, patients can be classified as 
having RA when at least 4 out of 7 criteria are satisfied (Table 1) 3. The most 
significant risk factors for RA are female gender, advanced age and a positive family 
history. 
 
Table 1. The American Rheumatism Association 1987 Revised Criteria for the 
Classification of Rheumatoid Arthritis 3.  
For classification purposes, a patient shall be said to have rheumatoid arthritis if 
he/she has satisfied at least 4 of these 7 criteria. Criteria 1 through 4 must have been 
present for at least 6 weeks.  
(PIP=proximal interphalangeal; MCP=metacarpophalangeal; MTP=metatarsophalangeal) 
 
Criterion Definition 
1. Morning stiffness 
Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement  
2. Arthritis of three or more 
joint areas 
At least three joint areas simultaneously have had soft tissue 
swelling or fluid (not bony overgrowth alone) observed by a 
physician. The 14 possible areas are right or left PIP, MCP, wrist, 
elbow, knee, ankle, and MTP joints 
3. Arthritis of hand joints 
At least one area swollen (as defined above) in a wrist, MCP, or 
PIP joint  
4. Symmetric arthritis 
Simultaneous involvement of the same joint areas (as defined in 
2) on both sides of the body (bilateral movement of PIPs, MCPs, 
or MTPs is acceptable without absolute symmetry)  
5. Rheumatoid nodules 
Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxtaarticular regions, observed by a physician. 
6. Serum rheumatoid factor 
Demonstration of abnormal amounts of serum rheumatoid factor 
by any method for which the result has been positive in <5% of 
normal control subjects 
7. Radiographic changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in or most 
marked adjacent to the involved joints (osteoarthritis changes 
alone do not qualify)  
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Changes in architecture of rheumatoid synovium 
 
Synovium is the soft tissue which lines the non-cartilaginous surfaces within joints 
that have a cavity between the bearing surfaces 4. The normal synovium consists of 
two anatomically distinct layers. The thin surface layer, called the synovial or intimal 
lining, is in direct contact with the intra-articular cavity and is comprised of 
macrophages and fibroblast-like synoviocytes (FLS). This synovial lining layer is only 
one to three cell layers deep, avascular and not supported by a basement membrane. 
The synovial sublining or subintima is relatively acellular, mainly consisting of 
connective tissue and blood vessels.  
 
In RA, the inflamed synovium is characterized by infiltration of macrophages, T-cells, 
B-cells and, to a lesser extent, dendritic cells (DC), natural killer (NK) cells and 
neutrophils. Neovascularization contributes to the recruitment of inflammatory cells. 
The intimal lining layer becomes hyperplastic, due to infiltration of macrophages and 
increased proliferation/survival of FLS. This results in formation of aggressive 
granulation tissue (pannus), which invades and destroys articular structures. 
Eventually, there is progressive cartilage destruction and erosion of the underlying 
bone.  
 
 
Disease heterogeneity 
 
There is growing evidence that patients classified as having rheumatoid arthritis by 
the American College of Rheumatology Classification Criteria (Table 1) are a broadly 
heterogeneous group. The heterogeneity most likely has its origin in the 
multifactorial nature of the disease, whereby specific combinations of environmental 
factors and a varying polygenic background are likely to influence not only 
susceptibility but also the severity and disease outcome. The heterogeneity of RA is 
reflected by marked variability in clinical presentation and responsiveness to 
different modes of anti-rheumatic treatment. Disease heterogeneity is also apparent 
in the histological features of synovium, displaying different levels of complexity of 
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lymphoid organization in subsets of patients (described in more detail below, see: 
Cells involved in synovial inflammation).  
 
The clinical presentation of patients with RA reveals striking heterogeneity with a 
spectrum ranging from complete symptom remission to severe disability. Patients 
diagnosed with early arthritis revealed 3 forms of arthritis outcome at 2 years’ follow-
up: self-limiting arthritis, persistent non-erosive arthritis, and persistent erosive 
arthritis 5. Clearly, heterogeneity is already reflected in the current method for 
disease classification (Table 1), which implies that different sets of criteria are applied 
to classify “the same” disease. Disease heterogeneity is further illustrated by the 
presence of distinct combinations of autoantibodies against multiple autoantigens in 
the serum. There is evidence of production of autoantibodies years before RA 
becomes clinically apparent and both Rheumatoid Factor (RF) and anti-CCP 
antibodies serve as diagnostic and prognostic markers in RA 6-8. However, only in 
approximately two thirds of RA patients RF is present, and subsets of RA patients 
may test positive for either RF or anti-CCP antibodies, or either positive or negative 
for both. (For more details on autoantibodies see below: Cells involved in synovial 
inflammation). 
 
The wide variation in responsiveness to virtually any treatment in RA is also 
consistent with the heterogeneous nature of the disease 9. Treatment with anti-TNF-α 
agents results in a dramatic response in about one third of patients; of the remaining 
patients, approximately half exhibit a partial response and the remaining patients 
have minimal improvement. Similar observations have been made for other therapies 
like treatment with CTLA4Ig, which blocks the interaction of CD80/86 on antigen 
presenting cells with CD28 on T cells 10, and B cell ablation therapy 11. This suggests 
that distinct disease mechanisms are at play in RA pathology. The relative 
contribution of the different mechanisms may vary among patients and, perhaps, in 
different stages of disease.  
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Disease initiation and perpetuation: antigen-specific and antigen-
independent mechanisms in RA pathology 
 
The event that initiates the immune response that results in inflammation of the 
synovial membrane is still unknown. Evidence obtained from animal models suggests 
that the induction phase of inflammatory arthritis is antigen-independent and driven 
by innate immune mechanisms 12. In addition, asymptomatic synovitis, during which 
changes in synovium are apparent, precedes clinically manifest arthritis in the 
earliest phase of RA 13. Based on these results, a model has been proposed for RA 
pathology that involves both antigen-specific and antigen-independent mechanisms 
14.  
 
According to this model, an unknown cause, eg. a pathogen gaining entry into the 
joint or repeated mechanical insults, activates the synovial lining cells and thereby 
induces the innate immune response. Activated lining cells start to produce pro-
inflammatory cytokines, which induce neovascularization and up-regulation of 
adhesion molecules on the synovial microvasculature, and chemokines, resulting in a 
chemotactic gradient 15;16. Circulating monocytes and lymphocytes are attracted by 
chemotaxis and are retained in the synovium after their counter-receptors bind to 
specific adhesion molecules on synovial blood vessels. Subsequently, recognition of 
articular antigens by lymphocytes can occur 14. Thereafter, perpetuation of the 
immune response can occur by both antigen-specific and antigen-independent 
mechanisms, eventually developing into a self-sustaining autoimmune process. Due 
to the enclosed joint cavity, the rheumatoid synovium provides an exceptional 
microenvironment for the perpetuation of the immune response.  
 
 
Cells involved in synovial inflammation 
 
Lymphocytes 
 
T cells in RA synovium are primarily of the helper/memory (CD4+/CD45RO+) 
phenotype and are biased toward the Th1 subtype, expressing the CCR5 and CXCR3 
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chemokine receptors 17 and the Th1 cytokines IFNγ and IL-17 18-20. Although T cell 
cytokines are relatively low in RA, synovial T cells can also contribute to the immune 
response by cell-cell contact dependent activation of other synovial cells. It has been 
shown that synovial fluid T cells can induce TNF-α production by macrophages in a 
cell contact-dependent fashion, which is enhanced and sustained by IL-15 21;22 and 
other pro-inflammatory cytokines, like TNF-α, IL-6, GM-CSF and IFNγ 23. In 
addition, direct contact with stimulated T cells induces the production of matrix 
metalloproteinase (MMP)-1 and prostaglandin in FLS 24. Another mechanism by 
which T cells contribute to disease is through stimulation of osteoclast-mediated 
bone resorption, which is regulated through the RANK (receptor activator of nuclear 
factor (NF)-κB)-RANKL(ligand) system. RANKL, also known as osteoclast 
differentiation factor (ODF), TNF-α-related-induced cytokine (TRANCE), or 
osteoprotegerin ligand (OPGL) 25, is expressed by T cells and FLS, and, in the 
presence of TNF-α and M-CSF, contributes to the activation and maturation of 
osteoclasts. The relevance of this mechanism for bone erosion had been confirmed in 
animal models 26-28. As noted above, it has been proposed that activation of the 
immune response by synovial T cells can occur in an antigen-independent manner, 
where T cells are activated by “bystander” cytokines, irrespective of local antigen 
expression, or by an antigen-specific response driven by autoantigens 14;21. Evidence 
exists that T cells in synovial tissue and synovial fluid are in a hyporesponsive state as 
a result of defective T-cell receptor signaling, and therefore have a decreased capacity 
to become activated by antigen 29. 
 
B cells can contribute to the immune response in RA in several ways. The most 
prominent feature of B cells in RA is the production of autoantibodies.  Many 
autoantibodies directed against multiple autoantigens have been described in RA 
30;31, including articular antigens, like cyclic citrullinated peptides (anti-CCP 
antibodies), or other self-antigens, like the Fc-component of other immunoglobulins 
(Rheumatoid Factor, RF). These autoantibodies can be categorized into two groups: 
those present in other autoimmune or inflammatory diseases, like RF, and those 
which seem to be relatively specific for RA, such as anti-CCP antibodies. Anti-CCP is 
currently the most specific marker for the early diagnosis of RA and predicts the 
erosive or non-erosive progression of the disease, and therefore the combined use of 
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RF isotypes and anti-CCP antibodies increases diagnostic and prognostic properties 
8;32. The production of autoantibodies in RA results in formation of immune 
complexes, which consist of immunoglobulins bound to their cognate antigens 33.  
The majority of immune complexes in RA contains RF, which initiates complex 
formation by binding to the Fc-component of other immunoglobulins and 
subsequently activates the complement system. This results in local inflammation 
and tissue destruction, and promotes neutrophil-mediated damage to cartilage 34;35. 
Another way by which B cells can enhance the immune response is by their ability to 
act as highly efficient antigen presenting cells (APC) and regulate T cell activation 
36;37.  
 
Different levels of lymphoid organization can be present in rheumatoid synovium 38. 
A diffuse inflammatory infiltrate in which infiltrating cells are scattered among 
tissue-resident cells is most common. In 40-50% of patients, a higher level of 
organization of the immune infiltrate occurs, in which T- and B cell aggregates are 
formed.  In approximately 25% of patients, these lymphoid structures show all 
characteristics of lymphoid tissue with germinal center formation: follicular dendritic 
cells (FDCs) present antigen to B cells, which results in B cell proliferation and 
affinity maturation, and the close network of myeloid DCs in the T cell zone optimizes 
the conditions for T cell activation. It has been proposed that the presence of these 
structures favors (auto)antigen recognition and perpetuation of immune activation 39. 
 
 
Monocytes/Macrophages 
 
Synovial macrophages consist of intimal, bone marrow-derived macrophages and 
subintimal macrophages, which are derived from circulating monocytes. In RA, 
monocyte/macrophage infiltration and activation correlates with the extent of 
inflammation in synovial tissue and with several clinical characteristics 40. Synovial 
macrophages express MHC class II and produce matrix metalloproteinases, 
chemokines and pro-inflammatory cytokines, such as TNF-α, GM-CSF, IL-1, IL-6, IL-
7, IL-8, IL-15 and IL-18. Many of these cytokines further activate either the source 
cell type or other cell types, resulting in a positive feedback-loop of immune 
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activation. For instance, IL-15 produced by macrophages can activate T cells to 
stimulate TNF-α-production by macrophages 22 and IL-7 enhances cell contact-
dependent activation of CD4+ T cells and monocyte/macrophages 41. Notably, 
macrophages are the major producers of the cytokines which were targeted by 
current anti-cytokine therapies, TNF-α and IL-1. 
 
 
Fibroblast-like synoviocytes  
 
FLS are mesenchyme-derived cells that occur in  two phenotypes in synovium: 
intimal and subintimal FLS 42. Only intimal FLS express high levels of VCAM-1 and 
CD55/DAF in synovium, but in vitro expression is inducible by cytokine stimulation 
in both intimal and subintimal FLS. Normally, FLS are in minimal contact with 
immune cells. In RA, the FLS phenotype and the interaction of FLS with leukocytes 
are altered, allowing for mutual stimulation and activation. Accumulating evidence 
indicates that FLS play a key role in RA pathology.  
 
FLS are the main cells involved in the formation of the hypertrophic, invasive front 
tissue called pannus, which consists of a mixed population of cells with intimal and 
subintimal features 42. Synovial lining hyperplasia may be the result of FLS 
hyperproliferation and/or increased FLS survival; evidence for involvement of both 
mechanisms has been accumulated over the years. Immunohistochemical studies on 
RA synovium using cell proliferation markers indicate that local proliferation of FLS 
contributes to hyperplasia 43. In vitro, RA FLS can grow in an anchorage-independent 
manner over multiple passages and can escape contact inhibition 44. Also, clonal 
expansion of FLS, in particular FLS derived from pannus lesions, has been described 
45. Several growth factors that can drive FLS proliferation are expressed in synovium, 
such as basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), 
transforming growth factor-β (TGF-β) and Activin A 46-48. In addition, pro-
inflammatory cytokines that are abundant in synovium can induce FLS proliferation, 
such as TNF-α 49, IL-1β 50 and macrophage migration inhibitory factor 51. Also, 
mutations and overexpression of oncogenes and genes involved in cell cycle 
regulation have been documented in RA. The proto-oncogene c-myc is overexpressed 
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in RA synovium 43 and inhibition of c-myc reduces the growth of RA FLS in vitro 52. 
Somatic,  heterogeneous mutations in the tumor suppressor gene p53 have been 
reported in RA FLS  which may contribute to increased proliferation of FLS 53;54. 
Furthermore, gene transfer of cell-cycle inhibitory proteins has a protective effect in 
animal models of arthritis 55;56. Evidence for the other mechanism that may 
contribute to synovial lining hyperplasia, i.e. defective apoptosis of FLS, has also been 
documented. Apoptotic cell death of FLS was rarely observed in rheumatoid nodules 
and synovial membranes 57. RA FLS resist apoptotic signals delivered through the 
major death pathways, Fas and TNF-α receptor by up-regulation of anti-apoptotic 
molecules, such as Bcl-2 58 and sentrin 59. In addition, lack of expression of tumor 
suppressor genes, such as PTEN which is an essential mediator of the Fas response 60, 
and mutations in p53 53 can contribute to defective apoptosis.  
 
Growing evidence indicates a prominent role for FLS in driving and modulating the 
immune response in RA. FLS produce pro-inflammatory cytokines like IL-6, GM-
CSF, IL-1, IL-15, IL-16, chemokines, like IL-8, MIP-1, RANTES and SDF-1, and many 
other inflammatory mediators such as iNOS and prostaglandin E2 and proangiogenic 
factors 61, thereby contributing to inflammation, chemotaxis and angiogenesis. Cell-
cell contact between FLS and other synovial cells can also modulate inflammation. 
Cooperation of intimal macrophages and FLS may be mediated through direct cell-
cell interactions via ligation of CD55 on FLS with CD97 on macrophages 62. Direct 
contact between FLS and T cells induces production of T cell cytokines, and, 
conversely, up-regulation of co-stimulatory molecules VCAM-1 and ICAM-1 in FLS 63. 
Thrombospondin-1 (TSP1), a CD47 ligand displayed on FLS can mediate T cell co-
stimulation and induce T cell proliferation 64. FLS can also prevent apoptosis of T 
cells 65 and B cells 66-68. 
 
FLS are one of the principle cells involved in effecting the destructive response. When 
RA FLS are co-implanted with normal human cartilage in SCID mice, recovery of the 
tissue reveals deep FLS invasion and destruction of the cartilage 69;70. The ability of 
FLS to erode the cartilage is separate from their proliferative capacity 71 and depends 
on secretion of matrix degrading enzymes, such as matrix metalloproteinases 
(MMPs) 72 and cathepsins 73. MMPs belong to a family of zinc-dependent proteases 
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that includes collagenases, gelatinases, stromelysins and membrane-type MMPs 72. 
MMPs are capable of degrading a variety of extracellular matrix protein components 
including collagens, proteoglycans, fibronectin and laminin.  
Pro-inflammatory cytokines such as TNF-α and IL-1β can induce MMP expression, 
and it has been shown that anti-TNF-α therapy results in a reduction of MMP-1 and 
MMP-3 expression 74. In addition to invasion and destruction of cartilage, FLS can 
also contribute to bone erosion. By expression of ODF, FLS can contribute to 
maturation and activation of osteoclasts 75, as was described above for T cells. It has 
also been suggested that FLS can directly invade bone and contribute to resorption 76. 
 
In sum, accumulating evidence indicates that FLS do not only react passively to pro-
inflammatory stimuli but contribute actively to RA pathogenesis. FLS exhibit a 
“transformed” phenotype, constituting stable long-term alterations that are 
maintained in the absence of environmental stimuli, enabling FLS to act as 
autonomous aggressors  77;78.  
 
It has been suggested that RA pathology consists of three distinct phases 14. The 
induction phase may be antigen-independent and involves synovial lining cells, which 
initiate the inflammatory response. Subsequently, during the inflammatory phase, 
the immune response is driven by lymphocytes, macrophages, and antigen-
presenting cells and may involve specific antigens. Finally, the latter phase of the 
disease may be independent of T cell control, involving autonomous activation of 
FLS. 
 
 
The RA cytokine network  
 
The immune response in RA is orchestrated by a complex network of cytokines and 
chemokines, which is both pleiotropic and redundant, and includes paracrine and 
autocrine effects 2;79-81. Macrophage and FLS products are abundant, whereas T cell 
cytokines such as IL-2, IFNγ  and IL-17 are present in relatively low concentrations. 
Macrophages produce IL-1 and TNF-α, which activate FLS.  FLS activated by TNF-α 
and IL-1β express in turn IL-6, GM-CSF, IL-8 and cytokines capable of T cell 
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activation, including IL-7, IL-15 and IL-18. Additionally, FLS-derived cytokines 
further activate macrophages, which creates a positive feedback mechanism between 
FLS and macrophages that perpetuates synovial inflammation 2;81. Currently, TNF-α 
and IL-1β are thought to represent the most important cytokines for RA pathology, 
forming a link between initiation/perpetuation of the disease and the subsequent 
inflammatory processes 79. The importance of cytokines in RA pathology is 
highlighted by the successful administration of anti-cytokine therapy using 
antibodies and soluble receptors that block the action of TNF-α 9. However, 
continuous administration of anti-cytokine therapy is required to maintain clinical 
benefits as immediate re-appearance of clinical symptoms follows treatment arrest. 
This indicates that the existence of an autonomous cytokine network alone cannot 
explain the perpetuation of inflammation in RA. 
 
 
Signal transduction pathways and transcription factors 
 
At the cellular level, pathological processes like inflammation, mitosis and 
invasiveness are regulated by signal transduction pathways that translate an 
extracellular signal into a transcriptional response. Cytokines and growth factors that 
are present in the extracellular milieu interact with cell-surface receptors that initiate 
signaling cascades resulting in the activation of transcription factors and the 
induction of gene expression.   
 
Nuclear factor-κB (NF-κB) is a transcription factor that is involved in multiple 
processes in RA, including development of Th1 responses, activation, abnormal 
apoptosis and proliferation of FLS, and differentiation and activation of bone 
resorbing activity of osteoclasts. It is rapidly activated via multiple pathways, 
including Toll-like receptor (TLR), TNF-α and IL-1 signaling. It regulates expression 
of a large number of inflammation-related genes such as cytokines (including TNF-α, 
IL-1, IL-6 and IL-8), adhesion molecules (ICAM-1), iNOS, RANKL and many others 
82.  Studies in animal models of RA have demonstrated that suppression of NF-κB 
enhances apoptosis in rat synovium 83, and reduces inflammation in collagen-
induced arthritis in mice 84.  
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The Mitogen Activated Protein Kinase (MAPK) pathway is also  implicated in RA. 
MAP kinases include the extracellular signal-regulated kinase (ERK), c-Jun N-
terminal kinase (JNK) and the p38 kinase families, all of which are activated in RA 85. 
Exposure to inflammatory stimuli such as IL-1 and TNF-α leads to rapid activation of 
MAPK and increased cytokine and MMP production. One of the key transcription 
factors activated by the MAP kinase JNK is Activator Protein-1 (AP-1). AP-1 is a 
dimeric transcription factor composed of elements of the Fos and Jun protein 
families 86. AP-1 binding sites are present in the promoter regions of many genes 
involved in RA, such as TNF-α and MMPs. Expression of c-Jun and c-Fos is increased 
in the synovial lining and correlates with RA severity 87. 
 
 
JAK-STAT signaling 
 
Another  pathway that has gained interest within RA research during the past years is 
the Janus Kinase/Signal transducer and activator (JAK-STAT) pathway. The JAK-
STAT pathway mediates signals for development, differentiation, growth control and 
apoptosis, as well as specialized functions in host resistance to pathogens 88-90.  In 
mammals, the JAK family comprises four members: JAK-1, JAK-2, JAK-3 and Tyk-2. 
Receptor-associated JAKs are are activated upon ligand-mediated receptor 
multimerization. The activated JAKs subsequently phosphorylate the receptors and 
the major substrates, STATs. The seven mammalian STATs (STAT-1, 2, 3, 4 5A, 5B 
and 6) are latent transcription factors that reside in the cytoplasm until activated by 
JAKs.  Phosphorylated STATs dimerize via a reciprocal SH2-phosphotyrosine 
interaction, translocate to the nucleus and bind specific regulatory sequences to 
activate or repress transcription of target genes 91.  Most STATs are widely expressed 
and may be activated by multiple ligands. However, certain cytokines preferentially 
activate particular STATs: e.g. IFNγ preferentially activates only STAT-1, whereas 
Type I IFNs activate both STAT-1 and STAT-2, and IL-6 activates predominantly 
STAT-3 but also STAT-1. Activation of a particular STAT protein may have divergent, 
and sometimes even opposing, biological effects, depending on the cell type and the 
microenvironment.  
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There are three major classes of negative regulators of JAK-STAT signaling: (i) 
protein tyrosine phosphatases (PTPs), including SHP-1 and SHP-2, which reverse the 
activity of JAKs 92; (ii) the suppressor of cytokine signaling (SOCS) family of proteins, 
which are induced by and inhibit many cytokine-signaling systems in a classic 
negative-feedback loop 93; and (iii), the protein inhibitors of STAT (PIAS) protein 
families that regulate transcription through various mechanisms, including the 
suppression of  STAT DNA-binding activity 94. 
  
An important role for JAK-STAT signaling in inflammatory arthritis has been 
suggested by studies demonstrating that  SOCS proteins can attenuate experimental 
arthritis. Mice lacking SOCS-1 display increased synovial inflammation and joint 
destruction in an IL-1-driven model of experimental arthritis that is dependent on a 
number of cytokines including GM-CSF, TNF-α, and IL-6 95. Peri-articular 
administration of an adenovirus producing SOCS-3 led to reduced inflammation and 
joint swelling and significantly reduced cartilage and bone destruction in both 
collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA) 96. It has been 
proposed that the inflammatory cytokines that drive pathology act through STAT-3 
activation, which mediates signaling by IL-6 and several other cytokines, whereby 
SOCS-3 is induced in an attempt to control these signaling cascades. This is in line 
with the finding that a dominant negative STAT-3-mutant also attenuates CIA 96. 
Furthermore, an IL-6 receptor knock-in mutation that causes hyperactivation of 
STAT-3 causes spontaneous development of arthritis 97  and IL6-/- mice are 
protected against joint inflammation and destruction in both CIA and AIA 98.    
 
In RA, JAK-STAT activation has also been reported, predominantly concerning 
STAT-3. Constitutive STAT-3 DNA binding activity was observed in mononuclear 
cells isolated from RA synovial fluid (SF) 99 and phosphorylation of STAT-3 is 
strongly increased in synovial tissue of RA patients compared to disease controls 96. 
In vitro studies using retroviral-mediated gene transfer of a dominant negative 
mutant of STAT-3 have shown that STAT-3 is essential for FLS survival, suggesting a 
role for STAT-3 in mediating the pathogenic properties of RA FLS 100. A good 
candidate for STAT-3 activation in vivo is IL-6, since it is highly expressed in RA and 
its presence in RA SF is responsible for STAT-3-activation in SF mononuclear cells 99. 
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Activation of STAT-1 has also been observed in RA: neutrophils derived from RA SF 
reveal persistent STAT-1 DNA binding activity. This is a result of preferential STAT-1 
activation by IL-6 contained in RA SF 101.  
 
It is unclear how STAT activation may affect RA pathology. STAT-3 is activated by IL-
6 and several other cytokines, including IL-10 and growth factors like EGF and 
PDGF. Activated forms of STAT-3 have been detected in many different tumors and 
STAT-3 has been shown to promote growth and survival of transformed cells 102. 
Conversely, STAT-1 has been associated with tumor suppression. STAT-1 mediates 
signaling to Type I and Type II IFNs, and can also be activated by several other 
cytokines such as IL-6, and some growth factors. STAT-1 -/- mice are highly 
susceptible to microbial and viral infections and tumor formation, and STAT-1 
activation can inhibit growth and promote apoptosis in fibroblasts and lymphocytes 
103-106. Although STAT-1 and STAT-3 can be activated simultaneously, their relative 
abundance may vary substantially in different cell types and under different 
conditions and is likely to have a major impact on how cells behave in response to 
different cytokines. They can mediate opposing biological effects in different cell 
types. In fibroblasts, STAT-1 activation inhibits growth and promotes apoptosis 
whereas STAT-3 activation promotes cell survival 107. In macrophages, however, 
STAT-3 exerts an anti-inflammatory effect 108, whereas STAT-1 activation has a pro-
inflammatory effect in these cells 109.  
 
In conclusion, activation of STATs may have divergent effects on RA pathogenesis, 
that can be either pathogenic or protective. Therefore, detailed analysis of the effects 
of activation of a particular STAT in a particular cell type is required to gain a better 
understanding of the regulation of the inflammatory response by JAK-STAT signaling 
in RA pathogenesis.  
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Scope and aims of this thesis 
 
This thesis describes the progression from gene expression profiling studies of RA 
synovial tissues and FLS toward functional analysis of the STAT-1 signaling pathway 
in FLS and its potential relevance to RA pathology (see figure on next page). 
 
Although many signal transduction pathways have been implicated in RA pathology, 
a comprehensive view of all the signaling pathways that are activated simultaneously 
and the biological processes they induce in the rheumatoid synovium is currently 
lacking. A thorough understanding of the various signaling pathways and their 
synergistic regulation of the inflammatory response in RA pathology is essential for 
the development of therapies targeting selective immune pathways. In addition, the 
biological processes underlying disease heterogeneity are as yet unclear. Stratification 
of homogenous groups of RA patients is imperative for selection of optimal anti-
rheumatic treatment.  
 
The aim of the first part of this thesis was to gain more insight into the ongoing 
biological processes in RA and their possible variability among RA patients by 
analyzing gene expression profiles in RA synovial tissues and FLS cultured from these 
tissues. We applied microarray technology for the generation of characteristic 
molecular signatures to identify biological patterns and test the hypothesis that RA 
heterogeneity is reflected in synovial tissue and FLS.  
 
Based on our results described in the first part, we formulated the hypothesis that the 
STAT-1 pathway may be involved in RA pathology. The aim of the second part of this 
thesis was to analyze the expression and activation pattern of STAT-1 in more detail 
in RA synovium. In addition, we investigated the biological effects of STAT-1 
activation in FLS and its potential relevance to RA pathology. 
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A combined holistic and reductionist approach for analyzing 
pathophysiologic mechanisms in RA pathology. 
The flowchart illustrates the concept of a functional genomics approach, that aims to 
analyze the entire interacting system of genes, complemented by the more classical 
biological approach that focuses on an individual pathway and its function. 
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Outline of this thesis  
 
Chapter 2 explains how the use of Microarray technology and the characterization 
of molecular signatures contribute to a better understanding of the biology of 
immunological processes and pathologic mechanisms in immune-related diseases. 
 
In Chapter 3, analysis of the gene expression signature of RA synovial tissues 
demonstrates the heterogeneity of the disease at the molecular level. At least  
two molecularly distinct forms of RA tissues are identified, one of which indicates a 
prominent role of an activated signal transducer and activator of transcription 1 
(STAT-1) pathway. 
 
Chapter 4  demonstrates that the heterogeneity of RA is also reflected in the gene 
expression signatures of FLS cultured from synovial tissues and provides evidence 
that the phenotypic subclassification of RA FLS is associated with a distinctive 
synovial tissue type. 
 
In Chapter 5, immunohistochemical analysis of synovial tissue further supports the 
notion that the STAT-1 pathway is activated in a subset of RA synovial tissues and 
phenotypically characterizes the specific synovial cell subsets in which STAT1 
activation occurs. 
 
Chapter 6 focuses on the effect of IFN-induced STAT-1 activation on FLS survival 
and proliferation and the specific intracellular processes that are involved.  
 
Finally, Chapter 7 integrates the described insights into the current understanding 
of the pathophysiologic mechanisms that are at play in RA. 
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Abstract
The analysis of gene expression in tissues, cells, and biologic systems has evolved in the last decade from the analysis of a selected
set of genes to an efficient high throughput whole-genome screening approach of potentially all genes expressed in a tissue or cell
sample. Development of sophisticated methodologies such as microarray technology allows an open-ended survey to identify
comprehensively the fraction of genes that are differentially expressed between samples and define the samples’ unique biology. This
discovery-based research provides the opportunity to characterize either new genes with unknown function or genes not previously
known to be involved in a biologic process. The latter category may hold surprises that sometimes urge us to redirect our thinking.
Here, we review the impact of large-scale gene expression profiling by DNA-microarray technology on basic and clinical aspects of
immunology.
D 2004 Elsevier Inc. All rights reserved.
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Introduction
Microarray technology gives us the opportunity to
study the mRNA expression of all the genes in the
genome simultaneously. DNA microarrays consist
thousands of different DNA sequences representing dis-
tinct genes attached at known locations on a solid phase,
for example, a glass slide. The slides can be hybridized
with probes derived from mRNA of tissue or cell
samples. The labeling strategies for probe preparation
vary from direct labeling of the mRNAs via first-strand
cDNA synthesis to linear amplification of mRNA in
cRNA using in vitro transcription [1–3]. The latter
procedure can be used for amplification and labeling of
mRNA in total RNA preparations in the nanogram range.
This approach allows analysis of rare cell populations
[4–10].
Essentially two types of array designs have been
developed for gene expression profiling. Affymetrix
makes use of a Perfect Match/Mismatch probe strategy.
Genes are represented by 11 to 16 oligonucleotides (25-
mers) on the genechip, each including the perfect match
probe and a mismatch probe that is identical except for a
single base mismatch in its center. In this design, one
fluorescent dye is used for labeling of a cRNA probe,
and the signal is detected using an optical scanning
device. Quantification of the hybridized probe is achieved
by comparison of the signals of the mismatch oligos
(nonspecific cross-hybridization) and the perfect match
oligo.
Another design involves arraying of double-stranded
cDNAs or single-stranded oligo’s (60 to 70-mers) on glass
slides (Fig. 1). In this case, either cDNA or cRNA probes
are made from two different samples, each fluorescent
labeled with spectrally distinct dyes. In most cases, the
cDNA or cRNA of the mRNA sample of interest is labeled
with Cy5 (red) that is compared to a reference mRNA
sample labeled with Cy3 (green) hybridized to the
same microarray. The ratio of the red to green fluo-
rescent intensity at any spotted gene sequence then
represents the ratio of the corresponding mRNA mol-
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ecules in the two samples. The ratios thus represent
the relative abundance of the transcript compared to the
reference sample. Samples that are hybridized against
the same reference sample can be compared to each
other.
Data analysis
In scientific research, we are used to a reductionist
approach of unraveling the complex interactions in biologic
processes. The expression and/or function of a few genes or
Fig. 1. Flow chart of cDNA microarray procedures. RNA is isolated from the experimental sample, which is typically labeled with Cy-5 during cDNA
synthesis and hybridized together with a common reference sample labeled with Cy3 on the same array. Each labeled cDNA will hybridize to its
complementary spotted sequence on the array, resulting in a red to green ratio for each spotted cDNA element. Hybridized microarrays are scanned, and
the resulting images can be analyzed. A red or a green spot contains a relatively higher or lower amount of RNA from the experimental sample,
respectively, while yellow spots contain equal amounts of RNA from the reference and experimental sample. Spots that did not hybridize to any labeled
sample appear as black. The use of the common reference sample allows comparison of the fluorescent red to green ratios for each spotted gene between
different arrays. Therefore, the data need to be centered (expressed relative to each other). For each gene, the median expression ratio across all arrays is
calculated. The red to green ratio of each spotted element is then subtracted (in log space) by the median ratio to remove any effect of the amount of
mRNA in the common reference pool. After centering, the data can be analyzed with a cluster program, which places genes (and arrays) with a
correlated expression pattern next to each other. Data is organized as follows: arrays are presented in columns; genes are positioned in rows. Genes that
show a relatively high expression compared to the other samples appear red; genes with a relatively low expression are represented by green; genes with
an equal expression across arrays appear black. Grey squares represent genes that show no significant hybridization signal.
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proteins is studied, in a well-defined patient group, animal
model or cell type, eliminating as many differences as
possible between the objects being compared. In fact, that
approach is still valid with the use of microarrays; the only
difference is the number of variables studied, which leads to
thousands of data points per sample. Analysis of these huge
data sets is a challenge, and many different algorithms have
been developed to organize the data and to correlate expres-
sion data to other biologic parameters. The approaches
include different clustering methods, principal component
analysis, or single value decomposition, as well as a super-
vised computer learning method that makes use of support
vector machines to predict the function of genes with
unknown function based on the similarities of expression
to genes with known function [11–14]. The amount of
information that can be retrieved from these data sets is
more than just the simple sum of these variables because of
the biologic relations between the different variables. We are
only at the beginning of exploring our possibilities. At
present, hierarchical clustering based on Pearson correlation
[15] is probably the most commonly used software. This
analysis forces data points into a strict hierarchy of nested
subsets. The data points are fashioned in a phylogenetic tree,
a dendogram, of clusters of genes in a hierarchically ordered
relationship, wherein the branch lengths represent the degree
of similarity between sets. Hence, gene expression profiles
that are similar across the experimental samples are clustered
together. From experience, it appears that many functional,
cell-specific, and/or biologic-related genes are expressed in a
correlated pattern constituting the same gene cluster. Arrays
that show a correlated expression profile will either be
clustered as well (unsupervised) or kept in a predetermined
location (supervised) category (e.g., based on the diagnosis
in clinical specimen) or order (e.g., temporal patterns). This
results in patterns of coordinated gene expression profiles
across the samples, which reflect differences in biology
between samples and/or differences in cellular composition
in the case of complex tissues. Alternatively, data may be
analyzed using ‘‘self-organizing maps’’ [15,16] where gene
expression data is transformed into vectors or coordinates in
an n-dimensional space, where n stands for the number of
variables. Next, the coordinates are placed in a simple map,
wherein similar coordinates are positioned next to each other
and different ones on the opposite side. Self-organizing maps
have been used to identify genes coordinately regulated
during macrophage differentiation in vitro [16].
For statistical testing of differences in gene expressions,
one can apply Significance Analysis of Microarrays (SAM)
[17], a convenient Excelk add-in, which generates a list of
genes that are differently expressed within one group or
between two or more groups of samples. SAM can be used
for analyzing the correlation of expression data with clinical
parameters including treatment, diagnostic categories, sur-
vival time, paired data (e.g., before and after treatment),
quantitative data (e.g., tumor volume), one-class data, and
correlation with time to study kinetics. SAM uses data
permutations to provide an estimate of the False Discovery
Rate for multiple testing. A q value is generated for each
gene that indicates the lowest false discovery rate at which a
gene is called significant. It is similar to the familiar P value,
adapted to the analysis of a large number of genes.
Gene expression profiling in immunology
Here, we review microarray research to characterize gene
expression in immunology to broaden our understanding of
the biology of immunologic processes and immune-related
diseases. Large-scale gene expression analysis is of great
relevance in the field of immunology to generate a global
view of how the immune systems attacks invading micro-
organisms, maintains tolerance, or creates a memory for past
infections. Besides availability of large-scale or full-genome
microarrays, specialized microarrays that contain a tailored
set of DNA sequences related to immunology are generated
and used. One of the most familiar microarrays used in
immunology research is the so-called ‘‘Lymphochip’’ that
contains a selected set of approximately 18.000 cDNAs that
are of immunologic or oncologic importance [18]. Funda-
mental questions in immunology address how the immune
system distinguishes between self- and nonself, and how
immune cell differentiation and growth is regulated. The
exciting part of microarray studies is that the many data
points that are generated cause unpredictable and unexpected
results, which may lead to new insights in immunology as
described below.
Innate immunity
Central to the type of the immune response that is
mounted in a given situation is the innate immune sys-
tem—a system that acts effectively to sense altered signals
without previous exposure to a pathogen, conferring broad
protection. This system controls and assists the acquired
antigen-specific immune response represented by T and B
lymphocytes, which both carry an infinite number of recep-
tor specificities that need to be exploited when necessary.
Since this system is also intimately linked to inflammatory
and modulatory processes, many human diseases result from
an aberrant innate immunity, either primary or secondary.
Therefore, basic questions that provide insight in regulation
of innate and adaptive immunity have been among the first to
be studied by genomics technology. The extensive experi-
ence that immunologists have with cellular aspects of im-
munology is highly beneficial in the generation of
homogeneous cell populations for genomics analyses of
specific cell subsets. Within such a framework, we may gain
an understanding of immune deregulation in autoimmune
diseases, inflammatory responses, and tumors.
Blood-borne monocytes are the progenitors of a variety
of cells including macrophages, dendritic cells (DCs), and
other phagocytic cells that patrol the blood and interstitial
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tissues and lie at the center of innate immunity. These cells
respond to infectious agents by recognizing molecular
patterns that are typical of microorganisms but are absent
in self-tissues. The global response of monocytes/macro-
phages to bacterial toxins from different microorganisms has
been analyzed by microarrays. A group of approximately
200 genes was demonstrated to be induced in response to
Gram-negative bacteria, whereas the relative abundance of
transcripts from approximately hundred genes was repressed
after pathogen exposure [5,19–21]. The most prevalent
classes of induced genes include cytokines (e.g., IL-1a, IL-
1b, IL6, IL-10, and TNFa) and chemokines (e.g., IL-8,
MIP1a and MIP1b), as well as cell surface receptors and
ligands (such as CD40 and CD40 ligand). A concomitant
expression of antiinflammatory cytokines, such as TGFb1,
TGFb2, and IL-10, was observed to control the proinflam-
matory potential. Further analysis of the genes that were
regulated revealed involvement in both systemic and local
effects, reflecting the complexity and multifaceted nature of
the physiologic response to immune activation. Remarkably,
the repression program contained many genes whose prod-
ucts are crucial to antigen degradation and presentation such
as CD14, CD64, cathepsin B, IP30, MHC class II, and HLA
DMa and b.
A systematic examination of the response program upon
stimulation with different microorganisms revealed a re-
markable stereotyped program of gene expression with a
core of induced genes that encode mainly proinflammatory
chemokines and cytokines and cytokine receptors such as
CCR6, CCR7, the IL-7 receptor, and the IL-15 receptor a-
chain. Despite these similarities, pathogen-specific responses
were observed [5,6].
In addition to monocytes/macrophages, DCs also play a
pivotal role in the innate immune response. DCs are of
crucial importance in the adaptive immune response. After
encounter with an infectious agent, immature, highly phago-
cytic DCs migrate from nonlymphoid tissues to draining
lymph nodes to prime T-cell responses. A systematic anal-
ysis of the gene expression program upon stimulation of
monocyte-derived DCs with distinct infectious microorgan-
isms revealed diversity in the response program towards
different pathogens, indicating that the innate DC response
is complex and highly dependent on the type of stimulus
given [22]. The common response program is characterized
by the rapid suppression of genes involved in pathogen
recognition and phagocytosis, an early and transient induc-
tion of cytokines and chemokines (IL-12p35, TNF, CCL3,
CCL4, and CXCL2) for recruitment of mononuclear cells at
the site of infection, followed by a phase of migratory
activity. Subsequently, chemokine receptors that respond
to lymph node chemokines become expressed.
Interindividual variation in innate immune responsiveness
Boldrick et al. [5] observed unexpected interindividual
differences in response to some bacteria and their products.
These investigators used peripheral blood mononuclear cells
(PBMNC) which were stimulated with several bacterial
stimuli, either whole-bacteria S. aureus, B. pertussis, E. coli,
or lipopolysaccharide (LPS) derived from the latter two
bacteria, and the response was followed in vitro over time.
LPS is widely known as Gram-negative bacterial toxin and
by itself could recreate most of the problems that are
observed during an authentic bacterial infection leading to
septic shock [23]. Surprisingly, part of the inductive response
was repeatedly different in one donor. Most of the genes that
showed a reduced induction profile fit in a group of IFNg
(interferon type II)/STAT (signal transducer and activator of
transcription) 1-responsive genes (Fig. 2), including some
genes that are important for an antiviral response, such as
OAS1 and MX1. An intriguing question is whether this
profile reflects genetic variation or whether this is due to
environmental changes such as a recent infection.
A more detailed study on interindividual differences in
blood cell gene expression profiles has recently been
reported by Whitney et al. [8]. In this study, unstimulated
whole-blood cells from 75 healthy donors were examined for
mRNA expression profiles on microarrays containingf37K
elements. The genes that show intrinsic differences in gene
expression between individuals were male- and female-
specific genes, MHC class II genes, TAP-2, and IFN-respon-
sive genes. The most consistent donor-dependent gene of all
was DDX17, a RNA helicase which is suggested to function
as a pre-mRNA splicing regulator [24]. Possibly, differential
Fig. 2. Diagram showing the activation of STAT proteins by ligation of
cytokines to their receptors. Binding of cytokines to their respective
receptors results in activation of JAKs (Janus kinases), protein tyrosine
kinases that are physically associated with the receptors. After phosphor-
ylation by activated JAKs, the receptor can act as a docking site for latent
cytoplasmic STATs. Upon binding to the cytokine receptor, STATs are
phosphorylated on tyrosine, after which they dimerize, translocate to the
nucleus, and subsequently initiate transcription. In addition, serine
phosphorylation of STATs is required for full transcriptional activity. Of
the seven known STAT family members, STAT-1 is essential for interferon
type I (IFNa and IFNh) and type II (IFNg) signaling.
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expression of DDX17 gives rise to interindividual differ-
ences in splice variants.
Interindividual variation in gene expression in peripheral
blood cells from healthy donors may be the result of genetic
differences and can therefore be used to identify poly-
morphic genes that influence the immune response and
may predispose to (auto)immune diseases.
Adaptive immunity
Both B- and T-lymphocytes can be recognized as the key
players in the adaptive immune response because of their
molecular and functional adaptation to invading pathogens.
Within both types of lymphocytes, subtypes and distinct
stages of differentiation exist, which are a consequence of
their functional adaptation to different antigens.
The differences between T cells and B cells are reflected
by the differential expression of many genes as was deter-
mined by microarray experiments, of which most have been
previously reported through classical approaches to search
for differences in gene expression, such as subtractive
hybridization. Each lymphocyte type has its specific gene
expression signature. The T-cell signature includes CD2,
TCR, and genes encoding TCR signaling proteins (LAT and
fyn). The B-cell signature contains genes like CD20, immu-
noglobulin genes, and genes encoding BCR components
such as CD79B. Although these two cell types are clearly
distinct, they also share remarkable similarities in their
activation program. The ‘‘activation gene expression signa-
ture’’ of T and B lymphocytes includes many genes that are
either induced or repressed upon activation [10,18,25].
Central to the activation status is the expression of the
transcription factor NF-kB. NF-kB factors play a central role
in immunity and members of this family (NF-kB1, NF-kB2,
RelB, c-Rel, and IkBa) are included in the activation gene
expression signature together with a prominent group of
target genes, consisting of cytokines, chemokines, and anti-
apoptotic genes like A1 (an antiapoptotic bcl-2 family
member) and c-IAP2. Differences that exist are at the level
of, for example, CCR7, CXCR5, and BCL-2 expression,
which are expressed at much higher levels in activated B
cells. The elevated expression of chemokine receptors is
likely to be involved in lymphocyte homing of activated B
cells.
One of the features of activated T cells is the repressed
expression of the genes for interferon receptors and for
STAT-1, which is involved in interferon signal transduction
[26].
T lymphocytes
A nice example of the way microarray studies may help to
address basic questions in immunology is revealed by a
study aimed to unravel the pathway of CD28 costimulation
in T cells. Triggering of TCR together with CD28 costimu-
lation allows for sustained activation and cell cycle entry.
Diehn et al. [27] have used human peripheral blood T cells
that were stimulated with antibodies to CD3 and/or CD28.
CD28 engagement elicited only a few changes in gene
expression, which yielded rather unexpected results. The
data showed that signals induced by anti-CD3 were ampli-
fied by costimulation with anti-CD28, with the most striking
enhancement of transcriptional activity of genes that are
responsive to the transcription factors NFAT. This effect
could be blocked by FK506, an inhibitor of the phosphatase
calcineurin, thereby interfering with the nuclear translocation
of NFAT proteins. Conventional biochemical techniques
were then used to demonstrate that stimulation of CD28
leads to reduced nuclear export of NFATc protein caused by
increased phosphorylation (and thus inactivation) of the
nuclear export kinase glycogen synthase kinase-3 (GSK3).
Even in the absence of CD3 stimulation, engagement of
CD28 stimulated the phosphorylation of GSK3, which
becomes more effective when NFAT is activated by CD3
stimulation. Without the use of microarrays, these findings
would have taken much longer to discover.
Among effector/memory T helper cells, a distinction can
be made based on the pattern of secreted proteins, dividing
them into Th1 cells, (expressing IFNg and TNF) involved in
phagocyte-dependent immune response, and Th2 cells
(expressing IL-4, IL-5, and IL-13) that promote IgE produc-
tion and eosinophil function. An unbalance in Th differen-
tiation may lead to pathology. Th1 cells may be held
responsible for tissue damage in inflammatory diseases such
as rheumatoid arthritis and inflammatory bowel disease. Th2
cells play a role in the pathogenesis of allergic reactions and
asthma. There is an increasing interest in the factors that
affect the creation and interconversion of Th1 and Th2 cells.
Studies to gain insight in the program that controls the
functional properties are of importance to define molecular
markers to distinguish these subsets in a clinical setting and
design strategies to selectively silence or reverse a detrimen-
tal Th cell subset. A few papers indicate that many more
genes than originally reported are differentially expressed in
early differentiating Th1 and Th2 cells [28,29]. In another
study [30], polarized human Th1 and Th2 cells were ana-
lyzed after several time points of stimulation on Affymetrix
chips containing a limited set of 250 human genes. Many
new genes were discovered, which were differentially
expressed in Th1 and Th2 cells including transcription
factors, cytokines and receptors, costimulatory molecules,
apoptosis-related genes, genes involved in migration and
adhesion, and genes with unknown function. We performed
experiments on fully polarized human Th1 and Th2 cells at
different time points of stimulation using the ‘‘Lymphochip’’
and identified 160 cDNA spots, partly representing different
clones of the same gene, which are differentially expressed
between Th1 and Th2 cells. Some of these genes are
differentially expressed at only a single time point after
activation, while others are expressed consistently higher
over time in either subset (Van der Pouw Kraan T.C.T.M.,
Van Baarsen L., and Verweij C.L., unpublished observa-
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tions). The genes include lytic proteins, costimulatory mem-
brane molecules, cytokines, chemokines, and genes involved
in signaling, transcriptional control, and cell differentiation.
The identification of these differentially expressed genes
provides a starting point for many future studies.
B lymphocytes
Gene expression profiling studies have also provided a
molecular definition of different phases in B-cell differenti-
ation. Array studies revealed a characteristic signature of B
cells in the anergic state [10]. Many of these genes have
established negative regulatory functions. On the other hand,
B-cell activation-specific genes, including the protoonco-
genes LSIRF/IRF4 and c-myc, the antiapoptotic molecule A1,
and the inhibitory transcription factor LKLF, implicated in
lymphocyte mitogenesis, were blocked in anergic cells. This
gene profile may explain how tolerance is maintained in B
cells.
Germinal center B cells differentiate into plasma cells or
memory B cells, while undergoing affinity maturation and
somatic mutation. Germinal center B cells and plasma cells
show distinct expression signatures [31]. Plasma cells show a
higher expression of plasmacytic differentiation regulators
blimp-1 and XBP-1. Interestingly, germinal center B cells
show an expression signature that is retained in lymphoma
cell lines [18] (see below). This latter profile can be
explained by the high expression of BCL-6, because the
dominant negative form of BCL-6 introduced into germinal
center derived B-cell lines is able to block terminal differ-
entiation into plasma cells [31].
Gene expression profiling in disease
Information about the differences in gene expression
between cells or tissues of healthy and diseased individuals
provides markers to differentiate between health and disease,
and disease states. In combination with biochemical re-
search, the expression profiles may provide clear insights
into the disease mechanisms. In the past years, several
studies have already illustrated how expression arrays pro-
vide classification criteria and mechanistic insights into
disease. The assembly of a database containing expression
signatures of various immune cells in different phases of
activation and differentiation would provide a valuable
resource to relate expression patterns observed in disease
states to immune physiology.
Autoimmune diseases
Maas et al. [32] compared gene expression levels in
PBMC of control individuals before and after immunization
with influenza vaccine to those of individuals with four
distinct autoimmune diseases including rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE), type I diabetes,
and multiple sclerosis (MS). The induced gene expression
profile of the normal immune response exhibited coordinate
changes in expression of genes with related functions over
time. Three days after immunization, genes encoding pro-
teins involved in key signal transduction pathways (e.g.,
PKC, phospholipase C, 1,2-DAG kinase, MAPK, STATs and
STAT inhibitors, AP-1, IFN regulatory proteins, and cell
cycle proteins) were expressed. After 3 weeks, the program
had shifted toward functional activity (chemokines, comple-
ment components and IFN-inducible proteins, and leukocyte
homing/adhesion molecules). The autoimmune patients dis-
played a similar gene expression profile unrelated to the
pattern of the immunized group. Two gene clusters were
differentially expressed between patients with an autoim-
mune disease and controls. Surprisingly, genes with a
distinct expression pattern in autoimmunity were not neces-
sarily ‘‘immune response’’ genes, but were genes that encode
proteins involved in, for example, apoptosis (such as
TRADD, TRAP1, TRIP, TRAF2, CASP6, and CASP8), cell
cycle progression (CDKN1B, CDKN2A, and BRCA1), and
cell differentiation (LIF and CD24).
Another study revealed remarkable results upon gene
expression profiling within SLE (n = 48). A characteristic
feature of the inflammatory autoimmune disease SLE is the
heterogeneity in the clinical presentation, therapy respon-
siveness, and severity of disease. Baechler et al. [9] deter-
mined the mRNA expression profiles of unstimulated PBMC
from SLE patients and controls. Distinct gene expression
patterns, consisting 161 genes, were identified for patients
and controls. Strikingly, in about 50% of the patients, a
dysregulated expression of the IFN pathway, that is, en-
hanced expression of mRNA for STAT-1 itself and a number
of genes that are dependent on STAT-1 for their transcription,
was observed. In addition, this pathway was associated with
more severe disease involving the kidneys, hematopoietic
cells, and/or the central nervous system.
To generate a molecular description of synovial tissue
from RA patients that would allow us to unravel novel
aspects of pathogenesis and identification of different forms
of disease, we profiled gene expression in synovial tissue
from affected joint tissues of patients with RA (n = 21) using
the ‘‘Lymphochip’’ and microarrays containing approxi-
mately 24,000 cDNA spots [33,34] (Fig. 3). Unsupervised
hierarchical clustering of the RA gene expression signatures
revealed considerable variability within the RA tissues
resulting in the identification of at least two molecular
distinct forms of RA tissues. The first group revealed
abundant expression of clusters of genes indicative of an
involvement of the adaptive immune response with evidence
for a prominent role of an activated STAT-1 pathway,
including STAT-1 signaling receptors and STAT-1 target
genes, among these STAT-1 itself [35]. Among the genes
overexpressed in this group of patients, a relative majority of
nine genes is located on chromosome 6p21.3, which harbors
the HLA genes and is responsible for one third of the genetic
influence on the development of rheumatoid arthritis. The
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expression profiles of the second group of RA tissues
revealed an increased tissue remodeling activity and a low
inflammatory gene expression signature, which is associated
with fibroblast dedifferentiation. In conclusion, these results
confirm the heterogeneous nature of rheumatoid arthritis and
suggest the existence of distinct pathogenic mechanisms that
contribute to RA as was suggested by Firestein and Zvaifler
[36]. The differences in expression profiles provide oppor-
tunities to stratify patients based on molecular criteria for
clinical studies and evaluation of targeted therapies.
Microarray analysis of MS lesions at autopsy revealed
increased expression of transcripts encoding inflammatory
cytokines such as IL-6, IL-17, and IFN-g, cytokine recep-
tors IL-1R, IL-18Rtype2, IL-11Ra, IL-17, and TNFRp75,
and downstream signaling pathways [37]. Comparison of
the gene expression profiles of active/acute lesions with
silent lesions revealed a number of genes whose transcripts
were at least twofold differentially expressed. Among these
genes were included those encoding FGF-12, IL-17, and the
interferon-induced 17-kD/15-kD protein mRNA.
Lawrance et al. [38] report on genes that distinguish two
forms of inflammatory bowel disease (IBD), ulcerative
colitis (UC), and Crohn disease (CD). Global gene expres-
sion resulted in the assignment of various cytokine and
chemokine genes, novel immune function-related genes
Fig. 3. Subclassification of rheumatoid arthritis (RA) patients. mRNA is
isolated from synovial tissues of affected joints from RA patients and
osteoarthritis patients (OA), hybridized to cDNA microarrays against a
common reference and analyzed as depicted in Fig. 1. This subcluster
represents genes involved in the adaptive immune response and STAT-1
pathway, and is part of a larger cluster that subdivides RA patients into a
group with a high and a low inflammatory gene expression signature
[33].
Fig. 4. Workflow for a systems biology approach. Knowledge from known
relationships between biologic molecules (databases, literature) combined
with data from large-scale screening studies involving different levels of
information transfer from genome to phenotype and function (transcript,
protein, and metabolite) will be used to create models. Models will be
validated using computational ‘‘dry’’ experiments. Subsequently, the model
will be tested using the appropriate biological systems and technology
platforms. Results from these analyses will form the basis for validation or
rejection of the model and remodeling, and the cycle will be repeated.
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such as IGHG3, IGLL2, and CD74, and also several IFN-
inducible proteins (e.g., IP-30, IP-16, and MTAP44).
In aggregate, these studies demonstrate the existence of
considerable variation in gene expression profiles between
individuals. One of the distinctive gene expression programs
involves the IFN/STAT signaling pathway [5,8]. The most
consistent intrinsic variable gene in healthy donors is
DDX17 [8], which was selectively expressed in a subgroup
of RA patients that showed a high degree of inflammation
and high expression of IFN-responsive genes. These find-
ings make it tempting to speculate that interindividual
differences that exist in healthy controls might explain
heterogeneity that is observed in immune-related diseases
such as SLE, RA, IBD, and MS. In this respect, it is worth
noting that Rozzo et al. [39] identified a genetic variant of
the interferon-inducible gene Ifi202 as a major factor that
contributes to disease susceptibility in the (NZBxNZW)F1
mouse model of systemic lupus.
Infectious diseases
Host–pathogen interactions constitute a major topic in
the genomics research of infectious diseases. Thus far, most
studies have concentrated on responses of host cells and cell
lines upon in vitro infection. In one of the first studies, Zhu
et al. [40] analyzed cytomegalovirus (CMV) infection of
human foreskin fibroblasts resulting in the identification of
increased expression of phospholipase A2 and COX2 lead-
ing to the subsequent increase of PGE2. Poole et al. [41]
used microarrays to analyze the expression profile upon
infection of human DMEV cells by Karposi sarcoma-asso-
ciated herpes virus. As mentioned above, others [5,22] have
compared the response of peripheral blood cells to a number
of pathogens and determined both common and unique
response programs by each pathogen to understand how
the immune reaction develops, as well as strategies used by
the pathogens to enhance or optimize their survival [42].
The results from these studies strongly suggest that an
analysis of the host expression patterns may be able to
distinguish infections caused by different pathogens.
Usage of a combination of murine cDNA microarrays,
cytokine-deficient mice, and confirmatory biologic assays
led to the identification of gene expression profiles that
associate with lethal type 1 (IL-12/IFN-g) and type 2 (IL-4)
polarized immune responses during infection with the
parasitic trematode Schistosoma mansomi [51]. These
results uncovered the contributions of previously unappre-
ciated disease mechanisms that contribute to parasite-in-
duced pathogenesis.
The reciprocal approach to host–pathogen interactions is
to gain a better understanding of pathogen responses to host
contact upon infection. These experiments require the ge-
nome sequence of the pathogen and microarrays containing
gene sequences of the respective pathogenic microorgan-
isms. The results of this pathogen genome-mining approach
may yield the identification of potential vaccine candidates,
as was exemplified by studies using N. meningitidis group B
bacteria [43].
Cancer
Microarrays have been particularly useful in the classifi-
cation of cancer. Alizadeh et al. [18] performed a systematic
survey to define the gene expression programs of normal
lymphocytes in different stages of differentiation and deter-
mined the extent to which these programs are inherited by
human lymphoid malignancies. The idea was to extend
markers for determining the cellular origins of lymphomas
that so far relied on the analysis of somatic hypermutation in
the variable regions. Such a reference database provides a
rich framework allowing interpretation of the gene expres-
sion signature in lymphoid malignancies. The knowledge
gained from the assembly of a reference database was applied
to classify diffuse large B-cell lymphoma (DLBCL), a
clinically heterozygous disease in terms of treatment re-
sponse and subsequent survival, for which no good diagnos-
tic parameters are available. Unsupervised hierarchical
clustering performed on expression data of lymph node
biopsies from DLBCL patients revealed two groups of
patients, one group showed characteristics of the gene
expression profile of germinal center B cells, while the other
showed expression profiles characteristic of activated periph-
eral blood B cells. This distinction turned out to be a good
predictor for survival. The 5-year survival probability for the
germinal center B-like group was 70%, whereas only 20% of
the activated B-like DLBCL patients survived for 5 years.
Golub et al. [44] clustered 38 tumor samples by creating
self-organizing maps (SOM) with a preset number of two or
four clusters (groups of patients) for new class discovery.
Subsequently, class predictors were identified from these
SOMs. For testing the class predictors consisting of various
numbers of genes (10–100), the one with the highest cross-
validation accuracy rate was used. A set of known ALL and
AML tumor samples was used to test how well this class
prediction method performed [44]. With two exceptions, all
38 samples were correctly grouped into AML and ALL,
while the distinction between B-cell and T-cell ALL was
made as well.
Others have identified sets of genes that predict the
clinical outcome of breast cancer patients. Van’t Veer et al.
[7] have used another strategy to classify breast tumors
according to their clinical behavior. A total of 78 sporadic
lymph node-negative patients were selected to identify a
prognostic gene expression signature for clinical outcome:
metastasis or disease-free status within 5 years. From the
25,000 genes on the arrays, a selection was made of 5000
genes that showed a set threshold of variation between the
samples. A supervised method was then applied to these
genes for the identification of the genes that are the best
predictors for clinical outcome. A list of 70 genes turned out
to be the best predictors for disease development with 83%
accuracy. Therefore, only a small group of genes within a
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large pool that showed interindividual variation in expres-
sion determines one important aspect of disease, namely,
metastasis. This method is very valuable for identifying
prognostic markers or classifiers. However, if the interest
is mainly the pathology of tumor development (or any other
disease), then unsupervised clustering is a better option, as
was done in another study on breast cancer aimed to classify
patients [45]. This study revealed at least four subgroups of
patients with different genetic programs that were informa-
tive concerning the biology of the tumors. The relation of the
obtained groups of patients to clinical parameters, such as
therapy responsiveness, is then a secondary question in such
studies. For instance, if the clusters demonstrate a poor
correlation with therapy responsiveness, the genetic program
of the diseased tissues is only partly inhibited by the current
therapy, and this therapy may therefore not be the optimal
one. The clustering method may reveal more novel targets
for therapy than the supervised classifier method, and when
applied, the outcome may correlate with the originally
identified groups of patients.
Tibshirani et al. [46] used an approach for cancer class
prediction called ‘‘nearest shrunken centroids’’ to identify
subsets of genes that characterize each class of tumors. This
method was successful in finding the smallest set of genes
that accurately predict classes and was in fact more accurate
than the one described by Golub et al. This method for
classification is available to the public through a software
package for class prediction called PAM (Prediction Anal-
ysis for Microarrays) at http://www.stat.stanford.edu/ftibs/
PAM.
Future aspects
This review demonstrates the impact of gene expression
profiling on basic and clinical immunology in the future.
With the disclosure of the human genome sequence [47,48],
the option to apply a genome-wide screening is now feasible.
The same holds true for the murine genome, which will make
it possible to apply whole-genome screening for common
animal models for basic immunologic questions and disease.
Gene expression profiling will lead to a molecular defi-
nition of disease. Consequently, autoimmune, immune defi-
ciency diseases, and malignancies that are currently defined
by their clinical phenotypes will soon be classified into
molecular subtypes based on functional genomics experi-
ments. In addition, the assembly of comprehensive gene
expression databases that contain molecular signatures of
specific cell subsets and biological networks will be useful to
understand the biologic basis of dysregulation in disease. It
can further be anticipated that this information will allow us
to determine how the disease pathway can be manipulated
pharmacologically with greater specificity than achieved by
current drugs. Furthermore, differences in responses between
individuals might provide a lead to explain how genetic
variation affects the immune system.
Since most infectious processes result in an ordered series
of host regulatory responses, gene expression profiles of host
cells could also be used to define the stage of the host
response in individual patients. In the ideal situation, patho-
gen-specific profiles may be recognized, which might be
particularly useful for rapid diagnosis, especially in those
cases where it is technically difficult or impossible to culture
the pathogen. In addition to diagnostic purposes, this will also
have considerable impact on therapy of infectious diseases.
Knowledge that will be gained by identifying the genes
that are expressed in a cell or tissue will make the biology of
the system more comprehensible. While this is in part true, it
is clear that transcriptomics information does not address the
regulation that occurs downstream of transcription, involv-
ing mRNA splicing, protein expression, and posttranslation-
al modification. A systems approach (Fig. 4) requires
integration of as many different data types as possible
including, besides gene expression data, information of the
proteome (the global inventory of all proteins in an organ,
tissue of individual cell type) and the metabolome (global
inventory of metabolites). Together, the data on the different
levels of information transfer from genome to phenotype
define a new approach to biology, which is termed ‘‘systems
biology’’ [49,50]—a computational modeling approach
aimed to understand the structure and dynamics of cellular
and organismal functions. Systems biology will certainly
become a mainstay of drug development, allowing identifi-
cation of novel drug targets.
In the near future, new analysis methods will evolve to
further improve the identification of relationships between
the expression levels of many genes, identify new signaling
pathways, further improve class prediction, and determine
genetic differences.
Acknowledgments
The authors thank the Netherlands Organization of Pure
Scientific Research and the Dutch Arthritis Association for
financial support.
References
[1] R.N. Van Gelder, M.E. von Zastrow, A. Yool, W.C. Dement, J.D.
Barchas, J.H. Eberwine, Amplified RNA synthesized from limited
quantities of heterogeneous cDNA, Proc. Natl. Acad. Sci. U. S. A.
87 (1990) 1663–1667.
[2] E. Wang, L.D. Miller, G.A. Ohnmacht, E.T. Liu, F.M. Marincola,
High-fidelity mRNA amplification for gene profiling, Nat. Biotech-
nol. 18 (2000) 457–459.
[3] L.R. Baugh, A.A. Hill, E.L. Brown, C.P. Hunter, Quantitative analysis
of mRNA amplification by in vitro transcription, Nucleic Acids Res.
29 (2001) E29.
[4] L. Luo, R.C. Salunga, H. Guo, A. Bittner, K.C. Joy, J.E. Galindo, H.
Xiao, K.E. Rogers, J.S. Wan, M.R. Jackson, M.G. Erlander, Gene
expression profiles of laser-captured adjacent neuronal subtypes,
Nat. Med. 5 (1999) 117–122.
[5] J.C. Boldrick, A.A. Alizadeh, M. Diehn, S. Dudoit, C.L. Liu, C.E.
 Chapter 2
44
Belcher, D. Botstein, L.M. Staudt, P.O. Brown, D.A. Relman, Ste-
reotyped and specific gene expression programs in human innate
immune responses to bacteria, Proc. Natl. Acad. Sci. U. S. A. 99
(2002) 972–977.
[6] G.J. Nau, J.F. Richmond, A. Schlesinger, E.G. Jennings, E.S. Lander,
R.A. Young, Human macrophage activation programs induced by bac-
terial pathogens, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1503–1508.
[7] L.J. Van’t Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M.
Mao, H.L. Peterse, K.K. van der, M.J. Marton, A.T. Witteveen, G.J.
Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. Bernards,
S.H. Friend, Gene expression profiling predicts clinical outcome of
breast cancer, Nature 415 (2002) 530–536.
[8] A.R. Whitney, M. Diehn, S.J. Popper, A.A. Alizadeh, J.C. Boldrick,
D.A. Relman, P.O. Brown, Individuality and variation in gene expres-
sion patterns in human blood, Proc. Natl. Acad. Sci. U. S. A. 100
(2003) 1896–1901.
[9] E.C. Baechler, F.M. Batliwalla, G. Karypis, P.M. Gaffney, W.A.
Ortmann, K.J. Espe, K.B. Shark, W.J. Grande, K.M. Hughes, V.
Kapur, P.K. Gregersen, T.W. Behrens, Interferon-inducible gene ex-
pression signature in peripheral blood cells of patients with severe
lupus, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2610–2615.
[10] R. Glynne, S. Akkaraju, J.I. Healy, J. Rayner, C.C. Goodnow, D.H.
Mack, How self-tolerance and the immunosuppressive drug FK506
prevent B-cell mitogenesis, Nature 403 (2000) 672–676.
[11] G. Sherlock, Analysis of large-scale gene expression data, Curr. Opin.
Immunol. 12 (2000) 201–205.
[12] M.P. Brown, W.N. Grundy, D. Lin, N. Cristianini, C.W. Sugnet, T.S.
Furey, M. Ares Jr., D. Haussler, Knowledge-based analysis of micro-
array gene expression data by using support vector machines, Proc.
Natl. Acad. Sci. U. S. A. 97 (2000) 262–267.
[13] O. Alter, P.O. Brown, D. Botstein, Singular value decomposition for
genome-wide expression data processing and modeling, Proc. Natl.
Acad. Sci. U. S. A. 97 (2000) 10101–10106.
[14] F. Valafar, Pattern recognition techniques in microarray data analysis:
a survey, Ann. N. Y. Acad. Sci. 980 (2002) 41–64.
[15] M.B. Eisen, P.T. Spellman, P.O. Brown, D. Botstein, Cluster analysis
and display of genome-wide expression patterns, Proc. Natl. Acad.
Sci. U. S. A. 95 (1998) 14863–14868.
[16] P. Tamayo, D. Slonim, J. Mesirov, Q. Zhu, S. Kitareewan, E.
Dmitrovsky, E.S. Lander, T.R. Golub, Interpreting patterns of gene
expression with self-organizing maps: methods and application to he-
matopoietic differentiation, Proc. Natl. Acad. Sci. U. S. A. 96 (1999)
2907–2912.
[17] V.G. Tusher, R. Tibshirani, G. Chu, Significance analysis of micro-
arrays applied to the ionizing radiation response, Proc. Natl. Acad.
Sci. U. S. A. 98 (2001) 5116–5121.
[18] A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A.
Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, J.I. Powell,
L. Yang, G.E. Marti, T. Moore, J.J. Hudson, L. Lu, D.B. Lewis,
R. Tibshirani, G. Sherlock, W.C. Chan, T.C. Greiner, D.D.
Weisenburger, J.O. Armitage, R. Warnke, L.M. Staudt, Distinct types
of diffuse large B-cell lymphoma identified by gene expression pro-
filing [see comments], Nature 403 (6769) (2000 Feb. 3) 503–511.
[19] H.L. Pahl, Activators and target genes of Rel/NF-kappaB transcrip-
tion factors, Oncogene 18 (1999) 6853–6866.
[20] C.S. Detweiler, D.B. Cunanan, S. Falkow, Host microarray analysis
reveals a role for the Salmonella response regulator phoP in human
macrophage cell death, Proc. Natl. Acad. Sci. U. S. A. 98 (2001)
5850–5855.
[21] M. Diehn, D.A. Relman, Comparing functional genomic datasets:
lessons from DNA microarray analyses of host –pathogen interac-
tions, Curr. Opin. Microbiol. 4 (2001) 95–101.
[22] Q. Huang, D. Liu, P. Majewski, L.C. Schulte, J.M. Korn, R.A. Young,
E.S. Lander, N. Hacohen, The plasticity of dendritic cell responses to
pathogens and their components, Science 294 (2001) 870–875.
[23] C.R. Raetz, C. Whitfield, Lipopolysaccharide endotoxins, Annu. Rev.
Biochem. 71 (2002) 635–700.
[24] C.G. Lee, RH70, a bidirectional RNA helicase, co-purifies with
U1snRNP, J. Biol. Chem. 277 (2002) 39679–39683.
[25] T.K. Teague, D. Hildeman, R.M. Kedl, T. Mitchell, W. Rees, B.C.
Schaefer, J. Bender, J. Kappler, P. Marrack, Activation changes the
spectrum but not the diversity of genes expressed by T cells, Proc.
Natl. Acad. Sci. U. S. A. 96 (1999) 12691–12696.
[26] T.K. Teague, D. Hildeman, R.M. Kedl, T. Mitchell, W. Rees, B.C.
Schaefer, J. Bender, J. Kappler, P. Marrack, Activation changes the
spectrum but not the diversity of genes expressed by T cells, Proc.
Natl. Acad. Sci. U. S. A. 96 (1999) 12691–12696.
[27] M. Diehn, A.A. Alizadeh, O.J. Rando, C.L. Liu, K. Stankunas, D.
Botstein, G.R. Crabtree, P.O. Brown, Genomic expression programs
and the integration of the CD28 costimulatory signal in T cell activa-
tion, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11796–11801.
[28] L. Rogge, E. Bianchi, M. Biffi, E. Bono, S.Y. Chang, H. Alexander,
C. Santini, G. Ferrari, L. Sinigaglia, M. Seiler, M. Neeb, J. Mous, F.
Sinigaglia, U. Certa, Transcript imaging of the development of human
T helper cells using oligonucleotide arrays, Nat. Genet. 25 (1) (2000
May) 96–101.
[29] T. Chtanova, R.A. Kemp, A.P. Sutherland, F. Ronchese, C.R. Mackay,
Gene microarrays reveal extensive differential gene expression in
both CD4(+) and CD8(+) type 1 and type 2 T cells, J. Immunol.
167 (2001) 3057–3063.
[30] H. Hamalainen, H. Zhou, W. Chou, H. Hashizume, R. Heller, R.
Lahesmaa, Distinct gene expression profiles of human type 1 and
type 2 T helper cells, Genome Biol. 2 (2001) 22.1–22.11.
[31] A.L. Shaffer, A. Rosenwald, E.M. Hurt, J.M. Giltnane, L.T. Lam,
O.K. Pickeral, L.M. Staudt, Signatures of the immune response, Im-
munity 15 (2001) 375–385.
[32] K. Maas, S. Chan, J. Parker, A. Slater, J. Moore, N. Olsen, T.M.
Aune, Cutting edge: molecular portrait of human autoimmune dis-
ease, J. Immunol. 169 (2002) 5–9.
[33] T.C. van der Pouw Kraan, F.A. Van Gaalen, P.V. Kasperkovitz, N.L.
Verbeet, T.J. Smeets, M.C. Kraan, M. Fero, P.P. Tak, T.W. Huizinga,
E. Pieterman, F.C. Breedveld, A.A. Alizadeh, C.L. Verweij, Rheuma-
toid arthritis is a heterogeneous disease: evidence for differences in
the activation of the STAT-1 pathway between rheumatoid tissues,
Arthritis Rheum. 48 (2003) 2132–2145.
[34] T.C. van der Pouw Kraan, F.A. Van Gaalen, T.W. Huizinga, E.
Pieterman, F.C. Breedveld, C.L. Verweij, Discovery of distinctive gene
expression profiles in rheumatoid synovium using cDNA microarray
technology: evidence for the existence of multiple pathways of tissue
destruction and repair, Genes Immun. 4 (2003) 187–196.
[35] A. Lehtonen, S. Matikainen, I. Julkunen, Interferons up-regulate
STAT1, STAT2, and IRF family transcription factor gene expres-
sion in human peripheral blood mononuclear cells and macro-
phages, J. Immunol. 159 (1997) 794–803.
[36] G.S. Firestein, N.J. Zvaifler, How important are T cells in chronic
rheumatoid synovitis?: II. T cell-independent mechanisms from be-
ginning to end, Arthritis Rheum. 46 (2002) 298–308.
[37] C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt, H. Garren,
A. Langer-Gould, S. Strober, B. Cannella, J. Allard, P. Klonowski, A.
Austin, N. Lad, N. Kaminski, S.J. Galli, J.R. Oksenberg, C.S. Raine,
R. Heller, L. Steinman, Gene-microarray analysis of multiple sclerosis
lesions yields new targets validated in autoimmune encephalomyelitis,
Nat. Med. 8 (2002) 500–508.
[38] I.C. Lawrance, C. Fiocchi, S. Chakravarti, Ulcerative colitis and
Crohn’s disease: distinctive gene expression profiles and novel
susceptibility candidate genes, Hum. Mol. Genet. 10 (2001)
445–456.
[39] S.J. Rozzo, J.D. Allard, D. Choubey, T.J. Vyse, S. Izui, G. Peltz, B.L.
Kotzin, Evidence for an interferon-inducible gene, Ifi202, in the sus-
ceptibility to systemic lupus, Immunity 15 (2001) 435–443.
[40] H. Zhu, J.P. Cong, G. Mamtora, T. Gingeras, T. Shenk, Cellular gene
expression altered by human cytomegalovirus: global monitoring with
oligonucleotide arrays, Proc. Natl. Acad. Sci. U. S. A. 95 (1998)
14470–14475.
 Genomics in the immune system
45
[41] L.J. Poole, Y. Yu, P.S. Kim, Q.Z. Zheng, J. Pevsner, G.S. Hayward,
Altered patterns of cellular gene expression in dermal microvascular
endothelial cells infected with Kaposi’s sarcoma-associated herpesvi-
rus, J. Virol. 76 (2002) 3395–3420.
[42] I.D. Manger, D.A. Relman, How the host ‘sees’ pathogens: global
gene expression responses to infection, Curr. Opin. Immunol. 12
(2000) 215–218.
[43] M. Pizza, V. Scarlato, V. Masignani, M.M. Giuliani, B. Arico, M.
Comanducci, G.T. Jennings, L. Baldi, E. Bartolini, B. Capecchi,
C.L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S.
Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M.
Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin,
D.W. Hood, A.C. Jeffries, N.J. Saunders, D.M. Granoff, J.C. Venter,
E.R. Moxon, G. Grandi, R. Rappuoli, Identification of vaccine candi-
dates against serogroup B meningococcus by whole-genome sequenc-
ing, Science 287 (2000) 1816–1820.
[44] T.R. Golub, D.K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, J.P.
Mesirov, H. Coller, M.L. Loh, J.R. Downing, M.A. Caligiuri, C.D.
Bloomfield, E.S. Lander, Molecular classification of cancer: class
discovery and class prediction by gene expression monitoring, Sci-
ence 286 (1999) 531–537.
[45] C.M. Perou, S.S. Jeffrey, M. van de Rijn, C.A. Rees, M.B. Eisen, D.T.
Ross, A. Pergamenschikov, C.F. Williams, S.X. Zhu, J.C. Lee, D.
Lashkari, D. Shalon, P.O. Brown, D. Botstein, Distinctive gene ex-
pression patterns in human mammary epithelial cells and breast can-
cers, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9212–9217.
[46] R. Tibshirani, T. Hastie, B. Narasimhan, G. Chu, Diagnosis of mul-
tiple cancer types by shrunken centroids of gene expression, Proc.
Natl. Acad. Sci. U. S. A. 99 (2002) 6567–6572.
[47] J.C. Venter, M.D. Adams, E.W. Myers, P.W. Li, R.J. Mural, G.G.
Sutton, H.O. Smith, M. Yandell, C.A. Evans, R.A. Holt, J.D.
Gocayne, P. Amanatides, R.M. Ballew, D.H. Huson, J.R. Wortman, Q.
Zhang, C.D. Kodira, X.H. Zheng, L. Chen, M. Skupski, G.
Subramanian, P.D. Thomas, J. Zhang, G.L. Gabor Miklos, C.
Nelson, S. Broder, A.G. Clark, J. Nadeau, V.A. McKusick,
N. Zinder, A.J. Levine, R.J. Roberts, M. Simon, C. Slayman,
M. Hunkapiller, R. Bolanos, A. Delcher, I. Dew, D. Fasulo, M.
Flanigan, L. Florea, A. Halpern, S. Hannenhalli, S. Kravitz, S.
Levy, C. Mobarry, K. Reinert, K. Remington, J. Abu-Threideh, E.
Beasley, K. Biddick, V. Bonazzi, R. Brandon, M. Cargill, I.
Chandramouliswaran, R. Charlab, K. Chaturvedi, Z. Deng, F.V. Di, P.
Dunn, K. Eilbeck, C. Evangelista, A.E. Gabrielian, W. Gan, W. Ge, F.
Gong, Z. Gu, P. Guan, T.J. Heiman, M.E. Higgins, R.R. Ji, Z. Ke,
K.A. Ketchum, Z. Lai, Y. Lei, Z. Li, J. Li, Y. Liang, X. Lin, F. Lu,
G.V. Merkulov, N. Milshina, H.M. Moore, A.K. Naik, V.A. Narayan,
B. Neelam, D. Nusskern, D.B. Rusch, S. Salzberg, W. Shao, B. Shue,
J. Sun, Z. Wang, A. Wang, X. Wang, J. Wang, M. Wei, R. Wides,
C. Xiao, C. Yan, A. Yao, J. Ye, M. Zhan, W. Zhang, H. Zhang,
Q. Zhao, L. Zheng, F. Zhong, W. Zhong, S. Zhu, S. Zhao, D.
Gilbert, S. Baumhueter, G. Spier, C. Carter, A. Cravchik, T. Woodage,
F. Ali, H. An, A. Awe, D. Baldwin, H. Baden, M. Barnstead, I. Barrow,
K. Beeson, D. Busam, A. Carver, A. Center, M.L. Cheng, L. Curry, S.
Danaher, L. Davenport, R. Desilets, S. Dietz, K. Dodson, L. Doup, S.
Ferriera, N. Garg, A. Gluecksmann, B. Hart, J. Haynes, C. Haynes, C.
Heiner, S. Hladun, D. Hostin, J. Houck, T. Howland, C. Ibegwam, J.
Johnson, F. Kalush, L. Kline, S. Koduru, A. Love, F. Mann, D. May,
S. McCawley, T. McIntosh, I. McMullen, M. Moy, L. Moy, B.
Nelson, K. Nelson, C. Pfannkoch, E. Pratts, V. Puri, H. Qureshi,
M. Reardon, R. Rodriguez, Y.H. Rogers, D. Romblad, B. Ruhfel,
R. Scott, C. Sitter, M. Smallwood, E. Stewart, R. Strong, E. Suh,
R. Thomas, N.N. Tint, S. Tse, C. Vech, G. Wang, J. Wetter, S.
Williams, M. Williams, S. Windsor, E. Winn-Deen, K. Wolfe, J.
Zaveri, K. Zaveri, J.F. Abril, R. Guigo, M.J. Campbell, K.V.
Sjolander, B. Karlak, A. Kejariwal, H. Mi, B. Lazareva, T. Hatton,
A. Narechania, K. Diemer, A. Muruganujan, N. Guo, S. Sato, V.
Bafna, S. Istrail, R. Lippert, R. Schwartz, B. Walenz, S. Yooseph,
D. Allen, A. Basu, J. Baxendale, L. Blick, M. Caminha, J. Carnes-
Stine, P. Caulk, Y.H. Chiang, M. Coyne, C. Dahlke, A. Mays, M.
Dombroski, M. Donnelly, D. Ely, S. Esparham, C. Fosler, H. Gire,
S. Glanowski, K. Glasser, A. Glodek, M. Gorokhov, K. Graham,
B. Gropman, M. Harris, J. Heil, S. Henderson, J. Hoover, D.
Jennings, C. Jordan, J. Jordan, J. Kasha, L. Kagan, C. Kraft, A.
Levitsky, M. Lewis, X. Liu, J. Lopez, D. Ma, W. Majoros, J.
McDaniel, S. Murphy, M. Newman, T. Nguyen, N. Nguyen,
M. Nodell, The sequence of the human genome, Science 291
(2001) 1304–1351.
[48] E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J.
Baldwin, K. Devon, K. Dewar, M. Doyle, W. FitzHugh, R. Funke,
D. Gage, K. Harris, A. Heaford, J. Howland, L. Kann, J. Lehoczky,
R. LeVine, P. McEwan, K. McKernan, J. Meldrim, J.P. Mesirov,
C. Miranda, W. Morris, J. Naylor, C. Raymond, M. Rosetti, R. Santos,
A. Sheridan, C. Sougnez, N. Stange-Thomann, N. Stojanovic, A.
Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough, S.
Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R.
Deadman, P. Deloukas, A. Dunham, I. Dunham, R. Durbin, L.
French, D. Grafham, S. Gregory, T. Hubbard, S. Humphray, A. Hunt,
M. Jones, C. Lloyd, A. McMurray, L. Matthews, S. Mercer, S. Milne,
J.C. Mullikin, A. Mungall, R. Plumb, M. Ross, R. Shownkeen, S.
Waterston, R.H.Waterston, R.K.Wilson, L.W.Hillier, J.D.McPherson,
M.A. Marra, E.R. Mardis, L.A. Fulton, A.T. Chinwalla, K.H. Pepin,
W.R. Gish, S.L. Chissoe, M.C. Wendl, K.D. Delehaunty, T.L. Miner,
A. Delehaunty, J.B. Kramer, L.L. Cook, R.S. Fulton, D.L. Johnson,
P.J. Minx, S.W. Clifton, T. Hawkins, E. Branscomb, P. Predki,
P. Richardson, S. Wenning, T. Slezak, N. Doggett, J.F. Cheng,
A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M. Frazier, R.A. Gibbs,
D.M. Muzny, S.E. Scherer, J.B. Bouck, E.J. Sodergren, K.C. Worley,
C.M. Rives, J.H. Gorrell, M.L. Metzker, S.L. Naylor, R.S. Nelson,
D.L. Nelson, G.M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori,
T. Yada, A. Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki,
T. Taylor, J. Weissenbach, R. Heilig, W. Saurin, F. Artiguenave,
P. Brottier, T. Bruls, E. Pelletier, C. Robert, P. Wincker, D.R. Smith,
L. Doucette-Stamm, M. Rubenfield, K. Weinstock, H.M. Lee,
J. Dubois, A. Rosenthal, M. Platzer, G. Nyakatura, S. Taudien,
A. Rump, H. Yang, J. Yu, J. Wang, G. Huang, J. Gu, L. Hood,
L. Rowen, A. Madan, S. Qin, R.W. Davis, N.A. Federspiel,
A.P. Abola, M.J. Proctor, R.M. Myers, J. Schmutz, M. Dickson,
J. Grimwood, D.R. Cox, M.V. Olson, R. Kaul, C. Raymond, N.
Shimizu, K. Kawasaki, S. Minoshima, G.A. Evans, M. Athanasiou,
R. Schultz, B.A. Roe, F. Chen, H. Pan, J. Ramser, H. Lehrach,
R. Reinhardt, W.R. McCombie, B.M. de la, N. Dedhia, H. Blocker,
K. Hornischer, G. Nordsiek, R. Agarwala, L. Aravind, J.A. Bailey,
A. Bateman, S. Batzoglou, E. Birney, P. Bork, D.G. Brown, C.B.
Burge, L. Cerutti, H.C. Chen, D. Church, M. Clamp, R.R. Copley,
T. Doerks, S.R. Eddy, E.E. Eichler, T.S. Furey, J. Galagan, J.G. Gilbert,
C. Harmon, Y. Hayashizaki, D. Haussler, H. Hermjakob, K. Hokamp,
W. Jang, L.S. Johnson, T.A. Jones, S. Kasif, A. Kaspryzk, S. Kent,
W.J. Kent, P. Kitts, E.V. Koonin, I. Korf, D. Kulp, D. Lancet,
T.M. Lowe, A. McLysaght, T. Mikkelsen, J.V. Moran, N. Mulder,
V.J. Pollara, C.P. Ponting, G. Schuler, J. Schultz, G. Slater, A.F. Smit,
E. Stupka, J. Szustakowski, D. Thierry-Mieg, J. Thierry-Mieg, L.
Wagner, J. Wallis, R. Wheeler, A. Williams, Y.I. Wolf, K.H. Wolfe,
S.P. Yang, R.F. Yeh, F. Collins, M.S. Guyer, J. Peterson, A. Felsenfeld,
K.A. Wetterstrand, A. Patrinos, M.J. Morgan, J. Szustakowki, P. de
Jong, J.J. Catanese, K. Osoegawa, H. Shizuya, S. Choi, Initial sequenc-
ing and analysis of the human genome, Nature 409 (2001) 860–921.
[49] H. Kitano, Systems biology: a brief overview, Science 295 (2002)
1662–1664.
[50] L. Hood, Systems biology: integrating technology, biology, and com-
putation, Mech. Ageing Dev. 124 (2003) 9–16.
[51] K.F. Hoffmann, T.C. McCarty, D.H. Segal, M. Chiramonte, M. Hesse,
E.M. Davis, A.W. Cheever, P.S. Meltzer, H.C. Morse, T.A. Wynn,
Disease fingerprinting with cDNA microarrays reveals distinct gene
expression profiles in lethal type 1 and type 2 cytokine-mediated
inflammatory reactions, FASEB J. 15 (2001) 2545–5247.
46
Chapter 3
Rheumatoid arthritis is a heterogeneous disease
 Evidence for differences in the activation of the
STAT-1 pathway between rheumatoid tissues
Arthritis & Rheumatism 2003 August; 48(8):2132-45
48
 Gene expression profiles and RA heterogeneity
49
Rheumatoid Arthritis Is a Heterogeneous Disease
Evidence for Differences in the Activation of the STAT-1 Pathway
Between Rheumatoid Tissues
Tineke C. T. M. van der Pouw Kraan,1 Floris A. van Gaalen,2 Pia V. Kasperkovitz,3
Nicolette L. Verbeet,3 Tom J. M. Smeets,4 Maarten C. Kraan,4 Mike Fero,5
Paul-Peter Tak,4 Tom W. J. Huizinga,2 Elsbet Pieterman,2 Ferdinand C. Breedveld,2
Ash A. Alizadeh,5 and Cornelis L. Verweij1
Objective. To generate a molecular description of
synovial tissue from rheumatoid arthritis (RA) patients
that would allow us to unravel novel aspects of patho-
genesis and to identify different forms of disease.
Methods. We applied complementary DNA mi-
croarray analysis to profile gene expression, with a focus
on immune-related genes, in affected joint tissues from
RA patients and in tissues from osteoarthritis (OA)
patients as a control. To validate microarray data,
real-time polymerase chain reaction was performed on
genes of interest.
Results. The gene expression signatures of syno-
vial tissues from RA patients showed considerable vari-
ability, resulting in the identification of at least two
molecularly distinct forms of RA tissues. One class of
tissues revealed abundant expression of clusters of
genes indicative of an involvement of the adaptive
immune response. Detailed analysis of the expression
profile provided evidence for a prominent role of an
activated signal transducer and activator of transcrip-
tion 1 pathway in these tissues. The expression profiles
of another group of RA tissues revealed an increased
tissue remodeling activity and a low inflammatory gene
expression signature. The gene expression pattern in the
latter tissues was reminiscent of that observed in the
majority of OA tissues.
Conclusion. The differences in the gene expres-
sion profiles provide a unique perspective for distin-
guishing different pathogenetic RA subsets based on
molecular criteria. These data reflect important aspects
of molecular variation that are relevant for understand-
ing the biologic dysregulation underlying these subsets
of RA. This approach may also help to define homoge-
neous groups for clinical studies and evaluation of
targeted therapies.
Rheumatoid arthritis (RA) is a chronic inflam-
matory joint disease affecting synovial tissue in multiple
joints in which immune and nonimmune cellular systems
mediate pathology. Despite uncertainty about its etiol-
ogy, RA is thought to be an immune-mediated disease
that promotes inflammation and tissue destruction.
Rheumatoid synovial tissue is characterized by intimal
lining layer hyperplasia and infiltration of the sublining
by macrophages, plasma cells, T and B cells, and other
inflammatory cells that promote inflammation and tis-
sue destruction (1–3). However, the pathogenesis of RA
is still poorly understood, and fundamental questions
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remain to be answered regarding the precise molecular
nature and biologic significance of the inflammatory
changes.
Owing to the lack of knowledge of the etiology
and pathogenesis of RA, there is an awareness that
current methods for classifying this disease, based as
they are on a set of clinical variables supplemented with
minimal laboratory evidence in the form of molecular
markers, are not optimal. For RA, the classifying diag-
nosis is based on the presence of 4 of 7 criteria, which
include 5 clinical variables supplemented with radio-
graphic evidence for erosions and the presence of rheu-
matoid factor as laboratory evidence (4,5). Moreover,
the current modes of classification fall short with regard
to the challenge posed by the fact that diagnosed RA is
a heterogeneous disease in itself. The clinical presenta-
tion of RA may reveal striking heterogeneity, with a
spectrum ranging from mild to severe disease. In addi-
tion, marked variability in the features of synovial in-
flammation among RA patients has been described
(6–8). The wide variation in responsiveness to different
modes of antirheumatic treatment is consistent with this
notion (9,10). Hence, the data suggest that distinct
pathogenetic mechanisms contribute to disease in RA.
A powerful way to gain insight into the molecular
complexity and pathogenesis of arthritides has arisen
from complementary DNA (cDNA) microarray technol-
ogy (11–17), which provides the opportunity to deter-
mine differences in gene expression of a large portion of
the genome in search of genes that are differently
expressed between clinically diagnosed arthritides (18).
Therefore, we used microarrays containing 18,000
cDNA representing predominantly genes thought to be
of relevance in immunology.
In the present study, we have conducted a sys-
tematic characterization of gene expression in synovial
tissues from affected joints of patients with RA and
compared this expression with that in tissues from
patients with osteoarthritis (OA), a degenerative joint
disease characterized by progressive loss of cartilage, as
a control (19–22). Both diseases are complex clinical
entities that share clinical and demographic characteris-
tics, but they also harbor key differences in tissue
destruction and prognosis. Although the etiology of OA
is also unknown, it is believed that, in contrast to RA,
biomechanical insults and cartilage abnormalities are
primary events in the development of OA, with minor
subsequent activation of the immune response (23). In
our interpretation, we focused particularly on RA to
determine whether gene expression profiling could sub-
divide clinically diagnosed RA on the basis of molecular
criteria. In addition, by this approach novel insights into
the biologic dysregulation underlying RA might be
found.
PATIENTS AND METHODS
Patients and synovial tissues. Thirty patients (21 with
RA and 9 with OA) undergoing total joint replacement surgery
were included in the gene expression profiling study. Table 1
summarizes the characteristics of these patients. The RA
patients met the American College of Rheumatology (ACR;
formerly, the American Rheumatism Association) 1987 crite-
ria for RA (4,5), and the OA patients had primary OA of the
joint, based on the ACR criteria (24,25). Synovial tissue biopsy
Table 1. Demographic and clinical data of the patients with rheumatoid arthritis (RA) and osteoarthritis (OA) whose synovial tissue was studied
for gene expression profiling*
RAtotal
(n  21)
RAlow
(n  8)
RAinterm
(n  4)
RAhigh
(n  9)
OA
(n  9)
Age, mean years (range) 60 (22–85) 69 (56–85) 50 (22–77) 63 (24–77) 64 (52–85)
No. of women/no. of men 17/4 5/3 4/0 8/1 9/0
Laboratory variables
ESR, mean mm/hour (range) 34 (7–66) 27.5 (9–57) 19.5 (7–41) 47.8 (20–66)† 25 (9–53)
Leukocytes  106/ml, mean (range) 7.7 (5.1–16.8) 9 (6.2–16.8) 7.9 (5.1–10.0) 6.4 (4.5–11.5) 5.7 (3.4–10.1)
Erosive disease 18 (86) 6 (75) 4 (100) 8 (89) 0 (0)
Rheumatoid factor positive 17 (81) 7 (88) 2 (50) 8 (89) 0 (0)
Medication
DMARDs 19 (90) 7 (88) 4 (100) 8 (89) 1 (11)
Prednisone 3 (14) 2 (25) 0 (0) 1 (11) 1 (11)
* Except where indicated otherwise, values are the number (%) of patients. Three RA subgroups were defined according to their gene expression
profiles: a high-inflammation subgroup (RAhigh), an intermediate-inflammation subgroup (RAinterm), and a low-inflammation subgroup (RAlow).
ESR  erythrocyte sedimentation rate; DMARDs  disease-modifying antirheumatic drugs.
† P  0.008 versus RAlow and RAinterm groups, by t-test.
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Figure 1. Cluster diagram of the expression of 1,066 complementary DNAs (cDNA) in 30 experimental samples using the Lymphochips.
Log-transformed data (base 2) are represented in a matrix format wherein each row displays expression results for a single gene across the arrays
and each column shows the relative expression levels for all the genes in each tissue (28). Red represents relative expression greater than the median
expression level across all tissues, and green represents an expression level lower than the median expression level. The color intensity represents
the magnitude of the deviation from the median. Gray indicates missing or excluded data. Left panel shows a thumbnail representation of the
hierarchical clustering of the selected 1,066 cDNA. Colored bars labeled A–F to the right of this panel identify the locations of a category of clustered
genes with a related expression profile. Complementary DNAs are grouped on the basis of similarity in their relative expression across the different
tissues (A  T/B cell cluster; B  antigen-presenting cell cluster; C  transcription/signaling factors cluster; D–F  stromal cell–related gene
clusters). The dendrogram at the top lists the samples studied and provides a measure of the relatedness of the expression profile in each sample.
The branches of the dendrogram are color-coded by category of tissue sample (see Results for description of tissue groups). Right panel shows an
expanded view of cluster A, with genes listed that are characteristic for the defined gene cluster. Genes without designations are new genes of
unknown function derived from various lymphoid cDNA libraries. RA  rheumatoid arthritis; OA  osteoarthritis.
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samples, obtained from an independent group of 10 OA
patients and 9 RA patients with active arthritis of the knee
joint, were selected from various regions by arthroscopy
(2.7-mm arthroscope; Storz, Tuttlingen, Germany) under local
anesthesia (26) for immunochemistry analysis. The samples
were snap-frozen en bloc in Tissue-Tek OCT (Miles, Elkhart,
IN). The frozen blocks were stored in liquid nitrogen. Cryostat
sections (5 m) were mounted on glass slides (Star Frost
adhesive slides; Knittelgla¨ser, Braunschweig, Germany). The
glass slides were sealed and stored at 70°C until immunohis-
tologic analysis.
Messenger RNA (mRNA) isolation from tissue sam-
ples and labeling. After surgical resection, the synovial tissue
(1 gm) was dissected and quickly frozen in liquid nitrogen
and stored at –80oC. Total cellular RNA and mRNA were
isolated from the tissues by TRIzol reagent and the FAST
TRACK 2.0 kit (both from Invitrogen, Carlsbad, CA), respec-
tively, according to the manufacturer’s instructions. For gene
expression profiling by DNA microarray analysis, fluorescent
cDNA probes were prepared from a 1-g experimental mRNA
sample by oligo(dT)-primed polymerization using Superscript
II reverse transcriptase in the presence of Cy5-labeled dCTP as
described (online at http://cmgm.stanford.edu/pbrown/
protocols.html). A common reference mRNA sample that
consists of a mixture of mRNA isolated from 11 different cell
lines (15), synovial tissue, fibroblasts, and activated peripheral
blood mononuclear cells was labeled with Cy3.
Microarray procedures. DNA microarray analysis was
done essentially as described by Eisen and Brown (27). The
Cy5-labeled experimental cDNA and the Cy3-labeled common
reference sample were pooled and hybridized to the Lympho-
chips containing 18,000 cDNA spots representing genes of
relevance in immunology as described previously (14). One
OA sample was hybridized twice.
Data analysis. Analysis of microarray gene expression
data was performed as described (14), except that we used
genes with an expression level higher than 1.6 times back-
ground instead of 1.4 times background. The use of a common
reference sample allows the comparison of the relative expres-
sion levels across the tissue samples (14). Hierarchical cluster-
ing (28) (online at http://rana.lbl.gov/EisenSoftware.htm) was
applied to the gene axis as well as the tissue axis. The results
were visualized with Treeview (online at http://rana.lbl.gov/
EisenSoftware.htm). Full data can be viewed at the Stanford
Microarray Database (29) (online at http://genome-www.
stanford.edu/microarray).
Immunohistochemistry and microscopic analysis.
Stainings with monoclonal antibodies directed against signal
transducer and activator of transcription 1 (STAT-1) (clone 1
cat. no. 610115; BD Transduction Laboratories, San Jose, CA)
were performed as described previously (30). Coded sections
stained for STAT-1 were analyzed in a random order by
computer-assisted image analysis. Eighteen high-power fields
(hpf) were analyzed, representing an area of 2.1 mm2. The hpf
images were analyzed for total cell counts and integrated
optical density using a specialized algorithm (Syndia version
1.1) written in Quips for the Qwin analysis system (Leica,
Cambridge, UK), as described previously in detail (31).
Statistical analysis. Statistical analysis on microarray
data was performed using the Significance Analysis of Microar-
rays (SAM) method (32) (online at http://www-stat.stanford.edu/
tibs/SAM). Pearson’s correlation coefficient was used to deter-
mine the degree of correlation between clusters (expression ratios
of all genes within a cluster were averaged per tissue). A t-test was
used to test for differences in patient characteristics between the
patient groups and for differences in STAT-1 protein expression
levels between RA and OA patients.
RESULTS
Gene expression pattern and disease. We fo-
cused most of our analyses on a set of 1,066 cDNA,
including different cDNA representing the same genes,
whose transcripts varied in abundance by at least 2-fold
from their median level in at least 4 clinical samples.
Hierarchical clustering revealed a remarkable ordered
variation in gene expression patterns in RA and OA
tissues with clusters of genes having similar expression
patterns. To demonstrate that experimental noise or
artifact was negligible, distinct clones representing the
same genes were typically invariably clustered in adja-
cent rows. Without information about the identity of the
samples, the tissues were also organized on the basis of
overall similarity in their gene expression patterns (Fig-
ure 1). Correction of the weighting factor for distinct
clones representing the same gene spotted multifold did
not affect the tissue clustering. The structure of the
hierarchical dendrogram indicated that the gene expres-
sion patterns in RA tissues were considerably hetero-
geneous. The algorithm divided the RA tissues into two
groups. One group contained almost exclusively RA tissues
that clustered together with one outlying OA tissue.Within
this group, two subbranches, labeled green and red, were
evident. The remaining RA tissues clustered together with
the OA tissues in a group labeled blue.
The position of any tissue in the dendrogram is
determined by distinct biologic themes represented by
clusters of coordinately expressed genes. Therefore, the
molecular signature provides the basis for a biologic
interpretation. The most prominent distinction between
the two dominant tissue clusters was formed by genes
represented in cluster A, which contained a collection of
genes that are expressed by T and B cells. This cluster
revealed a difference in expression of genes involved in
an adaptive inflammatory response. The elevated ex-
pression of immunoglobulin genes present in this T/B
cell cluster indicates a high biologic activity of B cells
(Figure 1). Moreover, this cluster showed an increased
expression of matrix metalloproteinases (MMPs) 1 and
3, STAT-encoding genes, and STAT-induced genes.
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Increased expression of genes present in cluster
A (the T/B cell cluster), together with genes in cluster B
that were characteristic for antigen-presenting cells
(APCs), was typical of the red-labeled subbranch, which
contained exclusively RA tissues. Cluster B (Figure 2),
the APC cluster, contained many genes that encode
HLA class I, HLA class II, and associated molecules. In
the APC cluster, specific markers were found for several
immune cell types. Thus, the expression signature of the
RA tissues from the red subbranch indicated an influx of
inflammatory cells, which, in addition to B and T cells,
provided evidence for the presence of monocytes and
granulocytes.
A remarkable expression pattern was featured by
the C cluster, which contained genes whose products are
involved in intracellular signaling and transcriptional
regulation (Figure 3). Genes in this cluster were highly
expressed in those tissues showing high expression of
genes in the APC (B) cluster, as well as in a subgroup of
tissues from the blue-labeled group.
Another gene expression profile that distin-
guished between the tissue groups included genes that
were grouped together in the D, E, and F gene clusters
(Figure 3), which contained genes involved in stromal
cell differentiation. The expression of these genes was
relatively low in the red-labeled tissues. The D cluster
included the genes for MMP-11, MMP-13, osteonectin
(secreted protein, acidic and rich in cysteine), and cyclin
D1, which has a role in cell turnover. In addition to this
cluster, two other gene clusters with stromal cell–related
genes were identified. One of these was the E gene
cluster (involving genes for protocadherin-, secreted
frizzled-related protein 1, tissue inhibitor of metallopro-
teinases 2, membrane metallo-endopeptidase, and CD36
antigen [type I collagen/thrombospondin receptor]).
This cluster also contained genes that define an acti-
vated transforming growth factor 3 (TGF3) pathway,
such as TGF3, TGF receptor type III, and TGF-
stimulated proteins TSC-22 and Id3. Genes grouped in
the F cluster form a diverse set of genes involved in
miscellaneous biologic processes. The abundant expres-
sion of the gene clusters D, E, and F, indicative of
extracellular matrix (ECM) remodeling and cell turn-
over, was inversely correlated with a low infiltrate gene
expression signature, in particular, expression of the T/B
cell (A) gene cluster (r  0.74, P  0.0001).
Significance analysis of RA subtypes. Clearly, the
gene signatures indicated the existence of subtypes of
RA tissues. To confirm this, we reclustered the RA
Figure 2. Scaled-down representation of distinct gene expression
cluster B defined by hierarchical clustering. The diagram presents an
expanded view of the gene expression cluster B shown in Figure 1. The
genes on the right are known genes that are characteristic for the
defined gene cluster. See Figure 1 for definitions and explanations.
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Figure 3. Scaled-down representation of distinct gene expression clusters C–F defined by hierarchical clustering. The diagram presents an expanded
view of the gene expression clusters C–F shown in Figure 1. The genes on the right are known genes that are characteristic for the defined gene
clusters. See Figure 1 for definitions and explanations.
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tissues without including OA tissues (Figure 4). Indeed,
the hierarchical dendrogram revealed a subdivision of
RA tissues almost identical to that seen in Figure 1,
based on a considerable difference in their gene expres-
sion profiles, including having the T/B cell and APC
gene clusters on one side and the stromal cell gene
clusters on the other side. Of note, we could identify 3
subgroups according to their gene expression profiles: a
high-inflammation subgroup (RAhigh, red branch; n 
9), an intermediate-inflammation subgroup (RAinterm,
green branch; n  4), and a low-inflammation subgroup
(RAlow, blue branch; n  8).
Based on this subclassification of RA patients, we
next tested which of the genes differed significantly in
expression between the tissues from the RAhigh group
and those from the RAlow group, by applying the SAM
method (32). The comparison of the two groups identi-
fied 150 independent cDNA sequences (72 unknown
cDNA) with a statistically significant difference in ex-
pression of at least 2-fold in at least one copy of the gene
when multiple copies of the same gene were spotted
(Table 2). Based on the same criteria, we also tested
which of the genes differed significantly in expression
between the tissues from the OA group and those from
the RAhigh group and identified 197 independent se-
quences (including 85 unknowns). Remarkably, there
was a large overlap in genes that differed significantly in
expression between the RAhigh and RAlow tissue groups
and between the RAhigh and OA tissue groups.
A striking feature in the list of genes with signif-
icantly increased expression in the RAhigh tissues was the
presence of the STAT-1 gene. In addition, a number of
genes that fit in the STAT-1 activation pathway, includ-
ing potential STAT-1–inducing receptors (e.g., IL-2R,
BCR, CCR5) and STAT-1 target genes (e.g., STAT-1
itself, MMPs, GBP1, ICSBP, IP-10, caspase-1, TAP-1,
and IRF-1), were differentially expressed, which can be
viewed as one of the hallmarks of the expression pattern
of highly expressed genes in the inflammatory rheuma-
toid synovium. The expression levels of STAT-1 in the
RA patients were confirmed by real-time polymerase
chain reaction (PCR). With this technique, the differ-
ence in STAT-1 mRNA expression between the RAhigh
and RAlow groups was again seen (3.5-fold difference; P
 0.02). No significant differences in gene expression
between the RA low and OA tissues were revealed by the
SAM method using the Lymphochip.
In an independent study using synovial biopsy
material from patients with OA and RA, we could
confirm the differential expression of STAT-1 at the
protein level (Figure 5). This analysis revealed a higher
Figure 4. Discovery of rheumatoid arthritis (RA) subtypes by gene
expression profiling. Shown is hierarchical clustering of RA tissues
only. Three RA subgroups were defined according to their
gene expression profiles: a high-inflammation subgroup (RAhigh,
red branch), an intermediate-inflammation subgroup (RAinterm,
green branch), and a low-inflammation subgroup (RAlow, blue
branch). T/B T/B cell cluster; APC antigen-presenting cell cluster;
TFs  transcription/signaling factors cluster; stromal  stromal cell–
related gene clusters. See Results for description of tissue groups. See
Figure 1 for explanations.
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number of STAT-1–positive cells in the tissues of RA
patients (n  9) than in the tissues of OA patients (n 
10) (P  0.018 by t-test plus Welch correction) (Figure
5B). The STAT-1 intensity per positive cell increased
with increasing numbers of STAT-1–positive cells (r 
0.52, P  0.02) (data not shown). Positive cells were
predominantly found in the lymphoid aggregates and
intimal lining layer (Figure 5A). In analogy to the
molecular profiling data, we observed remarkable vari-
ability in STAT-1 expression in the rheumatoid synovial
biopsy specimens tested (Figure 5B).
Relationship between molecular profiles and dis-
ease parameters. The question then arose as to whether
the molecular definition of RA tissue subgroups was
associated with clinical differences between RA patients.
To address this possibility, the relationship with clinical
and demographic parameters was determined (Table 1).
No differences in clinical parameters were revealed. For
erythrocyte sedimentation rates (ESRs), a statistically
significant difference was observed between patients
whose tissues featured a fulminant inflammation signa-
ture (the RAhigh group) and those whose tissues clus-
tered in the RAlow and RAinterm groups (P  0.008 by
t-test). Thus, the molecular dissection of RA tissues
from joints that are subject to erosive disease apparently
identifies differences in systemic parameters.
DISCUSSION
OA and RA are related complex clinical entities
resulting from the interaction of multiple gene products.
The objective of this study was to generate a molecular
description of these diseases focused on immune-related
genes that would allow us to differentiate these arthrit-
ides, subclassify RA as a heterogeneous disease, unravel
novel aspects of RA pathogenesis, and identify genes
and biologic processes not hitherto associated with this
disease. We identified molecularly distinct forms of RA
synovium, which had expression patterns that suggested
the occurrence of different pathologic mechanisms. One
RA type expressed genes characteristic of ongoing in-
flammation, while another type expressed genes indica-
tive of an increased tissue remodeling activity reminis-
cent of the profile seen in OA tissues.
Previously, Zanders et al (17) applied high-
density cDNA arrays printed on nylon membranes.
Their analysis revealed an overall increased expression
of inflammation-related genes in rheumatoid tissue
compared with normal synovium. Since those investiga-
tors performed an analysis on pooled RA synovial tissue
compared with pooled tissue from healthy controls, their
strategy excluded an evaluation of disease heterogeneity
and might therefore have diluted differences that existed
between tissues. We chose to profile gene expression in
whole synovial tissue, which comprises heterogeneous
cell types, with the specific purpose of gaining a global
representative insight into the molecular changes asso-
ciated with OA and RA (19,33,34).
Gene expression profiling of synovial membranes
of RA and OA patients revealed a spectrum of expres-
sion that ranged from an extensive inflammatory expres-
sion signature, indicative of massive infiltration of mono-
nuclear cells, to an ECM remodeling activity, indicative
of fibrosis that is accompanied by a scarce cellular
infiltrate. What is also clear from the cluster analysis is
that all but one of the OA tissues formed a homoge-
neous group with a gene expression profile that reflected
the fibrosis arm of the spectrum. These data are in
accordance with data from histologic studies that sug-
gested that the amount of fibrosis was inversely propor-
tional to the extent of the cellular infiltrate, and that
fibrosis was mainly encountered in OA tissue (22). In the
present study, we have identified a class of genes
grouped in the stromal cell gene clusters that are likely
to be implicated in tissue fibrosis in OA.
The RA synovia showed considerable heterogen-
eity in gene expression, indicating the existence of
molecularly distinct classes of rheumatoid synovium.
The T/B cell and APC signatures were prominent fea-
tures in the RAhigh tissues. These features correlate with
increased expression of T and B cell genes, genes
involved in inflammation, and high expression of major
histocompatibility complex (MHC) class I and class II
genes as hallmarks of the activation of the immune
system (33,35–37).
Although it is not a priori evident whether mea-
surements of gene expression levels either reflect genu-
ine gene activity or are representative of the cellular
composition, it is most likely that these discrete, cell-
specific gene expression patterns at least indicated the
abundant presence of immune cells such as T and B cells
in the RAhigh tissues. The presence of such characteristic
cell-specific gene clusters correlates with reported data
on infiltration of mononuclear cells into the rheumatoid
synovium (6,19,33,34). Overexpression of these gene
clusters is consistent with increased ESRs. Another class
(RAlow) showed high expression of stromal cell genes
that is accompanied by a profile of a scarce cellular
infiltrate. An intermediate class (RAinterm) displayed a
gene expression profile that included both genetic pro-
files. These results indicate the existence of extreme
differences in cellular infiltration between RA synovial
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Table 2. Comparison of statistical differences in gene expression between the RAhigh and the RAlow subgroups and between the RAhigh subgroup
and the OA group*
RAhigh vs. RAlow RAhigh vs. OA
Fold difference, mean  SEM† q, mean† Fold difference, mean  SEM† q, mean†
B cells/T cells
CD79A  BCR  chain 3.24  0.16 0.33 3.22  0.87 0.20
CD75 2.60 0.33 2.89 0.15
NG7 25.73 0.33 12.25 0.15
CD27 2.21  0.16 0.33 1.86  0.19 0.26
SLP65  BLNK, B cell linker 2.20 0.33 1.82 0.36
Immunoglobulins (n  39) 17.44  1.83 0.35 12.49  2.00 0.18
CD21 4.52  3.02 1.36 3.52  2.02 0.22
PBEF, pre–B cell colony-enhancing factor 1.83 0.37 3.63 1.32  0.23 15.97
CD9 5.17  4.23 3.65 5.07  4.35 1.62
CD20 2.00  0.08 3.72 3.48  0.83 0.26
CD69 1.45  0.31 4.93 1.23  0.25 6.64
NK4 1.49  0.09 4.94 2.81  0.17 0.15
CD3 epsilon 1.71 4.95 2.02 0.36
CD79B  BCR  chain 1.93  0.22 5.21 1.94 0.20 2.01
T cell receptor gamma chain 1.39  0.37 11.93 2.08 0.15
CD37 1.00  0.14 19.88 1.67  0.19 1.10
T cell receptor beta chain 1.18  0.15 26.84 1.35  0.31 3.59
CD48 0.99  0.12 40.24 1.84 0.60 2.78
Proteases
Caspase-1 5.75  3.97 0.59 3.16  1.24 1.41
MMP1 5.11 1.06 13.12 0.15
MMP3 5.50 1.79 17.16 0.15
Cathepsin L 1.84  0.15 4.51 1.91  0.09 1.18
Disintegrin protease 1.80 7.78 2.00 1.63
Antigen presentation
PSMB9 2.26  0.08 0.33 2.23  0.08 0.15
CD14 1.90 0.95 2.33 0.15
CD74 1.76  0.18 1.64 2.65  0.40 0.26
TAP-1  peptide transporter 1.90 1.79 2.66 0.15
HLA class II (n  37, 51) 1.75  0.05 2.52 2.71  0.13 0.21
B2M, beta-2-microglobulin 1.76  0.34 2.83 1.81  0.47 1.36
HLA class I (n  12, 14) 1.59  0.09 3.91 2.08  0.15 0.30
Similar to TAP2E 2.23 4.46 1.96 4.46
Chemokines/receptors
BLC  BCA-1 3.30 0.33 6.71 0.15
FLMP receptor 1.74 1.06 2.21 0.15
SDF1 1.90 1.57 1.14 38.68
CXCR4 1.58  0.15 2.26 2.75  0.08 0.15
IP-10 1.88  0.73 2.78 2.12  1.24 2.58
RANTES 1.39  0.13 11.38 1.54  0.41 3.74
CCR5 1.40 13.37 2.15 0.15
CCR1 1.27 13.37 1.48 1.91
Oxidative stress
NCF1 1.97  0.29 2.66 2.13  0.34 1.19
CYBB, cytochrome b-245 beta 1.72  0.31 7.74 2.01 0.48 1.30
HSPC022 protein 1.30 21.86 2.35 0.26 0.15
Transcription factors
AA805683 4.60  0.06 0.33 3.38  0.03 0.15
c-fos 3.65  0.61 0.47 1.68  0.28 3.99
RAR-alpha-1 1.93 0.49 0.84 2.09 0.15
IRF-1 1.80  0.22 1.14 1.81  0.21 1.05
STAT-1 2.77  1.13 1.54 2.80  0.54 0.43
JunB 1.91  0.32 1.85 1.49  0.40 5.38
Staf50 1.77  0.23 2.98 1.83  0.18 0.99
ICSBP1 1.44  0.10 12.16 2.38 0.01 0.15
SREBF2 1.38  0.12 13.00 1.60 0.36 3.07
GMEB2 1.30 18.11 2.01 0.28
Signal transduction
TEK tyrosine kinase 14.53 0.33 10.33 0.15
PPP1R2, protein phosphatase inhibitor 2 2.50 0.33 1.99 0.15
FYB, FYN-binding protein 1.65  0.43 2.55 1.84  0.73 2.30
GSbeta 3.76  2.71 3.82 4.10  3.02 2.55
HCLS1 1.66  0.20 3.99 1.80  0.21 0.84
RKAG1 6.67  5.67 6.85 11.30 0.15
SIP-110 3.03 1.90 7.70 2.01  0.65 2.85
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Table 2. (Cont’d)
RAhigh vs. RAlow RAhigh vs. OA
Fold difference, mean  SEM† q, mean† Fold difference, mean  SEM† q, mean†
G-protein signaling
GBP1 1.75 0.11 1.20 2.07  0.11 0.19
ARL7 1.64  0.45 2.83 2.12  0.19 0.15
DOCK2 1.58 0.02 4.70 1.96  0.08 0.15
RHO GDI 2 1.41  0.15 4.76 1.70  0.23 0.66
RGS1 1.48 0.14 6.45 1.94  0.19 0.23
PTPN6 1.43 0.12 12.45 2.11  0.20 0.60
Adhesion
CD50 2.18  0.38 1.10 2.07  0.01 0.23
PSCD1 1.38 0.14 7.58 1.54  0.14 2.59
PTPRK 1.68 9.34 2.05 2.71
L-selectin 1.61 13.37 2.05 0.77
CD18 1.01 0.08 25.60 2.12  0.29 0.39
CD103 1.12 0.13 25.87 1.79  0.25 1.91
Cytokines/receptors
IL-6R 1.98  0.24 0.33 1.33  0.22 5.72
IL-15 1.56 0.53 1.32  0.12 5.28
CSF-1R 2.01 2.12 1.75 5.78
IL10R 1.70  0.12 2.80 2.00  0.30 0.38
GM-CSFR 1.58  0.12 4.44 2.02  0.32 0.54
IL-2R 1.48  0.14 7.77 1.76 0.25 1.59
IL-6R 1.11 31.91 11.43  10.13 0.83
Cell proliferation
GAPCenA 3.43 0.09 0.33 1.89  0.23 0.71
BTG2 2.46 0.39 0.76 1.77  0.16 0.55
ISG20 1.63  0.15 2.80 1.57  0.09 1.25
Cell surface molecules
FcRI-alpha 2.34 0.33 2.50 0.15
CD45 2.03 0.22 0.95 3.07  0.48 0.23
CD53 1.67 0.21 3.76 1.83  0.47 1.53
CD32 1.46 0.17 6.60 1.85  0.23 0.85
Miscellaneous
BCKDHA 2.22 0.33 2.10 0.15
Centaurin beta 2 3.52 0.33 2.49 0.15
Bone morphogenetic protein 6 2.30 0.33 1.41 3.87
Similar to TBC1 2.28 0.33 1.98 0.28
SEL1L 1.99–0.15 0.33 1.75  0.11 0.34
FGFR2, fibroblast growth factor
receptor 2
2.09 0.33 1.68 1.63
MCL1, myeloid cell leukemia sequence 1 2.00 0.11 0.68 1.55  0.15 2.22
RIZ 2.88 1.32 0.77 3.19  1.88 0.88
HNRPH1, heterogeneous nuclear
ribonucleoprotein H1
1.81  0.26 0.97 1.74  0.22 0.35
Apolipoprotein L3 2.13  0.07 1.31 1.94  0.07 0.87
HSP70 1.81 0.25 1.62 1.81  0.32 0.83
AIM2 1.81 0.26 1.76 2.19  0.80 1.02
WASPIP 1.73 0.24 2.22 1.84  0.26 0.53
MDS019 phorbolin-like protein 1.73 0.14 2.27 2.12  0.22 0.42
CHI3L2, chitinase 3-like 2 3.41 0.29 2.75 1.53  0.17 42.74
ALOX5 1.68 0.19 3.31 2.42  0.04 0.15
LLT1 C-type lectin 2.77 3.66 1.88 13.95
EVI2B 1.80 0.20 4.26 2.39  0.16 0.15
LCP1 1.28 0.04 7.04 2.18  0.20 0.19
PTB-4 2.18 1.43 12.34 4.37  3.90 3.06
CORO1A 1.50 0.25 12.70 1.84  0.33 2.03
MFNG 1.34 0.30 14.40 1.73  0.51 3.08
Gamma-parvin 1.06 14.49 1.61  0.21 2.77
SRM3000 1.29 0.02 16.90 1.85  0.21 0.83
BIN2 1.39 0.02 16.93 1.90  0.32 0.50
* Statistical analysis on microarray data was performed using the Significance Analysis of Microarrays method (online at http://www-
stat.stanford.edu/tibs/SAM). The q value (see ref. 48) is the lowest false discovery rate at which a gene is called significant. It is similar to the
familiar P value, adapted to the analysis of a large number of genes. A q value of 5 for a particular gene means that at a false discovery rate of 5%,
this gene will still be listed as significant. In this table, mean q values 5 (in boldface) are considered significant. See Table 1 for description of
rheumatoid arthritis (RA) tissue subgroups and for definitions. OA  osteoarthritis.
† If a gene was spotted more than once, the mean  SEM values of the fold change of distinct complementary DNAs representing the same gene
were calculated and presented, including their geometric mean q values.
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tissues. The combined analysis of cellular complexity,
together with a comprehensive overview of the concom-
itant gene expression profile, provides opportunities for
further research.
The expression data suggest involvement of two
distinct disease processes in rheumatoid pathogenesis,
which is in accordance with data from several studies
that indicated biologic heterogeneity in RA (6,19,33,34).
The existence of a spectrum of molecular variation that
may be translated into distinct pathophysiologic mecha-
nisms at the site of the lesion would fit a model proposed
by Firestein and Zvaifler (3), who suggested two pro-
cesses in the destruction stage of RA. One is a T
cell–mediated process that might progress to a T cell–
independent process that is centered on autonomous
fibroblast-like synoviocyte (FLS) aggression. This model
is further supported by data from several animal models
in which FLS acquire a degree of independence from T
cell control in late destructive disease, implying that an
autonomous role of stromal cell elements is responsible
for tissue destruction. Hence, both the T cell–involved
and the autonomous stromal cell form of disease might
drive destruction of bone and cartilage.
Clearly, the molecular dissection of the rheuma-
toid synovium allows for a biologic interpretation of
processes that take place in the tissues. Among the genes
that were significantly increased in the RAhigh tissue
group were genes indicative of an activated STAT-1
pathway (i.e., STAT-1 itself and a number of genes that
are dependent on STAT-1 for their transcription). The
induction of these genes is known to occur via the
activation of janus-activated kinases, resulting in the
phosphorylation and subsequent translocation of spe-
cific STAT proteins to the nucleus (38), where it directly
activates transcription of target genes including STAT-1
itself (38,39). We confirmed the differential STAT-1
expression by real-time PCR. Moreover, heterogeneity
in STAT-1 protein expression was also found upon
immunohistologic analysis of specimens from RA pa-
tients with active disease. These findings are in accor-
dance with recently reported data on increased STAT-1
protein expression in RA synovial tissues obtained dur-
ing joint replacement surgery, compared with normal
tissues (40).
Gene expression studies on macrophages and
fibroblasts from wild-type and STAT-1–deficient mice
revealed 66 genes that were part of the interferon-
(IFN)–induced STAT-1–dependent genetic profile
(41,42). A number of the genes from our analysis that
met our filtering criteria corresponded to the STAT-1–
dependent genes mentioned in those reports. This num-
Figure 5. Detection of signal transducer and activator of transcription
1 (STAT-1) in synovial tissue sections derived from patients with
rheumatoid arthritis (RA) and osteoarthritis (OA). A, Immuno-
histochemical staining of STAT-1 in RA and OA synovial tissue
sections. L  intimal lining layer; A  lymphoid aggregates (original
magnification  200). B, Increased STAT-1 expression in RA com-
pared with OA synovial biopsy specimens. Bars show the mean
percentage of STAT-1–positive cells per total number of nuclei.
In A, the RA synovial tissue section was obtained from a patient
with 77.6% STAT-1–positive cells, while the OA synovial tissue
section was obtained from a patient with 10.9% STAT-1–positive
cells.
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ber will probably increase when purified cells are used as
the source for gene expression profiling.
Activation of STAT-1 is involved in MHC class
I–restricted antigen presentation through up-regulation
of TAP-1, and it indirectly up-regulates MHC class II
genes (Table 2). Other genes induced by STAT-1, such
as MMPs, caspase-1, IP-10, IRF-1, GBP1, and ICSBP,
are also selectively up-regulated in RAhigh tissue (Table
2). Although not definitely proven, this suggests that
STAT-1 may be responsible for the activation of these
genes.
The STAT-1–dependent chemokine IP-10 at-
tracts T cells and monocytes, which suggests that
STAT-1 activation may also be partly responsible for the
inflammatory cell influx. The expression of STAT-1
coincided with increased expression of genes encoding
receptors activating STAT pathways (e.g., IL-6R, IL-
2R, CCR5, and BCR). The data indicated that in
addition to the increase in the number of STAT-1–
positive cells, the intensity per cell was increased. Hence,
conditions in the inflamed joint contribute to an increase
per cell. A likely explanation would be that increased
STAT-1 expression is a consequence of increased cyto-
kine activity in the synovium. STAT-1 can be activated
by a number of cytokines, including the type I and type
II IFNs, interleukin-6 (IL-6), IL-9, IL-11, oncostatin M,
and leukemia inhibitory factor, and by the chemokines
RANTES and macrophage inflammatory protein 1
(43,44). Although the prototype STAT-1–inducing cyto-
kine IFN is barely detectable in the rheumatoid syno-
vium, low doses of IFN are able to sensitize the
STAT-1 activation pathway, which has been shown to
yield increased STAT-1 activity upon subsequent activa-
tion (40).
Obviously, the various cytokines present in the
RA synovium create a complex situation with simulta-
neous activation of multiple signaling pathways that may
influence STAT-1 signaling (e.g., STAT-1 activation may
negatively influence the tumor necrosis factor  and
IFN/ signaling pathways [for review, see ref. 45]). The
importance of STAT activation in arthritis has been
demonstrated in an animal model; periarticular admin-
istration of adenoviral suppressor of cytokine signaling 3
dramatically reduced the severity of collagen-induced
arthritis and synovial IgG production (46). These find-
ings justify further research on the cell-specific expres-
sion of STAT signaling components, including the acti-
vating receptors and their ligands, which is crucial for
our understanding of the molecular and cellular events
that take place in the effector phase.
The abundant expression of specific chemokines
and their receptors revives data from studies proposing
that cell-specific expression of selective chemokines and
their cognate receptors is involved in the accumulation
of mononuclear cells in the inflamed synovium (47). In
the RAhigh tissues, we found significantly higher expres-
sion levels of the chemokine RANTES (and its receptors
CCR1 and CCR5), which activates STAT-1. The higher
expression of stromal cell–derived factor 1 plus its ligand
CXC receptor 4 may account for the attraction and
retention of T cells, B cells, and monocyte/macrophages,
while the expression of B lymphocyte chemoattractant
explains the increased B cell activity in the RAhigh
synovial tissue with greatly enhanced production of
immunoglobulins.
What does the molecular classification of RA
patients into the subgroups RAhigh and RAlow mean in
clinical terms? Based on the expression profiles, it
suggests that different pathologic mechanisms may con-
tribute to disease. However, we realize that the design of
this study does not allow any firm conclusions to be
drawn concerning the clinical parameters associated
with the molecular phenotype. Further studies, which
are necessary to address this issue, may provide a means
to dissect and analyze the rheumatoid synovium of these
patients and perform a thorough clinical association
study based on molecular variation among patients.
Moreover, since the molecular differences most likely
reflect distinct pathophysiologic processes underlying
disease, it is tempting to speculate that these differences
predict individual responsiveness to treatment. Hence,
the molecular stratification of patients may be helpful in
assembling homogeneous populations of patients, which
will improve the likelihood of observing efficacy in
clinical trials.
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Fibroblast-Like Synoviocytes Derived From Patients With
Rheumatoid Arthritis Show the Imprint of
Synovial Tissue Heterogeneity
Evidence of a Link Between an Increased Myofibroblast-Like Phenotype and
High-Inflammation Synovitis
Pia V. Kasperkovitz,1 Trieneke C. G. Timmer,1 Tom J. Smeets,2 Nicolette L. Verbeet,1
Paul P. Tak,2 Lisa G. M. van Baarsen,1 Belinda Baltus,1 Tom W. J. Huizinga,3
Elsbet Pieterman,3 Mike Fero,4 Gary S. Firestein,5 Tineke C. T. M. van der Pouw Kraan,1
and Cornelis L. Verweij1
Objective. Given the heterogeneity of gene expres-
sion patterns and cellular distribution between rheuma-
toid arthritis (RA) synovial tissues, we sought to deter-
mine whether this variability was also reflected at the
level of the fibroblast-like synoviocyte (FLS) cultured
from RA synovial tissues.
Methods. Gene expression profiles in FLS cul-
tured from synovial tissues obtained from 19 RA pa-
tients were analyzed using complementary DNA mi-
croarrays and hierarchical cluster analysis. To validate
the subclassification, we performed prediction analysis
and principal components analysis. Genes that differed
significantly in their expression between FLS cultures
were selected using Statistical Analysis of Microarrays
software. Real-time quantitative polymerase chain reac-
tion was performed to validate the microarray data.
Immunocytochemistry was applied to study the expres-
sion of the genes of interest in FLS and synovial tissues.
Results. Hierarchical clustering identified 2 main
groups of FLS characterized by distinctive gene expres-
sion profiles. FLS from high-inflammation synovial
tissues revealed increased expression of a transforming
growth factor /activin A–inducible gene profile that is
characteristic of myofibroblasts, a cell type considered
to be involved in wound healing, whereas increased
production of growth factor (insulin-like growth factor
2/insulin-like growth factor binding protein 5) appeared
to constitute a characteristic feature of FLS derived
from low-inflammation synovial tissues. The molecular
feature that defines the myofibroblast-like phenotype
was reflected as an increased proportion of
myofibroblast-like cells in the heterogeneous FLS pop-
ulation. Myofibroblast-like cells were also found upon
immunohistochemical analysis of synovial tissue.
Conclusion. Our findings support the notion that
heterogeneity between synovial tissues is reflected in
FLS as a stable trait, and provide evidence of a possible
link between the behavior of FLS and the inflammation
status of RA synovium.
Rheumatoid arthritis (RA) is a chronic inflam-
matory joint disease of unknown etiology that affects the
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synovial tissue in various joints. There is growing evi-
dence that RA is a heterogeneous disease. This is
reflected by marked variability in clinical presentation,
features of synovial inflammation (1–4), and responsive-
ness to different modes of antirheumatic treatment (5).
Accordingly, we demonstrated a high degree of hetero-
geneity upon large-scale analysis of gene expression in
synovial tissues from RA patients, which led to the
identification of 2 major subclasses of RA tissues (6,7).
One phenotype showed features of ongoing inflamma-
tory activity, whereas the other showed a low-
inflammation gene expression pattern and elevated ex-
pression of genes that play a role in stromal cell biology.
These data suggest that distinct pathogenic mechanisms
might be operational in clinically diagnosed RA.
Current evidence indicates that fibroblast-like
synoviocytes (FLS) in the rheumatoid synovium, which
constitute the synovial lining and are one of the principal
cells involved in pannus formation, are key players in the
destruction of cartilage and bone in the joint. These FLS
have been shown to proliferate in an anchorage-
independent manner, to lack contact inhibition, and to
constitutively express cytokines, oncogenes, and cell
cycle proteins, which is indicative of transformation
(8–10). There is evidence indicating that the trans-
formed phenotype of rheumatoid FLS constitutes stable
long-term alterations that are maintained in the absence
of an environmental stimulus (11,12).
It is now generally accepted that fibroblasts, as
the principal cells of stromal tissue, constitute a diverse
population of distinctly differentiated cell types that are
dependent on topography and local environment (13).
This gives rise to the hypothesis that heterogeneity at the
synovial tissue level might be associated with a specific
phenotypic characteristic of the resident fibroblast. In
this concept, synovial fibroblasts may become activated
or (de)differentiated in the disease process, which may
have profound effects on overall gene expression pat-
terns, with critical implications for matrix destruction,
tissue remodeling, and cellular interactions.
Given the heterogeneity in gene expression pat-
terns and cellular distribution between rheumatoid sy-
novium samples (1–4,6,7), we determined whether vari-
ability is also reflected at the level of FLS. We used
complementary DNA (cDNA) microarrays representing
24,000 human genes to analyze gene expression pat-
terns in FLS cultured from affected synovial tissue
obtained from 19 RA patients. We identified subgroups
of FLS that showed differences in their gene expression
profiles. Most strikingly, we observed that the molecular
classification of rheumatoid FLS matched the molecular
subclassification of the entire synovial tissue from which
they were derived. Detailed analysis of differentially
expressed genes revealed a correlation between inflam-
matory synovitis and the occurrence of myofibroblast-
like FLS.
PATIENTS AND METHODS
Patients. Synovial tissues were obtained periopera-
tively from patients who fulfilled the American College of
Rheumatology (formerly, the American Rheumatism Associ-
ation) 1987 revised criteria for RA (14). All patients gave their
informed consent, and the study protocol was approved by the
Medical Ethics Committee. Clinical and demographic data for
Table 1. Demographic and clinical data of the rheumatoid arthritis patients whose FLS were studied for gene expression
profiling*
FLS group
Total (n  19) Group I (n  9) Group IIa (n  6) Group IIb (n  4)
Demographic features
Age, mean (range) years 58 (22–80) 61 (44–80) 47 (22–68) 66 (47–76)
Sex, no. female/male 14/3 6/2 4/1 4/0
Disease duration, mean (range) years 13 (3–31) 14 (4–20) 14 (4–31) 8 (3–11)
Laboratory variables
ESR, mean (range) mm/hour 33 (7–63) 30 (15–51) 33 (7–57) 42 (21–63)
Leukocytes, mean (range), 106/ml 6.8 (0.0–10.5) 8.0 (6.2–9.1) 9.2 (7.7–10.5) 5.2 (5.1–5.4)
Erosive disease, % 100 100 100 100
Rheumatoid factor positive, % 82 75 80 100
Medications
DMARDs, % 100 100 100 100
Prednisone, % 18 25 0 25
* Except where indicated otherwise, values are the number (%) of patients. For 2 of the patients (1 in subgroup I and 1 in
subgroup IIa), no clinical data could be retrieved. FLS  fibroblast-like synoviocytes; ESR  erythrocyte sedimentation rate;
DMARDs  disease-modifying antirheumatic drugs.
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the 19 patients from whom FLS were cultured and extensively
studied using cDNA microarrays are summarized in Table 1.
Isolation of RA FLS. Synovial cells were obtained by
finely mincing freshly isolated synovial tissue, followed by
treatment with collagenase A for 2 hours at 37°C. FLS were
allowed to adhere to tissue culture plates, and nonadherent
cells were removed. FLS were grown to subconfluence (70%)
in culture flasks containing Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal calf serum
(FCS), and cells were routinely split. Experiments were per-
formed using FLS from the fourth to sixth passages. At this
time, there were 2% contaminating lymphocytes, natural
killer cells, and macrophages.
Microarray procedures. Messenger RNA (mRNA)
was isolated from cultured FLS using a Fast Track 2.0 kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. The DNA microarray procedure was performed
essentially as described previously (15). Fluorescent cDNA
probes were prepared from 1 g of experimental mRNA by
oligo(dT)-primed polymerization using Superscript II reverse
transcriptase in the presence of Cy5-labeled dCTP, as de-
scribed elsewhere (online at http://cmgm.stanford.edu/pbrown/
protocols.html). A common reference mRNA sample, consist-
ing of a mixture of mRNA isolated from 11 different cell lines
(16), was labeled with Cy3. The Cy5- and Cy3-labeled cDNA
were pooled and hybridized to Stanford Human Microarrays
that were printed at Stanford University Medical School.
Microarrays contained 24,000 cDNA clones, representing
17,400 genes.
Analysis of data. Analysis of microarray gene expres-
sion data was performed as described previously (6,17), except
that we used genes with an expression level 1.6 (instead of
1.4) times the background level. The use of a common
reference mRNA probe allows the comparison of relative
levels of expression across samples, as described previously
(16). Global normalization was applied to all cDNA spots to
adjust the red signal to the green signal, such that the average
ratio of all spots became 1. The red spot intensity and red local
background signal were divided by a normalization factor to
yield the normalized intensities for the red signal. To obtain
the normalization factor, the average natural log of the
background-subtracted red:green intensity ratio was calcu-
lated. The normalization value was obtained by raising e to
the average ln ratio (for details, see http://genome-www5.
stanford.edu/help/results_normalization.shtml#default). For all
further analyses, log2 red:green normalized ratios were used;
technically adequate data were available in at least 80% of the
experiments.
We used Cluster software (18) (online at http://
rana.lbl.gov/EisenSoftware.htm) to select genes with differen-
tial expression across the arrays. Genes that showed at least a
2-fold difference from the median expression level in at least 4
FLS samples or at least 2 FLS samples (see below) were
selected. Unsupervised hierarchical clustering was used for
FLS subclassification. The results were visualized with TreeView
software (online at http://rana.lbl.gov/EisenSoftware.htm).
Statistical analysis of the microarray data was per-
formed using Significance Analysis of Microarrays (SAM)
software (19) (available at: http://www-stat.stanford.edu/tibs/
SAM). SAM corrects for multiple testing by providing a false
discovery rate (q value), which is estimated using randomly
permuted data and which serves to indicate the statistical
significance of the genes on positively significant and nega-
tively significant gene lists. The determination of subclasses, as
shown in Figure 1, was used for a supervised analysis by
Figure 1. Hierarchical clustering of the expression of 484 cDNA in
fibroblast-like synoviocytes (FLS) from 19 patients with rheumatoid
arthritis (RA). Each row represents a single gene; each column
represents an individual FLS sample. Red bands indicate relative
expression greater than the median of all samples (ratio 1), green
bands indicate an expression level lower than the median (ratio 1),
black bands indicate equal expression levels (ratio near 1), and gray
bands indicate missing or excluded data. The intensity of each color
indicates the magnitude of the deviation from the median (see scale at
bottom). Bars to the right (labeled A, B, C) identify the locations of a
category of clustered genes with a related expression profile. We
selected genes whose transcripts varied in abundance by at least 2-fold
from their median level in at least 4 FLS samples. Pearson’s correla-
tion coefficient for the 2 main subclasses was r  –0.67; correlation
coefficients for the other nodes varied between r  0.09 and r  0.56.
LU  Leiden University; LB  Leydenburg Hospital.
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Multiclass SAM software (applied to all genes) to identify
genes showing a significantly different level of expression
between the 3 subclasses. Genes with a q value less than 5%
were considered significant (657 cDNA).
To determine which genes also showed at least a 2-fold
difference in expression in 1 subclass versus the remaining 2
subclasses, we used 2-class unpaired SAM analysis. Genes that
fulfilled both criteria are shown in Figure 2. Unsupervised
clustering of all 657 significant genes with a false discovery rate
of 5% (without a fold-change cutoff) resulted in exactly the
same subclassification of FLS (data not shown). Complete data
can be seen at the Stanford Microarray Database Web site (20)
(online at http://genome-www.stanford.edu/microarray).
Real-time quantitative polymerase chain reaction
(PCR). Total RNA was isolated using the RNeasy Miniprep kit
(Qiagen, Basel, Switzerland) and transcribed into cDNA using
the RevertAid First-Strand cDNA Synthesis kit (MBI Fermen-
tas, St. Leon-Rot, Germany) according to the manufacturers’
instructions. Primers were designed using Primer Express
software (PE Applied Biosystems, Foster City, CA). PCR
amplicons crossed an intron–exon boundary, assuring that they
were specific for cDNA. Real-time quantitative PCR was
performed on an ABI Prism 7900 Sequence Detection System
(PE Applied Biosystems). The reaction mixture was composed
of SYBR Green master mixture, 250 or 500 nM of each primer
and cDNA in a total volume of 20 l, according to the
manufacturer’s instructions. After real-time analysis, a melting
curve was established for all samples to ensure specific ampli-
fication. For each primer set, a negative control without
template DNA was included on each plate. A standard curve
was constructed for each gene to correct for different primer
efficiencies. Gene expression levels were expressed relative to
GAPDH.
Immunocytochemistry. Cells were transferred to Lab-
Tek II chamber slides (Nalge Nunc, Rochester, NY) at a
density of 5  103/well and cultured in HEPES buffered
DMEM supplemented with 10% FBS and 1% penicillin/
streptomycin/glutamine. Cells were fixed in methanol for 10
minutes and maintained at –20°C. After air-drying, the cells
were washed in phosphate buffered saline (PBS) containing
1% bovine serum albumin (BSA) and then incubated in 10%
normal donkey serum–PBS for 20 minutes to saturate nonspe-
cific binding sites. The cells were washed 3 times with 1%
BSA–PBS after each of the following steps.
All antibodies were diluted to their optimal concentra-
tion in 1% BSA–PBS. Anti–-smooth muscle actin (anti–-
SMA; DakoCytomation, Carpinteria, CA) and anti–-actin
(Santa Cruz Biotechnology, Santa Cruz, CA) were applied to
each well, and the wells were incubated for 1 hour. A negative
control was performed by incubating cells with 1% BSA–PBS
in the presence of the secondary antibodies after 3 washes in
PBS for 5 minutes each. Nuclei were stained with Hoechst
33342 stain. The slides were mounted with mounting medium
containing 15% Vinol 205, 30% glycerol, and 0.1% sodium
azide in PBS and examined by fluorescence microscopy.
Immunohistochemistry. Frozen synovial tissue sec-
tions were obtained and immunostained as described previ-
ously (21) using anti–-SMA. Biotinylated tyramine (Perkin
Elmer Life Sciences, Boston, MA) was used for amplification.
Statistical analysis. To test for significant similarities
in the classification of FLS and corresponding synovial tissues,
we used Fisher’s exact test. After testing for normality, Pear-
son’s correlation coefficient was calculated to determine the
degree of correlation between clusters (expression ratios of all
genes within a cluster were averaged per tissue sample or FLS
sample), between gene expression levels as measured by
microarray analysis and by real-time quantitative PCR, and
between gene expression levels as measured by real-time
quantitative PCR and cell counts obtained by semiquantitative
Figure 2. Cluster diagram of the genes expressed at significantly
different levels in the 3 classes (I, IIa, and IIb) of fibroblast-like
synoviocytes (FLS) from rheumatoid arthritis (RA) patients. The
Significance Analysis of Microarrays algorithm was used to select
genes showing significantly different levels of expression between the 3
FLS classes, with a false discovery rate of 5% (q  5%). The
correlated expression of these genes is shown after hierarchical
clustering. Pearson’s correlation coefficient between the 2 main sub-
classes was r  –0.79. The correlation coefficients for the other nodes
varied between r  0.12 and r  0.68. Representative genes with
functions in the insulin-like growth factor 2 pathway, complement
activation, oxidative stress, and tumor-like properties in FLS class I,
and genes representing the transforming growth factor  pathway in
FLS class IIb are indicated at the right. LB  Leydenburg Hospital;
LU  Leiden University.
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immunocytochemistry analysis. Statistical analysis was per-
formed using GraphPad Prism software (GraphPad Software,
San Diego, CA).
RESULTS
Gene expression patterns of FLS derived from
different RA patients. We characterized gene expression
profiles in cultured FLS from 19 patients with RA by the
use of cDNA microarrays. We selected a total of 484
genes whose expression varied at least 2-fold from the
median values in at least 4 of the 19 samples. Gene
expression data from these cell cultures were examined
in an unsupervised manner using hierarchical clustering
(18).
The clustering algorithm identified 2 main groups
of FLS samples, designated group I and group II (Figure
1). Within group II samples, 2 subbranches, IIa and IIb,
were apparent. To indicate the validity of the subclassi-
fication, we performed a prediction analysis using Pre-
diction Analysis of Microarrays software (22). In a
10-fold cross-validation analysis with a high prediction
strength, we were able to correctly predict the 3 distinc-
tive FLS subclasses for all 19 samples. For 18 of the 19
samples, the cross-validated prediction probabilities
were 0.9 for the correct class and 0.1 for the other 2
classes. In addition, we also performed a principal
components analysis (using Spotfire software; online at
http://www.spotfire.com) to select the genes that contrib-
uted most to the first 3 principal components. Unsuper-
vised hierarchical clustering of these genes (207 cDNA)
resulted in the identical subclassification of FLS into 3
groups (data not shown).
Significance analysis of genes differentially ex-
pressed between FLS subgroups. The most pronounced
differences between the FLS groups were among 3
clusters of coordinately expressed genes, designated A,
B, and C (Figure 1). To provide insight into the different
biologic properties between the respective FLS popula-
tions, we selected genes that differed significantly in
their expression (q 5%) between the FLS (sub)groups,
using the Multiclass SAM algorithm (19) (Figure 2). For
biologic interpretation of the differentially expressed
genes, we focused on genes that showed at least a 2-fold
higher expression in either FLS group I, group II, group
IIa, or group IIb compared with the remaining samples.
We observed 218 highly informative unique genes that
fulfilled these criteria, including 205 known genes (Fig-
ure 2) (Data obtained from the significance analysis of
genes differentially expressed between FLS subgroups
are available upon request from the corresponding
author.) The levels of expression of a number of discrim-
inating genes were confirmed by real-time quantitative
PCR (Table 2).
For group I FLS, we observed a significant in-
crease in insulin-like growth factor binding protein 5
(IGFBP-5; 3.8-fold) and insulin-like growth factor 2
(IGF-2; 3.4-fold) gene expression. IGF-2 is a growth
factor that has a broad range of physiologic functions,
including stimulation of cell division, differentiation,
migration, and growth, inhibition of apoptosis, and
regulation of transcription (23,24). IGFBP-5 functions
as a carrier protein for IGFs and is able to regulate cell
activity independently of IGFs in various ways. In-
creased expression of these genes strongly supports the
involvement of autocrine signaling in the proliferation
and survival of FLS.
Other biologic themes featured by genes that are
significantly increased in type I FLS are those involved
in the alternative pathway of complement activation
(factor H, C2 complement, clusterin, and C1r-like pro-
teinase) and those involved in oxidative stress (glutathi-
one S-transferase M1 and M4, glutathione peroxidase 4,
selenoprotein P plasma 1, and malic enzyme 3). This
cluster also contains the oncogenes MAF (v-maf muscu-
loaponeurotic fibrosarcoma oncogene homolog [avian]),
NBL1 (neuroblastoma, suppression of tumorigenicity),
MYB (v-myb myeloblastosis viral oncogene homolog
[avian]), TEM8 (tumor endothelial marker 8), and
RAB31 (member of the Ras oncogene family), which
may suggest tumor-like features.
One of the most intriguing findings was the
marked increase in several genes that are involved in the
transforming growth factor  (TGF) pathway in group
II FLS. Among these genes were the gene for activin A
(A) as a potential agonist and a number of response
genes, such as SERPINE1, COL4A1 (type IV collagen
1 chain), IER3 (immediate early response 3), and
TAGLN (transgelin) (25). The TGF pathway signature
was even more pronounced in FLS subgroup IIb. In
addition to the aforementioned genes, these FLS display
Table 2. Correlation between mRNA expression levels measured by
microarray analysis and by real-time quantitative polymerase chain
reaction
Gene Pearson’s r P
Insulin-like growth factor 2 0.98 0.0001
Insulin-like growth factor binding protein 5 0.85 0.008
Activin A 0.75 0.03
Matrix metalloproteinase 3 0.82 0.01
Vascular cell adhesion molecule 1 0.76 0.03
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Figure 3. Expression of -smooth muscle actin (-SMA) in cultured fibroblast-like synoviocytes (FLS)
from rheumatoid arthritis (RA) patients. Immunocytochemistry was performed using antibodies to detect
-actin (green) and -SMA (red). A, FLS from representative patients with a low proportion of
-SMA–positive cells (LU-25) and a high proportion of -SMA–positive cells (LB-21). Synovial tissue and
FLS subclasses are indicated for each patient. B, Proportion of -SMA–positive cells in FLS from group
I/IIa (LU-12, LU-25, and LU-51) and group IIb (LB-21) patients. Both the total cells and the
-SMA–positive cells were counted. Values are the mean and SD of 4 counts of 2 different stains. C,
Correlations between the proportion -SMA–positive cells and mRNA expression of -SMA, activin A,
and OSF-2 (periostin). FLS from 12 patients were analyzed, and both total cells and -SMA–positive cells
were counted. In addition, mRNA was isolated, and mRNA expression levels of -SMA, activin A, and
OSF-2 were measured by real-time quantitative polymerase chain reaction. Gene expression levels are
expressed relative to GAPDH.
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enhanced expression of an extended number of TGF
response genes, including COL3A1 (type III 1 chain)
(25), COL4A2 (26), OSF-2 (periostin) (27), SPARC
(osteonectin) (26,28), CYR61 (cysteine-rich angiogenic
inducer 61; CCN1) (26), SERPINH2 (serine or cysteine
proteinase inhibitor; Hsp47) (26), CALD1 (caldesmon
1), and ACTA2 (-SMA) (26). The prominent expres-
sion signature of these FLS reflects an activated TGF/
activin A pathway and is characteristic of a subpopula-
tion of fibroblasts, called myofibroblasts, that are
commonly identified by their expression of -SMA (29).
The de novo appearance of myofibroblasts is generally
thought to be responsible for both extracellular matrix
(ECM) deposition and wound healing.
Real-time quantitative PCR and immunocyto-
chemical analysis of FLS. Since myofibroblast-like char-
acteristics were such a prominent feature of group IIb
FLS, we performed immunocytochemistry for -SMA
on 4 FLS cultures that had been analyzed in the microar-
rays and from which cells were still available. The
-SMA, which is typically absent from fibroblasts, is the
most reliable marker of myofibroblasts (29), and it is one
of the most differentially expressed genes (5.9-fold up-
regulated; q 1.7 in group IIb FLS). Immunocytochem-
istry revealed the characteristic expression of -SMA in
cytoplasmic microfilaments (stress fibers) (29,30) in the
FLS cultures (Figure 3A). As anticipated, group IIb FLS
displayed a much higher proportion of -SMA–positive
cells than did FLS from the other subgroups (Figure 3A
and B). The proportion of -SMA–positive cells corre-
lated significantly (Pearson’s r 0.99, P 0.01) with the
levels of -SMA expression as measured by cDNA
microarray technology.
To further confirm and extend our findings, we
performed an independent study in which we analyzed
another series of 12 RA FLS samples by real-time
quantitative PCR to determine the expression of a
restricted number of differentially expressed genes:
-SMA, activin A, and OSF-2 for type IIb FLS; and
IGF-2 and IGFBP-5 for type I FLS. Normalized levels of
expression revealed a high degree of heterogeneity in
the expression of these genes; for example, the mean
(range) of expression of activin A was 1.7 (0.6–4.5), of
-SMA was 2.1 (0.7–8.9), and of IGFBP-5 was 2.1
(0.3–5.5). Consistent with the microarray data and in
contrast to IGF-2 and IGFBP-5 expression levels, the
expression of -SMA correlated significantly with the
expression of activin A and OSF-2 (Pearson’s r  0.77,
P  0.003 and r  0.78, P  0.003, respectively).
In addition, we performed immunocytochemical
analysis for -SMA on the 12 FLS cultures. The propor-
tion of -SMA–positive cells was highly variable among
the different cultures, ranging from a mean  SD of
0.1 0.2% to 21.2 0.9%; this finding is consistent with
the results of our gene expression profiling and real-time
quantitative PCR. Moreover, there was a highly signifi-
cant correlation between the proportion of -SMA–
positive cells and the expression of -SMA, activin A,
and OSF-2 at the mRNA level, as measured by real-time
quantitative PCR (Figure 3C).
Taken together, these findings indicate that the
differential expression of -SMA and other
myofibroblast-associated genes in the FLS groups, as
determined by cDNA microarray analysis, reflects a
difference in the percentage of -SMA–expressing cells
in the respective FLS cultures.
Correlation of the subclassifications of FLS with
those of the paired synovial tissues from which they
were derived. For 10 of the FLS cell lines analyzed by
microarray techniques, we also had microarray expres-
sion data for the synovial tissues from which the FLS
were derived. Analysis of the gene expression signatures
of these tissues resulted in the identification of at least 2
molecularly distinct forms of RA tissues (6). One class of
tissues, designated RAhigh, revealed abundant expres-
sion of genes indicative of ongoing immune activity. The
expression profiles of the other group of tissues, desig-
nated RAlow/intermediate, were indicative of low immune
activity and increased stromal cell activity. These results
provide evidence for the existence of distinct pathologic
disease mechanisms between the synovial tissues.
To help provide an interpretive framework for
the FLS subclassification in relation to the differential
gene expression signatures in synovial tissues, we com-
pared unsupervised hierarchical clustering of both the
FLS and the corresponding synovial tissues (Figure 4A).
We observed that the molecular subclassification of the
FLS closely matched the subclassification of the synovial
tissues from which they were derived (P  0.01 by
chi-square test), providing evidence that the phenotypic
subclassification of RA FLS is associated with a distinc-
tive synovial tissue type.
These results were corroborated when we evalu-
ated the combined FLS and synovial tissue data sets
from each patient (n  10) after unsupervised hierar-
chical clustering (Figure 4B). This analysis allowed us to
directly correlate the discriminating gene clusters be-
tween the FLS and the paired tissue samples. The cluster
diagram clearly showed that abundant expression of FLS
cluster B genes (B1 and B2), which are indicative of an
activated TGF/activin A pathway in type IIb FLS, co-
clustered with a high-infiltrate gene expression signa-
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ture, in particular, the tissue-derived antigen-presenting
cell (APC) gene cluster (Pearson’s r  0.74, P  0.015).
Furthermore, we observed that FLS cluster A genes
(A1 and A2), which are highly expressed in type I FLS,
were inversely correlated with the APC gene cluster
(r  –0.69, P  0.03). Hence, the data clearly indicate
that type IIb myofibroblast-like FLS are related to
tissues with a high-inflammation gene expression profile
(Table 3).
Expression of myofibroblast markers in lining
cells. To investigate whether the myofibroblast pheno-
type of cultured FLS is representative of synovial lining
FLS in situ, we performed immunohistochemical stain-
ing on synovial tissue sections using antibodies against
-SMA. In addition to bright staining for -SMA around
the blood vessels, which most likely corresponds to the
perivascular smooth muscle cells in these regions, we
observed clearly positive staining for -SMA in cells
located in the intimal lining layer (Figure 5). These
findings demonstrate the presence of myofibroblast-like
synoviocytes in the rheumatoid synovium.
DISCUSSION
RA is diverse in its clinical presentation and in
responsiveness to treatment. We previously identified
distinctive gene expression patterns among rheumatoid
synovium samples. In the present study, we demon-
strated that global gene expression profiling of FLS
cultured from these tissues readily distinguished differ-
ent FLS phenotypes that were significantly related to the
type of tissues (i.e., high or low/intermediate inflamma-
tion) from which they were derived. These data support
the notion that heterogeneity between synovial tissues is
reflected in the FLS as a stable trait, and provide
Figure 4. Correlation between subclasses of fibroblast-like synoviocytes
(FLS) and corresponding synovial tissue samples from patients with
rheumatoid arthritis (RA). A, Arrays were clustered by unsupervised
hierarchical clustering using a selection of genes that showed at least a
2-fold difference from the median expression level in at least 2 samples in
either data set. The subclassification of FLS matches that of the corre-
sponding synovial tissues (P 0.01 by chi-square test). B, Combined data
from the synovial tissues and corresponding FLS showing clusters with
correlated gene expression. Genes whose transcripts varied in abundance
by at least 2-fold from the median level in at least 3 samples were selected.
Genes representing the transforming growth factor  pathway in FLS
(clusters B1 and B2) correlate with tissue clusters indicating a high-
inflammation status (antigen-presenting cell and B cell clusters; Pearson’s
r  0.74, P  0.015). FLS cluster A genes (A1 and A2) are inversely
correlated with the APC gene cluster (r –0.69, P 0.03). LU Leiden
University; LB  Leydenburg Hospital.
Table 3. FLS gene expression signatures and their correlation with
synovial tissue inflammation*
High Inflammatory synovitis Low inflammatory synovitis
Synovial tissue (RAhigh) Synovial tissue (RAlow/intermediate)
High expression of T cell/B
cell and APC genes
Low expression of T cell/B
cell and APC genes
FLS group IIb FLS group I
Myofibroblast-like molecular
phenotype
High expression of genes
involved in
Activin A/TGF-induced
genes
Autocrine growth regulation
Cell transformation
Complement activation
Oxidative stress
* FLS  fibroblast-like synoviocyte; RA  rheumatoid arthritis (high
and low/intermediate indicate the inflammation profile); APC 
antigen-presenting cell.
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evidence of a link between the increased presence of
myofibroblast-like FLS and high-inflammation synovitis.
Our data indicate that in RA, distinctive fibro-
blast behavior is manifested upon in vitro culturing of
the cells and, thus, persists beyond the initial stimulus. In
vivo outgrowth or (de)differentiation of rheumatoid
FLS (sub)populations in response to local environmen-
tal conditions may explain the differences in the long-
term phenotype between fibroblasts. Indeed, studies in
which fibroblasts have been cultured under specific
conditions have shown that this may lead to stable
phenotypic features of these cells. Accordingly, it was
shown that prolonged exposure to specific agents, such
as mitogen-activated mononuclear cells, TNF, and hyp-
oxia, leads to changes in fibroblasts that persist for
several weeks (31). The mechanism leading to a perma-
nent imprint and autonomous behavior of the different
types of FLS in vivo may involve epigenetic alterations
or somatic DNA mutations, which can be the result of
the local production of genotoxic agents, such as reactive
oxygen and nitrogen species. In addition, environmental
conditions may also reduce the DNA repair mechanism
in RA, creating an environment that is prone to DNA
mutagenesis (32–34). Such DNA alterations may cause
the permanent production of growth and differentiation
factors (e.g., activin A, IGF-2/IGFBP-5) leading to the
distinct FLS phenotypes.
One of the most impressive findings is the dis-
covery of features of increased myofibroblast conversion
as the hallmark of FLS derived from high-inflammation
tissue. Mattey et al (30) have reported that the percent-
age of -SMA–expressing FLS can vary between 1% and
30% in cultures from different RA patients. Herein we
provide evidence that the differential proportion of
-SMA–expressing myofibroblast-like cells in the FLS
cultures is related to the inflammation status of the
synovial tissue. The current data clearly indicate that the
high -SMA–expressing type IIb FLS are related to
tissues with a high-inflammation gene expression profile
(Table 3). Immunohistochemical staining for -SMA,
one of the most reliable markers of myofibroblasts (29),
revealed the presence of -SMA–positive cells in situ in
the lining of the RA synovial tissues analyzed. Prelimi-
nary experiments indicated that the increased presence
of myofibroblast-like cells was confined to tissues that
were categorized as high-inflammation tissues by global
gene expression profiling (Kasperkovitz PV, et al: un-
published observations). These findings suggest the ex-
istence of a link between synovial inflammation and the
presence of myofibroblast-like cells in the intimal lining
layer.
How can we explain the induction of myofibro-
blasts and their persistence in the inflamed synovium? In
vitro studies have shown a prominent role of TGF as
the key cytokine in the evolution of lesions characterized
by myofibroblast formation (26). Furthermore, fibro-
blasts can be induced to differentiate into myofibroblasts
by treatment with TGF, which is thought to be respon-
sible for -SMA gene expression by fibroblasts (35).
Consistent with the findings reported by Mattey et al
(30), we demonstrated TGF-induced myofibroblast-
like differentiation in FLS in vitro (Kasperkovitz PV, et
al: unpublished observations). Interestingly, Ota et al
(36) reported the production of activin A, a member of
the TGF family, by rheumatoid FLS and its effect on
proliferation. Since activin A, the expression of which is
increased in the -SMA high-expressing FLS cultures, is
believed to signal via a similar pathway that involves
Figure 5. Myofibroblast-like cells in the rheumatoid arthritis synovial
lining in situ. Immunohistochemical analysis of -smooth muscle actin
(-SMA) expression as a marker for myofibroblast-like cells revealed
the presence of -SMA–positive cells in the synovial lining. High
expression of -SMA was also detected around blood vessels (top). A
higher-magnification view of the boxed area shown in the top panel is
shown at the bottom.
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activation of Smads 2 and 3 and to activate the same
gene response as TGF1, it is tempting to speculate
about a role for autocrine activin A activity in myofibro-
blast differentiation.
In general, the de novo appearance of myofibro-
blasts at sites of wound healing or tissue repair is
believed to be associated with active fibrosis and wound
contraction as well as small vessel formation (37). Dur-
ing normal wound healing, these cells disappear by
apoptosis when reepithelialization occurs. Pathologic
phenomena resulting in fibrosis, as is seen, for example,
in pulmonary fibrosis, are characterized by the perma-
nent presence of myofibroblasts that results in excessive
ECM deposition and in the production of soft tissue
deformation. Besides a role in the emergence of the
myofibroblasts, Smad2 signaling is important in protect-
ing against apoptotic stimuli (38), which may explain the
extended survival of FLS in RA. There is accumulating
evidence that the TGF/Smad pathway is counteracted
by the interferon-/STAT-1 pathway (39), which is
known to exert growth-inhibitory effects and has been
shown to be activated in synovial tissues (6) in associa-
tion with an activated Smad2 pathway in FLS. These
findings led us to hypothesize that the STAT-1 pathway
may contribute to the disappearance of myofibroblasts
by apoptosis but is insufficiently activated to complete
this process.
An additional property of the myofibroblast is its
capacity to produce cytokines and chemokines, as is
revealed in the gene clusters by increased expression of,
for example, stromal cell–derived factor 1, interleukin-8,
and interleukin-6 (40), albeit the differences did not
reach statistical significance. Given the inflammation
properties of these mediators, these cells appear to play
additional potentially important roles beyond the depo-
sition of ECM. The release of these mediators may
contribute to the recruitment of inflammatory cells and,
thus, explain the selective association with high-
inflammation tissues that we observed. Such amplifica-
tion of the inflammatory response may result in a
positive feedback loop, resulting in intensification and
progression of fibrosis (38). In view of these properties,
it appears that the persistence of myofibroblast-like FLS,
which have a dual role as key sources in abnormal ECM
deposition and as inflammatory cells, in the rheumatoid
synovium may play a crucial role in the pathogenesis of
progressive disease and increased cellularity in the rheu-
matoid synovium.
FLS that are related to tissues with a low-
inflammation profile are characterized by increased
expression of IGF-2 and IGFBP-5. IGF-2 and IGFBP-5
are tightly regulated in a network, which is consistent
with the general observation that IGFs and IGFBP-5 are
spatially and temporally coexpressed (41,42). IGF-2 is a
peptide hormone that plays a central role in the prolif-
erative capacity of many cells and cancers. The impor-
tance of IGF-1 receptor signaling in pathology might be
exemplified by the finding that IGF signaling alters the
apoptotic response of breast cancer cells to genotoxic
stress. Moreover, IGF signaling has been shown to be
partly responsible for the fibroblast proliferative re-
sponse in patients with fibrotic lung disorders. Increased
expression of IGFBP-5 by rheumatoid FLS has been
reported previously (43,44). IGFBP-5, whose expression
is mostly regulated by IGFs, has both IGF-dependent
and IGF-independent actions (45,46). Among other
genes that fit a role in the IGF response program, are
those encoding selenoprotein P, a selenium-supply pro-
tein involved in the prevention of oxidative stress (47).
Hence, our observation of the combined expression of
IGF-2 and IGFBP-5 in this group of FLS is supportive of
an activated IGF receptor pathway.
The variation among FLS suggests that distinct
pathogenic mechanisms influence disease. A particular
case for fibroblast complexity in relation to pathogenesis
has been presented in lung fibrosis (48). At least 4
morphologically distinct types of fibrotic changes with
different prognoses and responses to treatment have
been described that may have resulted from different
pathogenic mechanisms. Recently, 2 distinctive patho-
physiologic mechanisms that occur independently in RA
were proposed (49). One is a T cell–mediated process
and the other is a T cell–independent process wherein
FLS attain a degree of independence from T cell control.
In the context of that model, the myofibroblast-like FLS
can be considered part of a T cell–mediated disease
process. Group I FLS appear not to be associated with
massive infiltration of immune cells and could be con-
sidered immune-independent autonomous FLS aggres-
sors. Interestingly, it has been hypothesized that in
fibroblastic rheumatism, the development of typical
nodules could depend upon the presence of myofibro-
blasts (50).
Since the molecular differences that we observed
most likely reflect distinct pathophysiologic processes, it
is tempting to speculate on the existence of a relation-
ship to clinical parameters. Hence, the stratification of
patients according to molecular profiles may be helpful
in assembling homogeneous populations of patients for
clinical studies and intervention therapies. However, we
realize that the design of the current study does not
allow any firm conclusions to be drawn concerning the
 Synovial tissue and FLS heterogeneity in RA
75
clinical parameters associated with the molecular phe-
notype. Further studies are necessary to perform a
thorough clinical association study based on molecular
variations among patients.
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Background: Expression of signal transducer and activator of transcription 1 (STAT1), the mediator of
interferon (IFN) signalling, is raised in synovial tissue (ST) from patients with rheumatoid arthritis (RA).
Objectives: To determine the extent to which this pathway is activated by phosphorylation in RA synovium.
Additionally, to investigate the cellular basis of STAT1 activation in RA ST.
Methods: ST specimens from 12 patients with RA and 14 disease controls (patients with osteoarthritis and
reactive arthritis) were analysed by immunohistochemistry, using antibodies to STAT1, tyrosine
phosphorylated STAT1, and serine phosphorylated STAT1. Lysates of cultured fibroblast-like synoviocytes
stimulated with IFNb were analysed by western blotting. Phenotypic characterisation of cells expressing
STAT1 in RA ST was performed by double immunolabelling for STAT1 and CD3, CD22, CD55, or CD68.
Results: Raised levels of total STAT1 protein and both its activated tyrosine and serine phosphorylated
forms were seen in RA synovium as compared with controls. STAT1 was predominantly abundant in T and
B lymphocytes in focal inflammatory infiltrates and in fibroblast-like synoviocytes in the intimal lining layer.
Raised levels of STAT1 are sustained in cultured RA compared with OA fibroblast-like synoviocytes, and
STAT1 serine and tyrosine phosphorylation is rapidly induced upon stimulation with IFNb.
Conclusion: These results demonstrate activation of the STAT1 pathway in RA synovium by raised STAT1
protein expression and concomitantly increased tyrosine (701) and serine (727) phosphorylation. High
expression of STAT1 is intrinsic to RA fibroblast-like synoviocytes in the intimal lining layer, whereas
activation of the pathway by phosphorylation is an active process.
A
well characterised feature of rheumatoid arthritis (RA)
synovial tissue (ST) is a marked increase in cellularity.
Factors that contribute to ST hyperplasia are recruit-
ment and retention of inflammatory cells, enhanced cell
proliferation, and impaired apoptosis. Cytokines, derived
from activated synovial cells have a pivotal role in the
regulation of these processes.1
Critical in mediating virtually all cytokine driven signalling
are the members of the STAT (signal transducer and activator
of transcription) family of transcription factors, which are
involved in regulating gene expression and cellular activa-
tion, proliferation, and differentiation.2–4 Recently, we5 and
others6 demonstrated raised expression of STAT1 mRNA and
protein in the ST of patients with RA as compared with
disease controls, indicating that this pathway might be
involved in RA pathogenesis. STAT1 is essential for interferon
(IFN) signalling. IFNs are typically growth inhibitory and
promote immune recognition of target cells, and absence of
IFN/STAT1 signalling has been associated with increased
susceptibility to infection and tumour formation.7 Moreover,
STAT1 has been shown to be essential for growth restraint
imposed by IFNc and has important proapoptotic effects
through the regulation of caspases.8 9 Type I IFNs are
abundant in RA synovium,1 and limited expression of IFNc
has been shown.10 11
So far the association of STAT1 with RA only relies upon
the detection of overall STAT1 mRNA and protein in RA
synovium5 6 and observations in synovial fluid cells.12 No
information is yet available on the state of activation of
STAT1 in rheumatoid synovium. Activation of STAT1 involves
phosphorylation on tyrosine and serine residues, which are
required for the protein to exert its function. Upon binding to
the cytokine receptor, cytoplasmic STAT1 proteins are
phosphorylated on tyrosine, after which they can form
STAT1 homodimers or form complexes with other nuclear
factors, for example STAT1/STAT2/IRF9 heterotrimers, and
subsequently translocate to the nucleus to initiate transcrip-
tion. In addition, serine phosphorylation of STAT1 is required
for full transcriptional activity.13 14
In the present work we investigated the activation of
STAT1 protein in RA ST by studying its phosphorylation
compared with ST from disease controls, including patients
with osteoarthritis (OA) and reactive arthritis (ReA). In
addition, we characterised the expression and activation of
STAT1 in the various cell types in RA ST.
MATERIALS AND METHODS
Patients
ST was obtained from the actively inflamed knee joints of 26
patients, including 12 patients with RA (1987 American
College of Rheumatology (ACR) criteria15), 7 patients with
inflammatory OA (1987 criteria16), and 7 patients with ReA.
All material was obtained in the early 1990s; at that time ST
could be obtained from all patients before disease modifying
antirheumatic drug (DMARD) treatment was initiated.
Table 1 presents the clinical and demographic data of these
patients. All patients gave their informed consent and the
study protocol was approved by the medical ethics committee.
Knee joint arthroscopy and synovial biopsies
In all patients an arthroscopy was performed under local
anaesthesia using a small bore, 2.7 mm arthroscope (Storz)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: ACR, American College of Rheumatology; AP, alkaline
phosphatase; BSA, bovine serum albumin; DMARD, disease modifying
antirheumatic drug; FCS, fetal calf serum; FITC, fluorescein
isothiocyanate; HPF, high power field; HRP, horseradish peroxidase;
IFM, immunofluorescence microscopy; IFN, interferon; IHC,
immunohistochemistry; IOD, integrated optical density; OA,
osteoarthritis; RA, rheumatoid arthritis; ReA, reactive arthritis; ST,
synovial tissue; STAT, signal transducer and activator of transcription
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and using an infrapatellar skin portal for macroscopic
examination of the synovium and a second suprapatellar
portal for the biopsy procedure.17 Synovial biopsy samples
were obtained from multiple regions (>6) using a 2.5 mm
grasping forceps (Storz). Tissue samples were embedded en
bloc in Tissue Tek OCT compound (Miles Diagnostics,
Elkhart, IN) and snap frozen in liquid nitrogen. The frozen
blocks were stored in liquid nitrogen until sectioned for
staining. Sections (5 mm) were cut in a cryostat and mounted
on glass slides (Star Frost adhesive slides, Knittelgla¨ser,
Braunschweig, Germany); the slides were air dried at room
temperature, carefully packed, and sealed and stored at
280 C˚ until immunohistochemical staining was performed.
Antibodies
Serial sections were stained using the following monoclonal
antibodies and diluted as indicated for immunohistochem-
istry (IHC) and immunofluorescence microscopy (IFM): anti-
STAT1, 1:160 (BD Transduction Laboratories); anti-phospho-
STAT1-tyrosine (Y701), 1:40 (Zymed Laboratories Inc, San
Francisco, CA); anti-CD3, 1:320 for IHC, 1:100 for IFM (SK4,
Becton Dickinson, San Jose, CA); anti-CD22, 1:80 for IHC,
1:50 for IFM (CLB-B-Ly, 6B11, Sanquin, Amsterdam, The
Netherlands), anti-CD55, 1:20 for IHC, 1:25 for IFM (Bric
110, Sanquin); anti-CD68, 1:320 for IHC, 1:200 for IFM (KP1,
DAKO, Glostrup, Denmark). A polyclonal antibody was used
to detect phospho-STAT1-serine (S727), 1:1000 (Upstate
Biotechnology).
Immunohistochemistry
Sections were brought to room temperature, dried, and then
fixed with acetone for 10 minutes. Endogenous peroxidase
activity was inhibited using 0.1% sodium azide and 0.3%
hydrogen peroxidase in phosphate buffered saline. Staining
was performed as described previously.18 After a primary
incubation step with the antibody of interest, bound antibody
was detected using a three step alkaline phosphatase (AP)
method for CD3, CD22, CD55, CD68. An immunoperoxidase
method was used for STAT1 and phospho-STATs. For these
antibodies, except for STAT1, staining was performed using
biotinylated tyramine (Perkin Elmer Life Sciences, Boston,
MA) for amplification.
For double IHC, sections were incubated with anti-STAT1
overnight. Horseradish peroxidase (HRP) conjugated goat-
antimouse was added for 30 minutes, followed by swine-
antigoat-HRP for 30 minutes. To prevent binding to excess
antimouse antibody, sections were blocked with 10% normal
mouse serum (Sanquin) for 15 minutes. Subsequently,
sections were incubated for 60 minutes with fluorescein
isothiocyanate (FITC) conjugated anti-CD3, -CD22, -CD55, or
-CD68, followed by rabbit-anti-FITC (DAKO) and swine-
antirabbit-AP, each for 30 minutes. HRP activity was
detected using hydrogen peroxidase as substrate and
aminoethylcarbazole as dye (Sigma, St Louis, MO). AP
activity was detected using AP substrate kit III (Vector
Laboratories, Inc, Burlingame, CA 94010). Double stained
slides were not counterstained; single stained slides were
counterstained with Mayer’s haematoxylin (Sigma) and
mounted in Kaiser’s glycerol gelatin (Merck, Darmstadt,
Germany).
Digital image analysis
Sections analysed by immunohistochemistry were coded and
assessed by digital image analysis in random order as
described previously.19 Briefly, three separate representative
regions, including the intimal lining layer and synovial
sublining, were chosen for the evaluation of each section.
Six consecutive high power fields (HPFs) from each region
were captured and digitised, resulting in a total of 18 HPFs
(surface area ,2.1 mm2). Subsequently, sections were
Table 1 Demographic and clinical data of the 12 patients with RA and the control patients, including seven patients with OA
and seven patients with ReA, who were studied for expression of STAT1 and its tyrosine and serine phosphorylated forms. All
material was collected in the early 1990s; at that time synovial tissue could be obtained from all patients before DMARD
treatment was initiated
Patient
Diagnosis
(RA/OA/ReA)
Age
(years) Sex (M/F)
Disease duration
(months) Drugs
CRP
(mg/l)
ESR
(mm/1st h)
RF
(+/2)
Erosions
(+/2)
1 RA 47 M 6 2 10 17 + 2
2 RA 80 F 4 NSAID* 47 ND + +
3 RA 76 F 8 NSAID 11 46 2 +
4 RA 73 F 4 NSAID 18 72 + +
5 RA 57 F 4 NSAID 68 81 + +
6 RA 66 F 24 NSAID 19 37 + +
7 RA 60 F 180 NSAID 53 108 + +
8 RA 58 F 192 NSAID 48 74 + +
9 RA 44 M 2 NSAID 22 33 + 2
10 RA 54 F 108 NSAID 141 93 + +
11 RA 63 M 4 NSAID 40 65 + +
12 RA 71 F 12 NSAID 49 ND + ND
13 OA 77 F 0 2 7 17 2 2
14 OA 76 F 240 NSAID 11 24 2 2
15 OA 73 F 60 2 7 18 2 2
16 OA 74 F 192 NSAID 8 14 + 2
17 OA 54 F 6 2 6 14 2 2
18 OA 67 M 8 NSAID 3 10 2 2
19 OA 77 M 12 2 ND 43 2 2
20 ReA 37 F 3 2 3 14 2 2
21 ReA 27 M 1 NSAID ND ND ND 2
22 ReA 44 M 18 2 4 9 2 2
23 ReA 33 M 11 2 3 3 2 2
24 ReA 39 F 14 NSAID 7 0 2 2
25 ReA 22 M 1 NSAID ND ND 2 2
26 ReA 67 F 4 2 23 24 2 2
RA, rheumatoid arthritis; OA, osteoarthritis; ReA, reactive arthritis; NSAID, non-steroidal anti-inflammatory drug; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; RF, rheumatoid factor; ND, not determined.
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examined using a specialised algorithm written in the
program language QUIPS operating a Qwin based (Qwin
Pro V2.4; Leica, Cambridge, UK) computer assisted, colour
video image analysis system.19 20 To quantify staining for
STAT1, STAT1-P-Tyr, and STAT1-P-Ser in the analysed
regions, integrated optical density (IOD) was calculated as
the product of staining area and intensity21 and presented as
IOD/mm2 tissue. The total cell count of the measured regions
was determined by quantification of nuclear counterstaining,
which allowed for normalisation for cellularity in all regions.
Fluorescence microscopy
Double immunofluorescence was performed on sections of
four patients with RA. The staining procedure used is a
modification of the method described previously.18 Firstly,
sections were incubated with anti-STAT1 monoclonal anti-
body, followed by incubation with tetramethylrhodamine
isothiocyanate (TRITC) conjugated goat-antimouse IgG1
antibody (Nordic, Tilburg, The Netherlands). After use of
10% normal mouse serum (Sanquin) as blocking serum,
incubation with FITC labelled anti-CD3, -CD22, -CD55, or
-CD68 was performed on serial sections. Sections were
embedded in mounting medium (Vectashield, Vector Labs
Inc) and analysed by two independent assessors (PVK and
TJS). During the analysis, all cells that were double positive
for STAT1 and the respective CD marker were counted and
given as a percentage of the absolute number of either CD3+,
CD22+, CD55+, or CD68+ cells in the biopsy specimens.
Cell culture and stimulation
Fibroblast-like synoviocytes were obtained from synovial
biopsy samples of patients with RA who fulfilled the criteria
of the ACR15 and patients with OA (1987 criteria16). After
enzymatic digestion, fibroblast-like synoviocytes were grown
in culture flasks in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (FCS), and cells
were routinely split. Experiments were performed using third
to sixth passage fibroblast-like synoviocytes. At this time,
,2% contaminating lymphocytes, NK cells, or macrophages
were present. The day before an experiment, cells were
replated in medium containing 0.5% FCS. Stimulation was
performed for 30 minutes in six-well dishes using recombi-
nant human IFNb (Sanquin) at a final concentration of 250
U/ml. Cell extracts were prepared in ice cold RIPA buffer
(20 mM Tris; 150 nM NaCl; 1% sodium deoxycholic acid; 1%
NP-40; 0.1% sodium dodecyl sulphate; 50 mM NaF; 250 mM
Na3VO4; 10 mM Na2PHO4; 1 pill/50 ml of Complete (Roche)
protein inhibitor) and kept on ice on a shaking platform for
30 minutes. After centrifugation at 4000 rpm for 10 minutes,
supernatants were transferred to a fresh tube and frozen at
220 C˚ until further use.
Western blot analysis
Cell lysates of fibroblast-like synoviocytes were corrected for
total protein content (35 mg total protein per lane) and
fractionated on 7.5% sodium dodecyl sulphate-polyacryla-
mide gels and transferred to nitrocellulose membranes.
Membranes were blocked in Tris buffered saline-Tween/3%
bovine serum albumin (BSA) for 1 hour and then incu-
bated with the antibodies described above that were dir-
ected against STAT1, phospho-STAT1-tyrosine (Y701), or
phospho-STAT1-serine(S727) at a dilution of 1:500 in
Tris buffered saline-Tween/1% BSA. Enhanced chemilumine-
scence was used for detection.
Statistical analysis
The Mann-Whitney two sample test was used for comparison
of RA ST with control ST.
RESULTS
Activation of the STAT1 pathway in RA synovium
To obtain insight into the extent of activation of the STAT1
pathway in RA synovium, immunohistochemical studies
were performed on the ST of 12 patients with RA and 14
disease controls, including 7 patients with OA and 7 with
ReA (table 1). Only patients who had not yet been treated
with DMARDs were included in the study, and the RA patient
group consisted of patients with both early and longstanding
RA. Serial sections were stained for STAT1 and both its
phosphorylated forms, phospho-STAT1(Y701) and phospho-
STAT1(S727). STAT1 expression and phosphorylation was
predominantly abundant in the intimal lining layer and in
focal inflammatory infiltrates in the synovial sublining
(fig 1A).
To make a quantitative comparison between the patients
with RA and the control group, expression was quantified by
digital image analysis.19 20 Comparison of RA ST with ST of
disease controls showed that STAT1 protein expression was
raised in RA ST (expressed as mean (SD) IOD per mm2 of
tissue, 209 (214) v 24 (29) in disease controls, p=0.0097,
data not shown), which is consistent with our previously
reported results.5 Normalisation to the total number of cells
present in the sections shows that the difference is still highly
significant (p=0.014), indicating that this effect could not
merely be explained by differences in leucocyte infiltration.
In addition, we found that STAT1 phosphorylation on
tyrosine was significantly increased in RA ST as compared
with controls (p=0.017) as well as phosphorylation on
serine (p=0.029) (fig 1B). Calculation of the ratio of
phosphorylated STAT1 to total STAT1 present for each
patient showed no significant differences between patients
with RA and disease controls (p=0.70 and p=0.52 for
STAT1-P-Tyr/STAT1 and STAT1-P-Ser/STAT1, respectively),
which suggests that activation by phosphorylation may
increase concomitantly with STAT1 expression.
STAT1 is differentially expressed in RA synovial tissue
To evaluate specifically which cells in the different synovial
compartments express STAT1, immunohistochemical double
labelling was performed on the ST of four patients with RA
using antibodies to detect T cells (anti-CD3), B cells (anti-
CD22), fibroblast-like synoviocytes (anti-CD55), and macro-
phages (anti-CD68).
In the synovial sublining, STAT1 was mainly localised in
both B and T lymphocytes (figs 2A and B). Focal inflamma-
tory infiltrates of CD22+ B cells were found that exhibited
strongly positive staining for STAT1 (fig 2A). High STAT1
expression was also seen in CD3+ T lymphocytic aggregates.
Interestingly, in one patient both STAT1 positive T lympho-
cytic aggregates and T lymphocytic aggregates that were
entirely negative for STAT1 were seen (fig 2B). CD68+macro-
phages were abundant around lymphocyte clusters and in the
intimal lining layer. Regardless of their position in the tissue,
staining for STAT1 was relatively limited in these cells (fig 2D).
In contrast, CD55+ fibroblast-like synoviocytes in the
intimal lining layer stained strongly positive for STAT1
(fig 2C).
To make a quantitative assessment of the percentage of
STAT1+cells in these synovial cell populations, double
immunofluorescence was performed (fig 3A) on the ST of
four patients with RA who were not included in the previous
analysis. The results confirmed the observation that STAT1 is
expressed by B lymphocytes (fig 3B; mean (SD) STAT1+ cells
of total CD22+ cells=45 (5)%), T lymphocytes (54 (8)%),
and the majority of fibroblast-like synoviocytes (87 (9)%).
Only a limited number of macrophages (18 (15)%) were
found to be STAT1+. Taken together, these results indicate
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Figure 1 Increased STAT1 phosphorylation on tyrosine and serine in RA ST as compared with controls. Serial ST sections from 12 patients with RA
and 14 controls were stained for STAT1-phospho-tyrosine and STAT1-phospho-serine using aminoethylcarbazole as dye (A) representative sections
are shown. Counterstaining was performed using Mayer’s haematoxylin. (Original magnification6400.) Sections were analysed using computer
assisted digital image analysis (B). Results are shown as means, errors bars indicate SD; on the y axis the mean IOD per mm2 of tissue (see ‘‘Materials
and methods’’) is shown.
Figure 2 Immunohistochemical double labelling of the ST of four patients with RA (table 1; patients Nos 4, 5, 7, and 13; representative sections are
shown) for STAT1 and CD22+ B cells (A), CD3+ T cells (B), CD55+ fibroblast-like synoviocytes (C), or CD68+ macrophages (D). STAT1 was detected
using aminoethylcarbazole as dye (red) and CD molecules were detected using AP substrate (blue); no counterstaining was performed (see ‘‘Materials
and methods’’). (Original magnification6400.)
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that the abundance of STAT1 in the intimal lining layer is
predominantly due to expression by fibroblast-like synoviocytes.
STAT1 expression and activation in fibroblast-like
synoviocytes
To validate our in vivo observations, we assessed the
expression of STAT1 in RA and OA fibroblast-like synovio-
cytes by immunoblot analysis of lysates of cultured cells.
These studies disclosed higher expression of STAT1 in RA
fibroblast-like synoviocytes than in OA synoviocytes (fig 4),
which is consistent with our in vivo observations in whole ST.
Interestingly, although expression of STAT1 was sustained in
vitro, tyrosine phosphorylation was absent and only low basal
levels of serine phosphorylation were found in cultured
fibroblast-like synoviocytes from both patients with RA and
OA. Stimulation with IFNb rapidly induced both tyrosine and
serine phosphorylation. These results show that whereas
raised expression of STAT1 is a stable, instrinsic feature of RA
fibroblast-like synoviocytes, activation of STAT1 by phos-
phorylation is not sustained in culture. Induction of
phosphorylation on both tyrosine and serine residues appears
to be an active process, which can be induced by IFNb, a
cytokine that is abundantly expressed in RA synovium.
DISCUSSION
The prime aim of the present study was to extend our
understanding of the expression and activation of STAT1 in
RA. Previously, we5 and others6 reported that STAT1
expression is raised in RA synovium as compared with
controls, and STAT1 activation has been shown in rheuma-
toid synovial fluid cells.12 In the present work we provide
evidence for activation of the STAT1 pathway in RA
synovium and define the cell types that express STAT1.
Raised expression of STAT1 appears to be intrinsic to RA
fibroblast-like synoviocytes, whereas activation by phosphor-
ylation is an active process.
Regulation of signalling through the Jak-STAT pathway is
complex and occurs at several levels within the cell. Up
regulation of STAT1 mRNA and protein expression in
response to stimulation with IFNs have been described
previously.6 22 Key post-translational modifications include
tyrosine and serine phosphorylation, which are required for
dimerisation and full transcriptional activity of STATs.13 14
Our results demonstrate that activation of STAT1 in the RA
inflamed joint is not only reflected by increased expression of
STAT1 but also by increased phosphorylation on both
tyrosine (701) and serine (727) residues. The fact that
Figure 3 Double immunofluorescence
was performed on the ST of four
patients with RA (table 1; patients Nos
1, 2, 3, and 10). (A) STAT1
(tetramethylrhodamine) and CD22+ B
cells, CD3+ T cells, CD55+ fibroblast-
like synoviocytes, or CD68+
macrophages (fluorescein). No
counterstaining was performed.
(Original magnification6400.) (B)
Percentage STAT1+ cells of,
respectively, total CD22+, CD3+,
CD55+, or CD68+ cells. Bars represent
mean (SD) (n = 4).
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STAT1 activation is less pronounced in patients with OA and
ReA may reflect the differential expression of IFNb and IFNc
between diseases. These findings are in line with our
microarray results, which demonstrated an increased expres-
sion of IFN-induced genes in RA STs that display up
regulation of STAT1 mRNA.5 The observation that ratios of
phosphorylated STAT1 to total STAT1 for each patient are
comparable in patients with RA and controls suggests that up
regulation of STAT1 protein expression and its activation by
phosphorylation are concomitant events. Whether this is
really true, however, can only be determined if extensive
studies at the single cell level are performed.
In accordance with our microarray gene profiling
results,5 23 we observed considerable variation in STAT1
expression and activation among patients with RA and
controls. In the patient group studied patients with both early
and longstanding RA were included, and no correlations
between STAT1 activation and the duration of disease or
other clinical variables (table 1) were found. This, however,
may be due to the relatively small number of patients
studied. We investigated the expression profile of STAT1 in
the different synovial compartments in patients with RA by
using two different double labelling techniques. In the
synovial sublining we detected increased STAT1 protein
expression in focal inflammatory infiltrates of both B and T
lymphocytic origins. Interestingly, in one patient we detected
a STAT1 positive perivascular T lymphocytic aggregate (fig 3A,
second panel). Although the majority of lymphocytic
infiltrates in RA were STAT1 positive, in some aggregates
STAT1 expression was entirely absent. This can be seen in
fig 2, where a STAT1 positive T lymphocyte aggregate and an
adjacent STAT1 negative aggregate are shown (fig 2B). These
findings suggest that STAT1 is differentially expressed in
synovial lymphocytes, which may reflect the state of
activation and cellular differentiation of these cells.
STAT1 expression was also abundant in the intimal lining
layer. The vast majority of fibroblast-like synoviocytes in the
intimal lining layer expressed high levels of STAT1, whereas
only limited expression of STAT1 was found in macrophages,
regardless of their position in either intimal lining layer or
synovial sublining. This is particularly interesting in light of
the recent report by Hu et al,6 who demonstrated the
existence of a delicate regulatory system for STAT1 in IFNc
signalling. They showed that exposure of macrophages to
subthreshold concentrations of IFNc sensitises these cells to
subsequent IFNc stimulation, which results in increased
STAT1 expression. To find supporting evidence for the
occurrence of this mechanism in vivo, they stated that
STAT1 protein expression is increased in RA synovium,
particularly in the intimal lining layer. In their rationale they
implied that this might be due to intimal macrophages
displaying increased STAT1 expression as a result of the IFNc
responses that lead to tissue abnormality in RA. However, our
results demonstrate that the abundance of STAT1 in the
intimal lining predominantly results from STAT1 expression
by fibroblast-like synoviocytes.
It has been suggested that RA fibroblast-like synoviocytes
not only respond to stimulation by proinflammatory cyto-
kines but also show intrinsic molecular changes that are
maintained in the absence of external stimuli.24 25 Here we
demonstrated that increased expression of STAT1 in RA
compared with OA fibroblast-like synoviocytes is sustained in
culture. On the other hand, phosphorylation of STAT1 is
almost completely lost in vitro, indicating that this is an
active process that can be induced by cytokines in RA
synovium. This notion is supported by the observation that
STAT1 phosphorylation in fibroblast-like synoviocytes is
rapidly restored upon stimulation with the type I interferon
IFNb. IFNb is produced by fibroblast-like synoviocytes and
abundant in synovium. Therefore, conceivably, this mechan-
ism of STAT1 activation takes place in vivo in fibroblast-like
synoviocytes. Type I interferons are believed to have
immunosuppressive functions, including antiangiogenic
effects. On the other hand, IFNb produced by fibroblast-like
synoviocytes can act as a survival factor for T cells in the
rheumatoid joint.26 It is interesting to note that stimulation
with IFNc also induced STAT1 phosphorylation in fibroblast-
like synoviocytes (data not shown). Because IFNc expression
is absent in the synovial lining this mechanism of STAT1
activation may rather be of importance in other synovial cell
types.
Evidence for the importance of the Jak-STAT pathway in
RA pathogenesis is accumulating, and has so far mainly been
focused on the role of STAT3 and its growth promoting role.
Accordingly, Shouda et al demonstrated that blockade of
STAT3 by overexpression of SOCS3, a STAT3-induced
inhibitor of Jak-STAT signalling, suppressed experimental
arthritis.27 In contrast, an important effector function of
STAT1 is its growth inhibitory effect. STAT1 is required for
the growth restraint imposed by IFNa and IFNc28 and the
promotion of apoptosis.8 29 30 Krause et al showed that the
proapoptotic action of STAT1 is antagonised by STAT3,31
which appears to be essential for RA synoviocyte survival.
This is in line with the notion that STAT1 and STAT3 can
serve as a tumour suppressor and a tumour promoter,
respectively.7 Because our data demonstrate that besides the
STAT3 signalling pathway the STAT1 pathway also is
activated in fibroblast-like synoviocytes, it is tempting to
speculate that the proapoptotic signals delivered by STAT1 in
these cells in vivo are not strong enough to effectively
counteract the STAT3 derived survival signals.
STAT1 may have a role as transcriptional activator as a
STAT1 homodimer or as a constituent of a complex involving
other factors, for example the STAT1/STAT2/IRF9 hetero-
trimer. For the future it is challenging to know in which form
STAT1 exerts its biological effects in ST, and what part
activation of STAT1 plays in the fate of infiltrating
lymphocytes. A better understanding of the balance of
signals delivered through the different STAT pathways by
dissecting the individual pathways and evaluating their
contributions to either cell survival or growth arrest may
Figure 4 STAT1 expression is raised in RA compared with OA
fibroblast-like synoviocytes (top panel) and STAT1 tyrosine and serine
phosphorylation are induced by stimulation with IFNb (second and third
panels). Fourth passage RA and OA synoviocytes were treated with IFNb
(250 U/ml). Cell extracts were prepared 30 minutes after cytokine
stimulation, corrected for total protein content, and analysed by
immunoblotting.
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contribute to elucidating the disease mechanisms that are at
play in RA.
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Rheumatoid arthritis (RA) fibroblast-like 
synoviocytes (FLS) manifest an abnormal 
phenotype, characterized by increased 
proliferation, invasiveness and resistance to 
apoptosis. Recently, we provided evidence for 
activation of STAT-1 in RA synovial tissue, 
which was particularly prominent in FLS(1;2). 
To gain more insight into the biological effects 
of STAT-1 activation in RA FLS and its 
relevance for RA pathology, we have examined 
the effect of interferons (IFNs) on RA FLS 
survival and growth. Treatment of RA FLS 
with IFNα, IFNβ or IFNγ led to rapid 
phosphorylation of STAT-1 and induction of a 
STAT-1-specific transcriptional response, 
indicating that the IFN-response was functional 
in RA FLS. Measurement of DNA synthesis 
using [
3
H]-Thymidine revealed that IFNα, 
IFNβ and IFNγ suppressed RA FLS 
proliferation (>50% decreased) and overruled 
the proliferative effect of TNFα. The inhibitory  
effect was not due to induction of apoptosis by 
IFNs, as was indicated by Annexin V staining 
and propidium iodide (PI) exclusion. Analysis 
of the cell cycle distribution using PI staining 
demonstrated that whereas TNFα induced cell 
cycle progression to G2/M phase, this effect was 
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overruled by IFNα, IFNβ and IFNγ, which 
limited cell cycle progression and caused 
accumulation of cells in G0/1 phase. This effect 
correlated with induction of the Cyclin 
Dependent Kinase Inhibitor (CDKI) 
p21
Waf1/Cip1
, which inhibits CDK activity and 
may therefore mediate the IFN-induced 
limiting effect on cell cycle progression. These 
results indicate that IFN-treatment can 
negatively modulate the growth abnormalities 
of RA FLS, suggesting that  therapeutic 
approaches that selectively manipulate STAT-1 
may have beneficial effects in RA. 
 
Rheumatoid arthritis (RA) is an autoimmune 
disease that targets the synovial joints and is 
characterized by inflammatory cell infiltrates, 
hyperplasia of the synovial lining and destruction 
of cartilage and bone (3;4). Synovial lining 
hyperplasia is, in part, due to a marked increase in 
the number of fibroblast-like synoviocytes (FLS), 
a cell type that is thought to play a major role in 
RA pathogenesis. RA FLS contribute to 
inflammation, chemotaxis and angiogenesis by 
production of pro-inflammatory mediators  and 
mediate the destructive response by secretion of 
matrix degrading enzymes (5-7). In addition, RA 
FLS are one of the principle cells involved in the 
formation of the invasive, inflammatory front 
tissue called pannus, which invades and destroys 
cartilage.  
Growth factors and pro-inflammatory 
cytokines that are abundant in RA synovium are 
thought to drive activation and proliferation of 
FLS, which can be mimicked by culturing RA 
FLS with e.g. TNFα (8) or IL-1 (9). However, 
accumulating evidence indicates that RA FLS do 
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not only react passively to pro-inflammatory 
stimuli but exhibit a “transformed” phenotype, that 
is sustained in the absence of environmental 
stimuli and enables RA FLS to act as autonomous 
aggressors (5;10). When RA FLS are co-implanted 
with normal human cartilage in SCID mice, 
recovery of the tissue reveals deep FLS invasion 
and destruction of the cartilage (11;12). 
Furthermore, RA FLS can resist apoptosis (13;14) 
and are highly proliferative, growing in an 
anchorage-independent manner over multiple 
passages in vitro and escaping contact inhibition 
(15).  
The notion that FLS growth abnormalities 
contribute to RA pathogenesis has been supported 
by therapeutic approaches that were aimed at 
inhibiting the cell cycle in synovial cells. Cell 
cycle progression is dependent on the kinase 
activity of  cyclin/cyclin-dependent kinase (CDK) 
complexes (16). The kinase activity is inhibited by 
a group of cell cycle regulatory proteins called 
CDK inhibitors (CDKI) (17). CDKIs consist of 
two families that cooperate to govern the G1-to-S 
transition: the INK4 (inhibitors of cdk4) family, 
which includes the senescence gene p16ink4a, and 
the Cip/Kip (cdk2-interacting protein) family, 
which includes p21Waf1/Cip1 and p27Kip1. Forced 
expression of 16ink4a or p21Waf1/Cip1 genes within 
the joint by intra-articular administration using 
adenoviral gene transfer ameliorated experimental 
arthritis (18-20) and suppressed RA FLS growth in 
vitro (18;19).  
Cellular events like proliferation and cell cycle 
progression are tightly regulated by transcription 
factors. The family of Signal Transducers and 
Activators of Transcription (STAT) proteins is a 
group of transcription factors that transmit signals 
from the extracellular surface of cells to the 
nucleus and regulates  growth, differentiation, 
apoptosis, and transformation (21;22). STATs are 
cytosolic latent transcription factors that are 
tyrosine phosphorylated by Janus family tyrosine 
kinases (JAKs), allowing STAT protein 
dimerization and nuclear translocation. STATs 
then can modulate the expression of target genes. 
Of the seven mammalian STATs, STAT-3, which 
is activated by cytokines of the IL-6 family and a 
number of growth factors, has been strongly 
implicated in promoting cell growth and survival 
and cellular transformation (23). A role for STAT-
3 in mediating the pathogenic properties of RA 
FLS was supported by studies demonstrating that 
ablation of STAT-3 function induced RA FLS 
apoptosis and converted the action of EGF from a 
growth/survival factor to a death factor (24). 
Strikingly, induction of apoptosis was suppressed 
when STAT-1 activity was blocked. STAT-1 and 
STAT-3 have opposing actions on apoptosis and 
cell cycle processes, which may link their 
functional effects to cellular transformation 
(25;26). STAT-1 is activated by interferons (IFN), 
which include Type I IFNs (IFN? and IFN?) and 
Type II IFN (IFN?), and by several other cytokines 
and growth factors, and is required for IFN-
induced growth restraint and apoptosis in multiple 
cell types (27-29). Studies in an experimental 
animal model of arthritis using STAT-1 -/- mice 
showed exacerbation of arthritis, suggesting a 
protective effect of STAT-1 in this model. 
Recently, we provided evidence for activation of 
STAT-1 in RA synovial tissue, particularly in FLS 
(1;2). To gain more insight into the biological 
effects of STAT-1 activation in RA FLS and its 
relevance for RA pathology, we have examined 
the effect of IFNs on RA FLS survival and growth. 
 
 
EXPERIMENTAL PROCEDURES 
 
Preparation of Fibroblast-like Synoviocytes of 
Rheumatoid Arthritis Patients 
Synovial tissues were obtained perioperatively from 10 
RA patients who fulfilled the American College of 
Rheumatology (formerly, the American Rheumatism 
Association) 1987 revised criteria for RA (30;31). All 
patients gave their informed consent, and the study 
protocol was approved by the Medical Ethics 
Committee. Synovial cells were obtained by finely 
mincing freshly isolated synovial tissue, followed by 
treatment with collagenase A for 2 hours at 37°C. FLS 
were allowed to adhere to tissue culture plates, and non-
adherent cells were removed. FLS were cultured in 
HEPES-buffered Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal calf serum 
(FCS) and penicillin/streptomycin/glutamine in a 
humidified 5% CO2 atmosphere. Cells were harvested 
using Trypsin/EDTA and split routinely. To avoid 
contamination with other synovial cell types, 
experiments were performed using FLS after the third 
passage in tissue culture. All experiments described in 
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this report are representative of at least 3 independent 
experiment performed with RA FLS from 3 different 
patients. 
 
Reagents 
Recombinant IFN?A and IFN? were purchased from 
Calbiochem (Merck KGaA, Darmstadt, Germany). 
Recombinant IFN? and TNF? were obtained from 
Strathmann (Strathmann Biotec AG, Hamburg, 
Germany). Anti-P-STAT-1(Y701) monoclonal antibody 
was obtained from Zymed (San Francisco, CA, cat. No. 
33-3400); anti-P-STAT-2(Y689) was obtained from 
Upstate Biotechnology (Lake Placid, NY, cat. No. 07-
224) and anti-p21Waf1/Cip1 (BD Biosciences, San Jose, 
CA, cat. No. 556430). 
 
Cell Proliferation Assay 
Proliferation was evaluated by measuring DNA 
synthesis through the incorporation of [3H]-Thymidine. 
FLS were seeded in 96-well, flat-bottom culture plates 
at a density of 5000 cells/well. The next day, cells were 
stimulated with cytokines and [3H]-Thymidine (1 
µCi/well) was added. Every condition was tested in 
sextuplet and cells were cultured in DMEM containing 
10% FCS at all times. After incubation for 24h, FLS 
were lysed using a round of freeze-thaw cycle and 
transferred onto a membrane filter using a Harvester 96 
(TOMTEC, Hamdem, CT). [3H]-Thymidine 
incorporated into DNA was quantified using a 
scintillation counter 1450 MicroBeta Plus (Wallac, 
Freiburg, Germany).  
 
Flow Cytometry  
For analysis of the cell cycle distribution and apoptosis, 
a similar plating and cytokine stimulation protocol as 
for [3H]-Thymidine incorporation was used: FLS were 
plated at a low density (~15800 cells/cm2) and 
incubated with 10% FCS at all times. 
For cell cycle analysis, cells were harvested 
(floating cells, washed cells and adherent cells 
following trypsinization) and fixed in ice-cold 70% 
EtOH for >1h. Subsequently, cells were incubated at 
room temperature for 30 min. with staining solution 
containing 50 µg/ml propidium iodide (Sigma) and 100 
µg/ml RNAse A (Roche Applied Science) in PBS/1% 
BSA. 
For identification of apoptosis, cells were harvested 
(floating cells, washed cells and adherent cells 
following trypsinization), washed with PBS and then 
incubated at room temperature for 15 min. in staining 
solution containing 100 µg/ml propidium iodide 
(Sigma) and 1 µl Annexin V-FITC (BD Biosciences) 
per 100 µl Annexin-binding buffer (10 mM 
Hepes/NaOH pH=7.4/140 mM MaCl/ 2.5 mM CaCl2). 
UV-irradiated cells were used as a positive control and 
cells incubated with Annexin V-FITC only, propidum 
iodide only or buffer only were used as a negative 
control. 
Analysis was performed immediately after staining by 
flow cytometry using FACSCalibur (Becton Dickinson, 
San Jose, CA) and Cellquest software. 
 
Immunocytochemistry 
Cells were seeded into Lab-Tek II chamber slides 
(Nalge Nunc, Rochester, NY) at a density of 5000/well. 
The next day, cells were stimulated with cytokines for 
30 min. Optimal dilutions were determined for each 
cytokine. Immediately after stimulation, slides were 
placed on ice and washed with ice-cold PBS. Cells were 
fixed in methanol for 10 minutes and maintained at -
20°C. After air-drying, the cells were washed in 
phosphate buffered saline (PBS) containing 1% bovine 
serum albumin (BSA) and then incubated in 10% 
normal donkey serum-PBS for 20 minutes to saturate 
non-specific binding sites. The slides were washed 3 
times with 1% BSA-PBS after each of the following 
steps. All antibodies were diluted to their optimal 
concentration in 1% BSA-PBS and the wells were 
incubated for 1 hour. A negative control was performed 
by incubating cells with 1% BSA-PBS in the presence 
of the secondary antibodies after 3 washes in PBS for 5 
minutes each. Nuclei were stained with Hoechst 33342 
stain. The slides were mounted with mounting medium 
containing 15% Vinol 205, 30% glycerol, and 0.1% 
sodium azide in PBS and examined by fluorescence 
microscopy. 
 
Isolation of mRNA and cDNA Synthesis 
mRNA was specifically isolated as described  by 
capturing of poly(A+) RNA in streptavidin-coated tubes 
with a mRNA Capture kit (Roche Applied Science) and 
cDNA was synthesized with the reverse transcription 
system kit (Promega) following the manufacturer's 
guidelines, essentially as described previously (32). 
Cells (30.000 cells/well) were washed twice with ice-
cold PBS and harvested with 100 µl of lysis buffer. 
Lysates were incubated with biotin-labeled oligo(dT)20 
for 5 min at 37 °C, and then 50 µl of the mix were 
transferred to streptavidin-coated tubes and incubated 
for 5 min at 37 °C. After washing three times with 250 
µl of washing buffer, 30 µl of the reverse transcription 
mix (5 mM MgCl2,1x reverse transcription buffer, 1 
mM deoxynucleotide triphosphate, 0.4 unit of 
recombinant RNasin ribonuclease inhibitor, 0.4 unit of 
avian myeloblastosis virus reverse transcriptase, and 0.5 
µg of random hexamers in 30 µl of nuclease-free water) 
were added to the tubes and incubated for 10 min at 
room temperature followed by a 45-min incubation at  
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Gene Gene ID Oligonucleotides 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) 
2597 
5’-CCATGTTCGTCATGGGTGTG-3’ 
5’-GGTGCTAAGCAGTTGGTGGTG-3’ 
myxovirus (influenza virus) resistance 1 
(Mx1/MxA) 
4599 
5’-TTCAGCACCTGATGGCCTATC-3’ 
5’-GTACGTCTGGAGCATGAAGAACTG-3’ 
STAT-1 6772 
5’-TGCATCATGGGCTTCATCAGC-3’ 
5’-GAAGTCAGGTTCGCCTCCGTTC-3’ 
p16ink4a 1029 
5’-CATAGATGCCGCGGAAGGT-3’ 
5’-TCAGAGCCTCTCTGGTTCTTTCA-3’ 
p21Waf1/Cip1 1026 
5’-CGACTGTGATGCGCTAATGG-3’ 
5’-CGGTGACAAAGTCGAAGTTCC-3’ 
p27Kip1 1027 
5’-GGAGAAGCACTGCAGAGACATG-3’ 
5’-CTCCACCTCTTGCCACTCGTA-3’ 
 
 
 
 
 
 
 
42 °C. To inactivate avian myeloblastosis virus reverse 
transcriptase and separate mRNA from the streptavidin-
biotin complex, samples were heated at 99 °C for 5 min, 
transferred to microcentrifuge tubes, and incubated in 
ice for 5 min. Then, they were diluted 1:5 in nuclease-
free water and stored at –20 °C until analysis. 
  
Real-time PCR 
Real-Time PCRs were performed as described 
previously (32). Briefly, oligonucleotides (see Table 1) 
were designed using Primer Express 2.0 computer 
software (Applied Biosystems) and were provided by 
Invitrogen. Oligonucleotide specificity was computer 
tested (BLAST; National Center for Biotechnology 
Information) by homology search with the human 
genome. Additionally, dissociation curve analysis was 
performed at the end of every run, showing in all cases 
one single peak at the Tm (melting temperature of the 
amplicon) predicted by the Primer Express 2.0 software. 
The efficiency of the primers was tested in preliminary 
experiments with a pool of cDNA of the samples used 
in the present study and maintained an average of 90%. 
PCRs were performed in an ABI 7900HT sequence 
detection system (Applied Biosystems) using SYBR 
Green Master Mix (Applied Biosystems) according to 
the manufacturer's guidelines. The fluorescence 
monitoring occurred at the end of each cycle. The Ct 
(cycle at the threshold) value is defined as the number 
of PCR cycles where the fluorescence signal exceeds 
the detection threshold value, which is fixed above 10 
times the S.D. of the fluorescence during the first 15 
cycles and typically corresponds to 0.2 relative 
fluorescence unit. This threshold is set constant 
throughout the study and corresponds to the log linear 
range of the amplification curve. The normalized 
amount of target reflects the relative amount of target 
transcripts with respect to the expression of the 
endogenous reference gene. In this study, the 
endogenous reference gene chosen was glyceraldehyde 
3-phosphate dehydrogenase. 
 
Statistical analysis 
Statistical analysis was performed using One-way 
analysis of variance and Bonferroni’s multiple 
comparison test. 
 
 
RESULTS 
 
IFN-dependent activation of STAT-1 and induction 
of IFN-response genes in RA FLS  
To confirm that RA FLS have the capacity to 
functionally respond to IFNs, we analyzed the 
phosphorylation and nuclear translocation of 
STAT-1 and STAT-2 using immunocytochemistry 
after treatment of RA FLS with Type I IFNs 
(IFN?, IFN?) and Type II IFN (IFN?). Typically, 
IFN? activates only STAT-1, whereas Type I IFNs 
also activate STAT-2, which is required for 
formation of the ISGF3 transcriptional complex 
that mediates Type I IFN signaling (33). IFN 
treatment rapidly induced STAT-1 
phosphorylation and nuclear translocation in a 
dose-dependent fashion, and doses of IFN? (1000 
u/ml), IFN? (200 u/ml) and IFN? (1000 u/ml) that 
Table 1. Primer pairs. Gene ID: Entrez Gene, National Center for Biotechnology Information.  
Primer pairs are shown with forward primer on top and reverse primer on bottom.
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were optimal for generation of activated STAT-1 
molecules were determined (Fig. 1A) after testing 
a range of dilutions for each cytokine: IFNa 
(10.000, 1000, 100, or 10 units/ml), IFNb (200, 
100, 50, or 25 units/ml) and IFNg (1000, 200, 100, 
or 50 units/ml) (not shown). As anticipated, IFN? 
activated only STAT-1, whereas IFN? and IFN? 
activated both STAT-1 and STAT-2. Next, we 
wished to determined the mRNA expression levels 
of STAT-1-inducible genes. mRNA was prepared 
from IFN-stimulated RA FLS at 0, 2, 4, 6 and 24 h 
after stimulation and analyzed for expression of 
MxA, which is a GTPase that is involved in the 
antiviral response and that is preferentially 
induced by Type I IFNs (34). Given the capacity 
of activated STAT-1 to up-regulate its own 
expression at the mRNA level (35), we also 
measured mRNA levels of STAT-1 itself. TNF?-
stimulated RA FLS were included as an additional 
control for cytokine response specificity. As 
anticipated, expression of MxA was strongly 
induced by Type I IFNs and weakly by IFN?, 
whereas it was absent in control and TNF?-
stimulated RA FLS (Fig. 1B). In addition, all IFNs 
rapidly up-regulated  STAT-1 expression. 
Collectively, these data suggest that the IFN 
response is functional in RA FLS, leading to 
STAT-1 activation and induction of a 
transcriptional response. 
 
 
IFN?, IFN? and IFN?  suppress DNA synthesis in 
RA FLS 
IFN-induced growth restraint has been reported in 
many cell types, and required transcriptionally 
active STAT-1 (27). To investigate the effect of 
IFNs on RA FLS proliferation, we measured DNA 
synthesis in RA FLS using a [3H]-Thymidine 
incorporation assay. Since high cellular density or 
low-serum concentrations may permanently affect 
RA FLS growth (18), RA FLS were plated at a 
low density (~15800 cells/cm2) and incubated with 
10% FCS at all times. Cells were exposed to either 
IFN?, IFN? or IFN? alone or in combination with 
TNF?. TNF?, which is a key cytokine in RA 
pathology, is abundant in synovium and stimulates 
RA FLS proliferation (8). After 24 h, RA FLS 
exposed to IFN?, IFN? or IFN? showed a 
significant reduction in DNA synthesis of more 
than 50%  compared to the unstimulated control 
(Fig. 2). DNA synthesis was suppressed in a dose-
dependent manner, and maximum inhibition was 
observed at the same doses of IFNs that were 
optimal for generation of activated STAT-1 
molecules (Fig. 1A), as was determined by testing 
dilutions ranging from 10x to 1:1000 of these  
doses (data not shown). As anticipated, treatment 
of RA FLS with TNF? alone strongly stimulated 
DNA synthesis (~225% compared with control).  
However, when cells were exposed to TNF? in 
combination with IFN?, IFN? or IFN?, DNA 
synthesis was suppressed to levels similar to those 
observed after IFN-treatment alone. Although 
proliferation rates varied among RA FLS from  
different RA patients, the IFN-induced suppressive 
effect on DNA synthesis was consistent in 10 
independent experiments performed with RA FLS 
from 5 different patients. These results indicate 
that IFN?, IFN? and IFN? suppress RA FLS 
proliferation and, moreover, that this effect is 
sufficiently strong to overrule the stimulatory 
effect of TNF?. 
 
 
IFN-induced suppression of RA FLS proliferation 
is not due to increased apoptosis 
To determine whether the IFN-induced 
suppression of DNA synthesis was due to 
induction of apoptosis, we analyzed levels of 
apoptotic and necrotic cell death in RA FLS after 
treatment with IFNs. Using a similar plating 
protocol to the [3H]-Thymidine uptake 
experiments, RA FLS were treated with IFN?, 
IFN? or IFN? for 24 h or 48 h. UV-irradiated RA 
FLS were used as a positive control for apoptosis. 
Apoptosis was assessed using flow cytometry and 
staining with Annexin V, which detects early 
apoptotic cells, and propidium iodide (PI), which 
stains late apoptotic and necrotic cells. Early 
apoptotic cells (positive for Annexin V and 
negative for PI) and late apoptotic/necrotic cells 
(positive for both) were quantified and the 
percentage of the total cell population was 
determined for each population (Fig. 3). Whereas 
apoptosis was apparent in the UV-irradiated RA 
FLS, there was no significant difference in the 
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Figure 1. STAT-1 and STAT-2 activation and induction of IFN-response genes by IFNα, IFNβ and IFNγ in RA FLS.  
A. RA FLS were seeded in chamber slides (5000 cells/well) and incubated with 10% FCS at all times. Cells were treated with 
IFNα (1000 units/ml), IFNβ (200 units/ml) or IFNγ (1000 units/ml) for 30 min. After fixation/permeabilization, cells were 
stained for Tyrosine phosphorylation of STAT-1 and STAT-2 (STAT-1-(Y701) and STAT-2-(Y689)) and examined for 
immunofluorescence. Hoechst staining (not shown) was used to confirm the nuclear localization of phosphorylated STAT-1 
and STAT-2.  
B. RA FLS were plated onto 24-well dishes (30.000 cells/well) and incubated with 10% FCS at all times. After treatment with 
IFNα (1000 units/ml), IFNβ (200 units/ml) or IFNγ (1000 units/ml) for 0, 2, 4, 6 or 24 h, cells were lysed, and mRNA was 
prepared. Untreated cells and cells treated with TNFα (100 u/ml) were used as a control. The relative abundance of MxA and 
STAT-1 transcripts was determined by real-time PCR using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
endogenous reference gene.  
 
A 
B 
Figure 2. Suppression of DNA synthesis by IFNα, IFNβ and IFNγ in RA 
FLS.  
RA FLS were cultured in 96-well plates (5000 cells/well) in medium 
with 10% FCS alone or in medium with IFNα (1000 units/ml), IFNβ 
(200 units/ml), IFNγ (1000 units/ml), TNFα (100 u/ml) or a combination 
of cytokines for 24 h. [3H]-Thymidine incorporation by untreated cells 
was set to 100%. Values are means of sextuplet cultures +/- STDEV. 
One-way analysis of variance P<0.0001; Bonferroni’s multiple 
comparison test: Control vs. IFNα, IFNβ or IFNγ, P<0.05, P<0.01, 
P<0.01, respectively; TNFα vs. TNFα+ IFNα, IFNβ or IFNγ, all 
P<0.001. 
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 levels of apoptosis in RA FLS treated with IFN?, 
IFN? or IFN? for 24 or 48 h compared to 
unstimulated cells, indicating that the IFN-induced 
suppression of RA FLS proliferation is not due to 
increased apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IFN?, IFN? and IFN?  limit cell cycle progression 
in RA FLS 
Next, we wished to test the hypothesis that IFN 
treatment prevented cell cycle progression in RA 
FLS. For this purpose, we measured the cellular 
DNA content using flow cytometry and PI staining 
of RA FLS exposed to either TNF?, IFN?, IFN? 
or IFN? alone or to IFNs in combination with 
TNF? for 24 h. Since starvation of RA FLS may 
alter expression of cell cycle regulatory genes and 
therefore permanently affect RA FLS growth (18), 
non-synchronized cell populations were used. 
Analysis of the cell cycle phase distribution 
clearly revealed that IFNs limited cell cycle 
progression (Fig. 4A). Whereas TNF? treatment  
decreased the proportion of cells in G0/1 phase 
and induced progression to G2/M phase, treatment 
with IFN?, IFN? or IFN? increased the proportion 
of cells in G0/1 phase to ~80%, compared to 
~65% in unstimulated cells and ~57% in cells 
treated with TNF? alone (Fig. 4B). This effect 
was observed both in the absence and presence of 
TNF?, indicating that the suppressive effect of 
IFNs overrules the proliferative effect of TNF?, 
which further supports our findings from the [3H]-
Thymidine uptake experiments. Furthermore, 
although RA FLS proliferation rates varied among 
different patients, the IFN-induced accumulation 
of cells in G0/1 was consistent, which is also in 
accordance with our previous results. To 
supplement data on RA FLS apoptosis (Fig. 3), we 
determined the subdiploid DNA content during 
cell cycle analysis (not shown), which further 
corroborated our observation that IFN-treatment 
does not induce apoptosis. Thus, it appeared that 
IFN?, IFN? and IFN? inhibit RA FLS 
proliferation by limiting S-phase entry and/or 
progression, causing accumulation of cells in G0/1 
phase. 
 
 
Induction of the cyclin-dependent kinase inhibitor 
p21Waf1/Cip1 by IFNs 
To elucidate the mechanism by which IFNs cause 
accumulation of RA FLS in G0/1 phase, we 
wished to determine whether IFN treatment 
affected the expression of CDKIs, which 
inactivate cyclin-CDK complexes and are thus 
essential in the inhibition of cell cycle progression. 
In RA FLS, expression of the CDKIs p16ink4a, 
p21Waf1/Cip1 and p27Kip1 has been reported (18), 
which all have been associated with the induction 
of cell cycle arrest in G1 phase (17). Therefore, we 
prepared mRNA from non-synchronized, IFN-
/TNF? treated RA FLS at 0, 2, 4, 6 and 24 h after 
stimulation and analyzed the expression levels of 
p16ink4a, p21Waf1/Cip1 and p27Kip1 (Fig. 5A).  
Figure 3. IFN-induced suppression of RA FLS 
proliferation is not due to cytotoxicity.  
RA FLS were plated onto 6-well dishes (120.000 
cells/well) and treated with IFN? (1000 units/ml), IFN? 
(200 units/ml) or IFN? (1000 units/ml) with 10% FCS for 
24 h or 48 h. UV-irradiated FLS (30 s.) were used as a 
positive control for apoptosis; untreated cells were used a 
negative control. Cells were analyzed by flow cytometry 
for Annexin V staining, which detects early apoptotic 
cells, and propidium iodide (PI) uptake, which detects late
apoptotic and necrotic cells. Early apoptotic cells 
(positive for Annexin V and negative for PI) and late 
apoptotic/necrotic cells (positive for both) were quantified
and the percentage of the total cell population was 
determined for each population. 
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A
B
Figure 4. IFNα, IFNβ and IFNγ limit cell cycle 
progression in RA FLS and overrule the stimulatory 
effect of TNFα. 
A. RA FLS were plated onto 6-well dishes 
(120.000 cells/well) and cultured in 
medium with 10% FCS alone or in 
medium with TNFα (100 u/ml) alone or a 
combination of TNFα with IFNα (1000 
units/ml), IFNβ (200 units/ml) or IFNγ 
(1000 units/ml) for 24 h. Cells were 
stained with PI and analyzed by FACS. 
Markers for G0/1-phase (M1), S-phase 
(M2) and G2/M-phase (M3), are indicated. 
B. The number of cells in G0/1, S and G2/M-
phase of the cell cycle was  determined for 
each histogram; the proportions of the 
total cell population are shown. 
 
A 
B 
Figure 5. IFNα, IFNβ and IFNγ induce 
expression of the cyclin dependent 
kinase inhibitor (CDKI) p21Waf1/Cip1. 
A. RA FLS were plated onto 24-
well dishes (30.000 cells/well) 
and incubated with 10% FCS 
at all times. After treatment 
with IFNα (1000 units/ml), 
IFNβ (200 units/ml) or IFNγ 
(1000 units/ml) for 0, 2, 4, 6 
or 24 h, cells were lysed, and 
mRNA was prepared. 
Untreated cells and cells 
treated with TNFα (100 u/ml) 
were used as a control. The 
relative abundance of the 
cyclin dependent kinase 
inhibitors (CDKIs) p16ink4a, 
p21Waf1/Cip1 and p27Kip1 
transcripts was determined by 
real-time PCR using 
glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as 
endogenous reference gene.  
B. RA FLS were seeded in 
chamber slides (5000 
cells/well) and incubated with 
10% FCS at all times. Cells 
were treated with IFNα (1000 
units/ml), IFNβ (200 units/ml) 
or IFNγ (1000 units/ml) for 2, 
4, 6, 8 or 24 h. After 
fixation/permeabilization, 
cells were stained for 
p21Waf1/Cip1. Cell density was 
comparable in all areas 
shown.  
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Strikingly, expression of p21Waf1/Cip1 was strongly 
affected by IFN treatment: whereas p21Waf1/Cip1 
mRNA levels in control and TNF?-treated RA 
FLS decreased slightly over time, treatment with 
IFN?, IFN? or IFN? rapidly induced a >2-fold  
increase in p21Waf1/Cip1 mRNA expression which 
peaked after 2 h and declined afterward. 
Conversely, expression of p16ink4a increased over 
time, but was not affected by IFN-/TNF? 
treatment, and p27Kip1 expression fluctuated over 
time, showing a similar trend under all conditions. 
Combined treatment with IFNs and TNF? 
rendered the same results (data not shown). To 
confirm the observed induction of p21Waf1/Cip1 
expression at the protein level, we performed 
immunocytochemistry on RA FLS for p21Waf1/Cip1 
after treatment with IFNs for 2, 4, 6, 8 or 24 h. 
p21Waf1/Cip1 protein levels were markedly increased 
after 6 h in IFN-treated RA FLS relative to the 
unstimulated control (Fig. 5B). Thus, treatment of 
RA FLS with IFN?, IFN? and IFN? induces 
expression of the CDKI p21Waf1/Cip1, which inhibits 
CDK activity and may therefore mediate the IFN-
induced accumulation of RA FLS in G0/1 phase.  
 
 
DISCUSSION 
 
In the present work, we demonstrate that IFN?, 
IFN? and IFN? can inhibit RA FLS proliferation 
by limiting cell cycle progression, resulting in 
accumulation of cells in G0/1 phase. Cell growth 
inhibition was correlated with STAT-1 activation 
and up-regulation of STAT-1 target genes, 
including the cyclin dependent kinase inhibitor 
p21Waf1/Cip1.  
IFN-induced growth restraint and apoptosis 
have been described in multiple cell types and 
were shown to be dependent on transcriptionally 
active STAT-1 (27-29). Whether IFNs have 
growth inhibitory and/or cytotoxic effects strongly 
depends on the cell type, and on the doses of IFNs 
that are used. Since our previous results 
demonstrated STAT-1 activation in RA FLS in the 
synovial lining (2), we wished to mimic this 
activation process in culture and determined the 
doses of IFN?, IFN? and IFN? that were optimal 
for generation of activated STAT-1 molecules. At 
these doses, no cytotoxic effect was observed. 
However, all IFNs inhibited cell cycle progression 
and caused accumulation of cells in G0/1 phase. 
Moreover, this effect overruled the proliferative 
effect of TNF?, which is a key mediator of RA 
pathology. This finding is in agreement with a 
previous report by Alvaro-Gracia et al., who 
demonstrated that IFN? inhibited TNF?-induced 
DNA synthesis and collagenase production in RA 
FLS (36). However, in contrast to our results, they 
observed no effect of IFN? on DNA synthesis 
relative to the control, which may be due to the 
dose they used. 
Concomitantly with the inhibition of cell cycle 
progression by IFN?, IFN? and IFN?, expression 
of the CDKI p21Waf1/Cip1 was up-regulated, 
whereas expression levels of p16ink4a and p27Kip1 
were not affected. We have also tested the gene 
expression of several other cell cycle regulatory 
genes, including cyclins D1, D2, D3, E1, E2 and 
the proto-oncogene c-myc (not shown), and 
p21Waf1/Cip1 appears to be the one that is strongly 
regulated by IFNs.  
p21Waf1/Cip1 was identified as a direct regulator 
of CDK activity that has a broad specificity for 
CDKs and inhibits proliferation both in vitro and 
in vivo, inducing cell cycle arrest in G1 (37-39). In 
addition to its role as a negative regulator of cell 
growth, growing evidence suggests that p21Waf1/Cip1 
can modulate multiple biological functions, 
including apoptosis and differentiation, and may 
directly regulate transcription (17;40).  
The role of p21Waf1/Cip1 in RA pathology 
remains to be fully evaluated. A study by 
Taniguchi et al. revealed no expression of 
p21Waf1/Cip1 in RA synovial tissues (18), whereas in 
a study by Perlman et al. p21 expression was 
demonstrated in the RA synovial lining, but its 
expression was reduced compared with OA 
synovial lining (41). Both studies report induction 
of p21Waf1/Cip1 expression in cultured FLS upon 
serum starvation, which is decreased compared 
with OA FLS. Reduced expression of p21Waf1/Cip1 
in RA was also reported in lymphocytes of RA 
patients (42). Studies in animal models suggest 
that increasing local expression of p21Waf1/Cip1 is an 
effective therapeutic strategy: forced expression of 
p21Waf1/Cip1 within the joint by intra-articular 
administration using adenoviral gene transfer 
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ameliorated experimental arthritis (19;20). In 
addition, adenovirus-mediated expression of p21 
induced G0/1 arrest in cultured FLS without 
inducing cytotoxicity (19;41). Furthermore, p21 
gene transfer down-regulated expression of 
various inflammatory mediators, including matrix 
metalloproteinase-1 and -3, IL-6 and IL-8 and 
reduced activation of the transcription factors NF-
?B and AP-1 (41;43). Thus, lack of p21Waf1/Cip1 
expression in RA synovium may contribute to 
pathology by increasing lining hyperplasia and 
production of proinflammatory mediators.  
While originally identified as a transcriptional 
target of p53, the p21Waf1/Cip1 gene is a target for 
diverse transcription factors, including STAT-1 
(44). STAT-1-mediated induction of p21Waf1/Cip1 
was shown to be essential for IFN-induced cell 
growth arrest (45;46). In line with these reports, 
IFN-dependent cell cycle inhibition and up-
regulation of p21Waf1/Cip1 expression in RA FLS 
correlated with STAT-1 activation and induction 
of expression of STAT-1 itself. It has been 
suggested that STAT-1 activation in RA FLS can 
oppose the proliferative effect of STAT-3 in FLS 
(24), which is supported by our observations.  
Interestingly, p21 can directly modulate the 
STAT-1/3 balance by interacting with STAT-3 
and suppressing its transcriptional activity (47).  
We have previously reported evidence for the 
involvement of STAT-1 in RA (1;2). A subset of 
RA synovial tissues exhibited gene expression 
consistent with ongoing inflammation and 
activation of STAT-1, whereas the gene 
expression profile of the other subset of RA 
synovial tissues was more similar to osteoarthritis 
tissue (1). It is not clear whether these differences 
reflect different classes of RA or different stages 
in the disease. Evidence for the latter has been 
provided by de Hooge et al., who described 
temporal differences in STAT-1 activation during 
the course of experimental arthritis (48). They 
compared wild-type (WT) and STAT-1 -/- mice 
during the acute and chronic phases of the disease. 
STAT-1 expression and activation in WT mice 
were restricted to the chronic phase of the disease, 
and STAT-1 deficiency resulted in exacerbation of 
arthritis. The authors propose a role for STAT-1 as 
a negative regulator of arthritis, mediated by 
induction of SOCS-proteins. Our results suggest 
that STAT-1 activation may have additional 
protective effects in RA by negatively modulating 
the growth abnormalities of RA FLS. The 
occurrence of activation of STAT-1 in RA during 
the course of disease may therefore represent a 
reactive attempt to limit ongoing inflammation. 
The relationship between the phase of disease, 
STAT-1 activation and expression of SOCS 
proteins and p21 warrants further investigation. 
The question remains which cytokine(s) is/are 
responsible for STAT-1 activation in synovial 
lining cells. Expression of IFN? is very low in 
synovium and predominantly found in the 
sublining around lymphocytic infiltrates (49;50). 
The most likely candidate responsible for STAT-1 
activation in RA FLS seems IFN?, which is highly 
expressed in synovium, particularly in the intimal 
lining layer (51;52). Strikingly, IFN? is produced 
by FLS (51;53), which suggests an autocrine 
activation process, perhaps as part of a reactive, 
negative feedback loop. The importance of IFN? 
production by FLS is highlighted by a recent study 
by Treschow et al., who demonstrated that IFN? 
deficiency prolonged experimental arthritis and 
resulted in increased activation of FLS in vitro 
(54). In addition, IFN?-competent fibroblasts were 
able to ameliorate arthritis in IFN?-deficient 
recipients. Interestingly, administration of 
recombinant IFN? ameliorated experimental 
arthritis, suggesting that supplementing autocrine 
IFN? signaling may enhance its beneficial effect 
(53). However, treatment of RA patients with 
IFN? has been unsuccessful so far, which may be 
due to pharmacokinetic issues (55;56).  
Our results suggest that IFN-treatment can 
negatively modulate the growth abnormalities of 
RA FLS, suggesting that  therapeutic approaches 
that selectively manipulate STAT-1 may have 
beneficial effects in RA. Additional experiments 
will be required to determine whether the IFN-
induced effect is dependent on STAT-1 alone and 
to gain a better understanding of the interaction of 
IFN-treatment with autocrine effects. 
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Introduction 
 
Despite intense research efforts, the pathology of Rheumatoid Arthritis (RA) is still 
poorly understood. Attempts to understand the pathogenesis are partly hampered by 
the fact that RA is a heterogeneous disease, which is reflected in the clinical 
presentation, treatment responsiveness and the histological features of RA synovium. 
Therefore, it has been proposed that RA is not a pathogenetically single disease entity 
but rather a so called “final common pathway” that may be the result of a variety of 
pathologic processes. Both immune- and non-immune disease mechanisms have 
been implicated in RA pathology, but a more comprehensive understanding is needed 
of the ways in which the various pathophysiologic mechanisms contribute to disease. 
Fundamental questions remain to be answered regarding the precise molecular 
nature and biological significance of the inflammatory changes in RA synovium and 
how these relate to disease heterogeneity. 
 
By definition, nearly every aspect of a disease phenotype should be represented in 
gene expression signatures of multiple genes in the affected tissue. Studies that 
analyze affected tissues in cancer clearly show that gene expression profiling made it 
possible to predict prognosis, to identify new classes of diseases, and potentially to 
predict response to treatment, which may eventually allow for patient-tailored 
therapy strategies 1-3.  In addition, large-scale gene expression profiling provides a 
mechanistic insight into the disease process by yielding a comprehensive view of the 
various signaling pathways that are activated simultaneously, thereby allowing for the 
identification of biological themes.   
 
We have applied a functional genomics approach to analyze the system of genes in 
affected RA synovial tissue and FLS and complemented this by a more reductionist 
approach focusing on an individual pathway and its relevance to RA pathology. 
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Evaluating rheumatoid arthritis heterogeneity by microarray technology 
 
Gene expression profiling of synovial tissues of RA and OA patients using cDNA 
microarrays revealed a remarkable variation in gene expression profiles that allowed 
us to identify molecularly distinct forms of RA synovium 4. One RA subgroup 
expressed genes characteristic of ongoing inflammation, while another type 
expressed genes indicative of an increased tissue remodeling activity reminiscent of 
the profile seen in OA tissues. These results were corroborated by an independent 
study in which we performed global gene expression analysis on RA synovial tissues 
using microarrays containing ~24,000 cDNA spots representing a random set of 
genes 5. In addition, heterogeneity was apparent in gene expression profiles of RA 
FLS 6. Based on distinctive gene expression patterns, we identified different FLS 
phenotypes. The molecular subclassification of rheumatoid FLS matched the 
molecular subclassification of the entire synovial tissue from which they were 
derived, indicating that RA heterogeneity is reflected in FLS as a stable trait.  
 
At present it is unclear what the molecular subclassification of RA synovial tissue and 
FLS means in clinical terms. Although we found an association between a high-
inflammation signature in synovial tissue and an increased erythrocyte 
sedimentation rate (ESR) 4, the study design did not allow any firm conclusions to be 
drawn concerning the clinical parameters associated with the molecular phenotype. It 
is likely that the molecular differences reflect distinct pathophysiologic processes 
underlying disease. However, it is unclear whether these differences are related to the 
stage and/or severity of disease or if they reflect differences in e.g. the action of 
different genetic factors or interactions between genes and environmental factors.  
 
To understand the biological basis of this molecular heterogeneity, it is essential to 
integrate the information on differential gene expression in synovial tissues and FLS 
with data on expression profiles in the other compartments of the body. Given the 
systemic nature of the disease, this approach is highly useful for evaluating spatial 
and temporal dynamics of pathophysiologic changes that are involved in RA 
pathology. Differential gene expression profiles in peripheral blood mononuclear 
cells (PBMC) have been described in RA patients relative to healthy controls (HC) 7, 
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which revealed increased expression of immune/inflammatory genes in RA patients. 
Furthermore, differential gene expression has been described in PBMC from early RA 
compared to established RA 8, which revealed a gene expression signature in early RA 
that showed some overlap with that seen in the normal immune response to viral 
antigen, possibly reflecting the response to an unknown infectious agent. Thus, these 
studies suggest that molecular heterogeneity in RA is also reflected in cellular 
compartments outside the affected tissue. Currently, in our laboratory a study is 
ongoing to compare gene expression profiles in whole blood from 25 RA patients and 
25 HC, which will further address this issue. Furthermore, to assess the clinical 
relevance of the molecular differences, a thorough clinical association study will be 
required to integrate the information from genomics and proteomics research with 
clinical parameters. Ultimately, this information will help clinicians to select 
subgroups of RA patients for optimal treatment and research purposes. 
 
 
Linking synovial tissue inflammation state to FLS phenotype  
 
Perhaps the most striking aspect of our gene expression profiling results was the 
observation that distinct FLS phenotypes were significantly related to the type of RA 
synovial tissue from which they were derived 6. FLS from high-inflammation synovial 
tissues revealed increased expression of a transforming growth factor β/Activin A–
inducible gene expression profile that is characteristic of myofibroblasts, a cell type 
considered to be involved in wound healing, whereas increased production of growth 
factor (insulin-like growth factor 2/insulin-like growth factor binding protein 5) 
appeared to constitute a characteristic feature of FLS derived from low-inflammation 
synovial tissues. This suggests that the synovial microenvironment can induce 
changes in FLS phenotype that are manifested upon in vitro culturing of the cells 
and, thus, persists beyond the initial stimulus. Therefore, these findings reinforce the 
concept of a transformed character of FLS. The mechanism leading to such a 
permanent imprint and autonomous behavior of the different types of FLS in vivo is 
currently under investigation in our laboratory. It may involve epigenetic alterations 
or somatic DNA mutations, which may cause the permanent production of growth- 
and differentiation factors leading to the distinct FLS phenotypes.  
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The molecular feature that defines the myofibroblast-like phenotype in the FLS 
derived from high-inflammation synovial tissues was reflected as an increased 
proportion of myofibroblast-like cells in the FLS population in vitro, as was revealed 
by the characteristic expression of smooth muscle actin (SMA) in stress fibers 6. 
Myofibroblast-like cells were also found in RA synovial tissue. The involvement of 
myofibroblast-like FLS in RA pathogenesis was further supported by a recent study 
by Aidinis et al. 9. Using a twin high-throughput approach, they identified actin 
cytoskeletal rearrangements in FLS as a pathophysiological determinant of disease in 
a TNF-driven animal model of RA. Arthritic mouse FLS exhibited pronounced stress 
fibers and focal adhesion kinase-positive islands, adhered to various extracellular 
matrix components with increased affinity in vitro and displayed a more elongated 
shape in vivo, which are all prominent features of myofibroblasts. However, data on 
the expression of SMA, which is the most reliable marker of myofibroblasts 10 , in 
arthritic mouse FLS are not available yet. In our study, we identified the 
myofibroblast phenotype as part of an entire transforming growth factor 
(TGF)β/Activin A-inducible gene expression profile 6 and demonstrated that FLS can 
be induced to differentiate into myofibroblasts in vitro by treatment with TGFβ and 
Activin A (unpublished observation). Aidinis et al. propose that the induction of the 
myofibroblast-like phenotype in FLS is the result of reduced expression of gelsolin, 
which is an actin-binding protein that is involved in transduction of signals into 
dynamic cytoskeletal rearrangements 9. They demonstrate disease exacerbation in 
gelsolin knock-out mice and confirm its reduced expression in human RA FLS 
compared to OA FLS. Interestingly, although gelsolin expression was overall 
decreased in RA, it expression revealed remarkable heterogeneity, which is in line 
with our discovery that the myofibroblast-like phenotype is apparent in only a subset 
of RA FLS. Clearly, further investigation is needed to identify the myofibroblast-
inducing factor and the role of myofibroblasts in RA pathology. 
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Evidence for the occurrence of distinct disease mechanisms during RA 
pathology 
 
The results obtained from our gene expression profiling studies on RA synovial tissue 
4 and FLS 6 would fit a model proposed by Firestein and Zvaifler 11.  They proposed 
two distinctive pathophysiologic mechanisms that occur independently in RA: One is 
a T cell-mediated process that might progress to a T cell-independent process that is 
centered on autonomous FLS aggression. The identification of distinctive RA synovial 
tissue types based on high- or low-inflammation gene expression profile would 
therefore argue in favor of both a T cell-involved and an autonomous stromal cell 
form of disease. Furthermore, in the context of this model, the myofibroblast-like FLS 
can be considered part of a T cell-mediated disease process. The other subgroup of 
FLS that is characterized by increased expression of growth factors and appears not 
to be associated with massive infiltration of immune cells in synovium could be 
considered immune-independent autonomous FLS aggressors.  
 
 
Characterization of the  STAT-1 pathway and its activation in RA 
synovium 
 
Because similar fluctuations in gene expression suggest similar function or 
involvement in a common pathway, the identification of genes that have similar 
expression patterns may provide mechanistic insight into the disease process. 
Detailed analysis of the high-inflammation synovial tissue signature provided 
evidence for a prominent role of an activated Signal Transducer and Activator of 
Transcription 1 (STAT-1) pathway in this subgroup of RA synovial tissues 4. STAT-1 
activation was reflected by increased expression of STAT-1 target genes, including 
STAT-1 itself, and a number of potential STAT-1-inducing receptors. To further 
corroborate these data, we analyzed STAT-1 protein expression in synovium of RA 
patients and disease controls. Whereas overall STAT-1 protein levels were increased 
in RA relative to disease controls, we observed remarkable heterogeneity among RA 
patients which was in agreement with our gene expression profiling results. Since the 
RA synovia tested in this study were obtained during joint replacement surgery, i.e. 
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during end-stage disease, we next analyzed STAT-1 protein expression and 
phosphorylation in RA synovial tissue biopsies from patients with active disease 12. 
Overall, STAT-1 expression and phosphorylation were significantly increased in RA 
synovial tissue compared to disease controls. These findings were in line with a 
previous report demonstrating increased STAT-1 expression in RA synovial tissues 
obtained during joint replacement surgery relative to normal controls 13 and were 
recently confirmed by Walker et al., who reported increased expression of STAT-1 in 
synovium of patients with active RA compared to normal and disease controls 14. In 
addition, evidence for increased STAT-1 activation in RA has been documented in RA 
synovial fluid (SF) cells 15 and local STAT-1 expression and activation were observed 
in the inflamed synovium during the course of experimental arthritis 16. 
 
The cellular levels of STAT-1 protein, and in particular the relative abundance to 
other signaling molecules such as STAT-3, are likely to have a major impact on how 
cells behave in response to different cytokines 13;17. Recent evidence has indicated that 
differential modulation of STAT-1 protein levels is used by the immune system to 
selectively modify cytokine-mediated responses in distinct cellular subsets 18. 
Therefore, we next investigated the cellular expression pattern of STAT-1 in RA 
synovium 12. This revealed differential expression of STAT-1 in synovial cell subsets, 
with STAT-1 being particularly prominent in the synovial lining. Phenotypic 
characterization revealed that this was predominantly due to expression by FLS, 
whereas STAT-1 expression in macrophages was relatively low. The latter finding is in 
contrast to a suggestion made by Hu et al., who also observed high amounts  of STAT-
1 in the RA synovial lining layer and attributed this to expression of STAT-1 by 
macrophages 13. Interestingly, the high amounts of STAT-1 in RA FLS were sustained 
in culture, indicating that this is a stable feature of RA FLS. We also observed STAT-1 
in T- and B-lymphocytes. However, STAT-1 expression levels in synovial lymphocytes 
were variable and may reflect the state of activation and cellular differentiation of 
these cells.  
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Evaluating the role of STAT-1 signaling in RA pathology 
 
Activation of STAT-1 can have divergent biological effects in different cell types. To 
gain more insight into the functional effects of STAT-1 activation in RA FLS and its 
relevance to RA pathology, we examined the effect of interferon (IFN)-induced STAT-
1 activation on FLS survival and growth (unpublished results). We demonstrated that 
Type I and Type II IFNs can inhibit RA FLS proliferation by limiting cell cycle 
progression, which correlated with STAT-1 activation and up-regulation of STAT-1 
target genes, including the cyclin dependent kinase inhibitor (CDKI) p21Waf1/Cip1. 
These results suggest that STAT-1 activation negatively modulates the growth 
abnormalities of RA FLS and may therefore have a protective effect in RA. This 
notion is supported by studies in animal models that demonstrated that forced 
expression of p21Waf1/Cip1 within the joint ameliorated experimental arthritis 19;20. The 
effects of STAT-1 activation in T cells on pathology are not clear. Although STAT-1 
was shown to be essential for the antiproliferative response to Type I IFN in 
lymphocytes 21, a study by Pilling et al. has suggested that STAT-1 activation by Type I 
IFN is responsible for rescue of T cells from apoptosis and the persistence of 
lymphocytes in the rheumatoid synovium 22. Therefore, STAT-1 activation in T cells 
may mediate both pathogenic and protective effects in RA, possibly depending on the 
stage of differentiation of the cells.  
 
Additional evidence for an overall protective effect of STAT-1 in RA has been 
provided by de Hooge et al., who demonstrated that STAT-1 deficiency resulted in 
exacerbation of experimental arthritis 16.  The authors propose a role for STAT-1 as a 
negative regulator of arthritis, mediated by induction of SOCS-proteins. This view has 
been supported by studies demonstrating a protective effect of SOCS-1 and SOCS-3 in 
experimental arthritis 23;24.  
 
Interestingly, de Hooge et al. observed temporal differences in STAT-1 expression 
and activation during the course of experimental arthritis in wild-type mice 16. STAT-
1 expression and activation in wild-type mice were restricted to the chronic phase of 
the disease, which argues in favor of the view that the differential gene expression 
profiles that we observed in RA synovial tissues 4 reflect different stages in the disease 
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rather than different classes of RA. The occurrence of activation of STAT-1 in RA 
during the course of disease may therefore represent a reactive attempt to limit 
ongoing inflammation. Further investigation is needed to elucidate the relationship 
between the phase of disease, STAT-1 activation and its effect on expression of cell 
cycle regulatory proteins and feedback inhibition by SOCS-proteins.  
 
The question remains which ligand(s) is/are responsible for STAT-1 activation in RA 
synovium. The most likely candidate is IFNβ, which is highly expressed in synovium, 
especially in the intimal lining layer 22;25, whereas expression of IFNγ is very low in 
synovium and predominantly found in the sublining around lymphocytic infiltrates 
26. Strikingly, IFNβ is produced by FLS 22;27, suggesting an autocrine activation 
process, perhaps as part of a reactive, negative feedback loop. The importance of 
IFNβ production by FLS is highlighted by a recent study by Treschow et al., who 
demonstrated that IFNβ deficiency prolonged experimental arthritis and resulted in 
increased activation of FLS in vitro 28. In addition, IFNβ-competent fibroblasts were 
able to ameliorate arthritis in IFNβ-deficient recipients.  
 
If STAT-1 activation in RA synovium is indeed a reactive attempt to limit 
inflammation, then it is clearly not strong enough to resolve chronic inflammation. 
Therefore, therapeutic approaches that selectively manipulate STAT-1 signaling and 
thereby supplement autocrine mechanisms may have beneficial effects in RA. 
However, although treatment with recombinant IFNβ showed promising results in 
experimental arthritis 27, treatment of RA patients with IFNβ has been unsuccessful 
so far, which may be due to pharmacokinetic issues 29;30. Future studies will be 
required to determine if this therapeutic approach is feasible.  
  
 
 
 
 
 General Discussion
111
References 
 
 1.  van,d., V, Y.D.He, L.J.van't Veer, H.Dai, A.A.Hart, D.W.Voskuil, G.J.Schreiber, J.L.Peterse, C.Roberts, 
M.J.Marton, M.Parrish, D.Atsma, A.Witteveen, A.Glas, L.Delahaye, d.van, V, H.Bartelink, S.Rodenhuis, 
E.T.Rutgers, S.H.Friend, and R.Bernards. 2002. A gene-expression signature as a predictor of survival in 
breast cancer. N. Engl. J. Med. 347:1999-2009. 
 2.  't Veer,L.J., H.Dai, M.J.van de Vijver, Y.D.He, A.A.Hart, M.Mao, H.L.Peterse, K.K.van der, M.J.Marton, 
A.T.Witteveen, G.J.Schreiber, R.M.Kerkhoven, C.Roberts, P.S.Linsley, R.Bernards, and S.H.Friend. 
2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536. 
 3.  Cleator,S. and A.Ashworth. 2004. Molecular profiling of breast cancer: clinical implications. Br. J. 
Cancer 90:1120-1124. 
 4.  van der Pouw Kraan TC, F.A.Van Gaalen, P.V.Kasperkovitz, N.L.Verbeet, T.J.Smeets, M.C.Kraan, 
M.Fero, P.P.Tak, T.W.Huizinga, E.Pieterman, F.C.Breedveld, A.A.Alizadeh, and C.L.Verweij. 2003. 
Rheumatoid arthritis is a heterogeneous disease: Evidence for differences in the activation of the STAT-1 
pathway between rheumatoid tissues. Arthritis Rheum. 48:2132-2145. 
 5.  van der Pouw Kraan TC, F.A.Van Gaalen, T.W.Huizinga, E.Pieterman, F.C.Breedveld, and C.L.Verweij. 
2003. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray 
technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes 
Immun. 4:187-196. 
 6.  Kasperkovitz,P.V., T.C.Timmer, T.J.Smeets, N.L.Verbeet, P.P.Tak, L.G.van Baarsen, B.Baltus, 
T.W.Huizinga, E.Pieterman, M.Fero, G.S.Firestein, van der Pouw Kraan TC, and C.L.Verweij. 2005. 
Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial 
tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-
inflammation synovitis. Arthritis Rheum. 52:430-441. 
 7.  Bovin,L.F., K.Rieneck, C.Workman, H.Nielsen, S.F.Sorensen, H.Skjodt, A.Florescu, S.Brunak, and 
K.Bendtzen. 2004. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and 
effect of rheumatoid factor. Immunol. Lett. 93:217-226. 
 8.  Olsen,N., T.Sokka, C.L.Seehorn, B.Kraft, K.Maas, J.Moore, and T.M.Aune. 2004. A gene expression 
signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann. Rheum. Dis. 
63:1387-1392. 
 9.  Aidinis,V., P.Carninci, M.Armaka, W.Witke, V.Harokopos, N.Pavelka, D.Koczan, C.Argyropoulos, 
M.M.Thwin, S.Moller, W.Kazunori, P.Gopalakrishnakone, P.Ricciardi-Castagnoli, H.J.Thiesen, 
Y.Hayashizaki, and G.Kollias. 2005. Cytoskeletal rearrangements in synovial fibroblasts as a novel 
pathophysiological determinant of modeled rheumatoid arthritis. PLoS. Genet. 1:e48. 
 10.  Gabbiani,G. 2003. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 
200:500-503. 
 11.  Firestein,G.S. and N.J.Zvaifler. 2002. How important are T cells in chronic rheumatoid synovitis?: II. T 
cell-independent mechanisms from beginning to end. Arthritis Rheum. 46:298-308. 
 12.  Kasperkovitz,P.V., N.L.Verbeet, T.J.Smeets, J.G.van Rietschoten, M.C.Kraan, van der Pouw Kraan TC, 
P.P.Tak, and C.L.Verweij. 2004. Activation of the STAT1 pathway in rheumatoid arthritis. Ann. Rheum. 
Dis. 63:233-239. 
 13.  Hu,X., C.Herrero, W.P.Li, T.T.Antoniv, E.Falck-Pedersen, A.E.Koch, J.M.Woods, G.K.Haines, and 
L.B.Ivashkiv. 2002. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat. 
Immunol. 3:859-866. 
 14.  Walker,J.G., M.J.Ahern, M.Coleman, H.Weedon, V.Papangelis, D.Beroukas, P.J.Roberts-Thomson, and 
M.D.Smith. 2005. Expression of Jak3, STAT1, STAT4 and STAT6 in inflammatory arthritis: Unique Jak3 
and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann. Rheum. Dis. 
 15.  Yokota,A., M.Narazaki, Y.Shima, N.Murata, T.Tanaka, M.Suemura, K.Yoshizaki, H.Fujiwara, 
I.Tsuyuguchi, and T.Kishimoto. 2001. Preferential and persistent activation of the STAT1 pathway in 
rheumatoid synovial fluid cells. J. Rheumatol. 28:1952-1959. 
 16.  de Hooge,A.S., F.A.van de Loo, M.I.Koenders, M.B.Bennink, O.J.Arntz, T.Kolbe, and W.B.Van den Berg. 
2004. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced 
arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum. 50:2014-
2023. 
 17.  Qing,Y. and G.R.Stark. 2004. Alternative activation of STAT1 and STAT3 in response to interferon-
gamma. J Biol. Chem. 279:41679-41685. 
 18.  Gil,M.P., R.Salomon, J.Louten, and C.A.Biron. 2005. Modulation of STAT1 protein levels: A mechanism 
shaping CD8 t cell responses in vivo. Bl. 
 19.  Nonomura,Y., H.Kohsaka, K.Nasu, Y.Terada, M.Ikeda, and N.Miyasaka. 2001. Suppression of arthritis by 
forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints. Int. Immunol. 
13:723-731. 
 20.  Nasu,K., H.Kohsaka, Y.Nonomura, Y.Terada, H.Ito, K.Hirokawa, and N.Miyasaka. 2000. Adenoviral 
transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J. 
Immunol. 165:7246-7252. 
 21.  Gimeno,R., C.K.Lee, C.Schindler, and D.E.Levy. 2005. Stat1 and Stat2 but not Stat3 arbitrate 
contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol. Cell Biol. 25:5456-
5465. 
 Chapter 7
112
 22.  Pilling,D., A.N.Akbar, J.Girdlestone, C.H.Orteu, N.J.Borthwick, N.Amft, D.Scheel-Toellner, C.D.Buckley, 
and M.Salmon. 1999. Interferon-beta mediates stromal cell rescue of T cells from apoptosis. Eur. J. 
Immunol. 29:1041-1050. 
 23.  Egan,P.J., K.E.Lawlor, W.S.Alexander, and I.P.Wicks. 2003. Suppressor of cytokine signaling-1 regulates 
acute inflammatory arthritis and T cell activation. J Clin. Invest 111:915-924. 
 24.  Shouda,T., T.Yoshida, T.Hanada, T.Wakioka, M.Oishi, K.Miyoshi, S.Komiya, K.Kosai, Y.Hanakawa, 
K.Hashimoto, K.Nagata, and A.Yoshimura. 2001. Induction of the cytokine signal regulator SOCS3/CIS3 
as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest 108:1781-1788. 
 25.  van,H.J., T.J.Smeets, P.Blankert, and P.P.Tak. 2005. Expression of interferon beta in synovial tissue 
from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive 
arthritis. Ann. Rheum. Dis. 64:1780-1782. 
 26.  Fonseca,J.E., J.C.Edwards, S.Blades, and N.J.Goulding. 2002. Macrophage subpopulations in 
rheumatoid synovium: reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments. 
Arthritis Rheum. 46:1210-1216. 
 27.  Van Holten,J., K.Reedquist, P.Sattonet-Roche, T.J.Smeets, C.Plater-Zyberk, M.J.Vervoordeldonk, and 
P.P.Tak. 2004. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage 
destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 6:R239-
R249. 
 28.  Treschow,A.P., I.Teige, K.S.Nandakumar, R.Holmdahl, and S.Issazadeh-Navikas. 2005. Stromal cells 
and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient 
mice. Arthritis Rheum. 52:3739-3748. 
 29.  Tak,P.P. 2004. IFN-beta in rheumatoid arthritis. Front Biosci. 9:3242-3247. 
 30.  Van Holten,J., C.Plater-Zyberk, and P.P.Tak. 2002. Interferon-beta for treatment of rheumatoid 
arthritis? Arthritis Res. 4:346-352. 
 
 
Summary
114
 Summary
115
From genomics to STAT-1 in Rheumatoid Arthritis 
 
Rheumatoid arthritis (RA) is a severe, chronic inflammatory joint disease that occurs 
in about 1% of the population. The disease is associated with swelling and pain in 
multiple joints and destruction of cartilage and bone, which causes significant joint 
deformity and disability. The pathology of RA is characterized by inflammation of 
synovial tissue, which is the soft tissue that lines the joint cavity, and formation of an 
aggressive front tissue (pannus), which invades and destroys articular structures. The 
cause of RA is still unknown and its pathology is thought to be mediated by both 
immune and non-immune mechanisms. However, RA pathology is complex and still 
poorly understood. Increasing evidence suggests that RA is not one single disease, 
but rather a diagnosis given to a condition that may be the results of a variety of 
pathological processes. Thus, fundamental questions remain to be answered 
regarding the nature of RA. 
 
New avenues for biomedical research have been opened over the past few decades. 
With the completion of the Human Genome Project, the entire human genome - 
which is defined as the whole hereditary information of an organism that is encoded 
in the DNA - has been sequenced and mapped. The set of genes that is active in a cell 
a at a given time determines the biological processes that occur. The activity of a 
particular gene can be measured by quantifying the mRNA that is transcribed from 
this gene. Microarray technology provides a unique tool to catch the whole set of 
genes in action. Basically, the technology allows us to take a “photograph” which 
captures the activity of all genes in a given cell or tissue, at a given time or under a 
given condition, which results in a so-called gene expression pattern or profile. In this 
way, it is now possible to study the ways in which molecular components work 
together to perform function, rather than focusing only on individual genes and 
molecules. 
 
In Chapter 2, microarray technology and its impact on basic and clinical 
immunology research are described.  cDNA microarrays have been used to study the 
gene expression response in specific immune-cell subsets under various conditions. A 
better understanding of both innate and adaptive immune responses provides the 
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basis for understanding the processes underlying deregulation in immune-mediated 
disease. In addition, the generation of characteristic molecular signatures of cells and 
tissues under pathophysiological conditions can help to identify individuals with 
similar biological patterns and give insight into the molecular basis  of pathological 
processes. 
 
In Chapter 3, we characterized gene expression profiles of affected synovial tissues 
from RA patients and patients with osteoarthritis (OA) as a control using microarrays 
containing ~18,000 cDNAs representing predominantly genes thought to be involved 
in immunological processes. The gene expression signatures of synovial tissues from 
RA patients showed considerable variability, resulting in the identification of at least 
two molecularly distinct forms of RA tissues. One class of tissues revealed a gene 
expression profile indicative of influx of inflammatory cells and activation of the 
adaptive immune response. At the cellular level, pathological processes like 
inflammation are regulated by signal transduction pathways that translate an 
extracellular signal into a transcriptional response. Detailed analysis of the gene 
expression profile of this subgroup of RA synovial tissues provided evidence for a 
prominent role of an activated signal transducer and activator of transcription 1 
(STAT-1) pathway. STAT-1 activation was reflected by increased expression of STAT-1 
target genes, including STAT-1 itself, and a number of potential STAT-1-inducing 
receptors. The expression profiles of another group of RA tissues revealed an 
increased tissue remodeling activity and a low inflammatory gene expression 
signature. The gene expression pattern in the latter tissues was reminiscent of that 
observed in the majority of OA tissues. Taken together, our data demonstrate that the 
heterogeneous nature of RA is reflected in differential gene expression profiles in 
synovial tissues, and suggest a role for the STAT-1 pathway in a subset of RA synovial 
tissues.  
 
In Chapter 4, we analyzed the gene expression profiles in fibroblast-like 
synoviocytes (FLS) cultured from the RA synovial tissues described in Chapter 3 and 
several other RA tissues using cDNA microarrays. Hierarchical clustering identified 2 
main groups of FLS, characterized by distinctive gene expression profiles. Strikingly, 
the molecular subclassification of rheumatoid FLS matched the molecular 
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subclassification of the entire synovial tissue from which they were derived. FLS 
derived from synovial tissues that showed a gene expression profile characteristic of 
high ongoing inflammation revealed increased expression of a transforming growth 
factor β/Activin A–inducible gene expression profile that is characteristic of 
myofibroblasts, a cell type considered to be involved in wound healing. Conversely, 
increased production of growth factor (insulin-like growth factor 2/insulin-like 
growth factor binding protein 5) appeared to constitute a characteristic feature of FLS 
derived from synovial tissues that harbored features of low inflammation and high 
tissue-remodeling activity. Therefore, these results suggest a link between 
inflammatory synovitis and the occurrence of myofibroblast-like FLS. The molecular 
feature that defines the myofibroblast-like phenotype was reflected as an increased 
proportion of myofibroblast-like cells in the heterogeneous FLS population. 
Myofibroblast-like cells were also found upon immunohistochemical analysis of 
synovial tissue. These findings support the notion that heterogeneity between 
synovial tissues is reflected in FLS as a stable trait, and provide evidence of a possible 
link between FLS phenotype and the inflammation status of RA synovium. 
 
Elaborating on Chapter 3, we studied the activation state of STAT-1 in RA synovium, 
which is described in Chapter 5. We applied immunohistochemistry to analyze 
STAT-1 protein expression and STAT-1 Tyrosine- and Serine-phosphorylation in 
synovial tissue of RA patients and disease controls. Digital image analysis was used 
for quantitative analysis. Overall, STAT-1 expression and phosphorylation were 
significantly increased in RA synovial tissue compared to disease controls and were 
particularly prominent in the synovial lining. However, in analogy to the molecular 
profiling data, we observed remarkable variability in STAT-1 expression among the 
RA synovia tested. Phenotypic characterization of synovial cell-types revealed that 
STAT-1 was expressed by T- and B-lymphocytes. Strikingly, the abundant STAT-1 
expression in the synovial lining appeared to be predominantly due to expression by 
FLS, whereas STAT-1 expression in macrophages was relatively low. Increased 
expression of STAT-1 was sustained in cultured RA FLS, suggesting that this is an 
intrinsic feature of RA FLS. STAT-1 phosphorylation was lost in culture, indicating 
that STAT-1 phosphorylation is an active process that is inducible by cytokines 
present in the RA synovium. This is in line with the observed pattern of STAT-1 target 
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gene induction in the gene expression data and supports the notion that the STAT-1 
pathway is activated and functional in a subset of RA synovial tissues.  
 
To gain more insight into the functional effects of STAT-1 activation in RA FLS and 
its relevance for RA pathology, we examined the effect of interferon (IFN)-induced 
STAT-1 activation on FLS survival and growth, which is described in Chapter 6. 
Treatment of RA FLS with IFNα, IFNβ or IFNγ led to rapid phosphorylation of STAT-
1 and induction of a STAT-1-specific transcriptional response, indicating that the IFN 
response was functional in RA FLS. Measurement of the proliferation rate revealed 
that IFNα, IFNβ and IFNγ suppressed RA FLS proliferation and that this effect 
overruled the stimulatory effect of TNFα. No significant difference in the levels of 
apoptosis in RA FLS treated with IFNα, IFNβ or IFNγ was observed compared to 
unstimulated cells, suggesting that the inhibitory effect was not due to induction of 
apoptosis. Analysis of the cell cycle distribution revealed that whereas TNFα 
treatment induced cell cycle progression to G2/M phase, treatment with IFNα, IFNβ 
or IFNγ limited cell cycle progression and caused accumulation of cells in G0/1 phase. 
The IFN-induced limiting effect on cell cycle progression correlated with induction of 
the Cyclin Dependent Kinase Inhibitor (CDKI) p21Waf1/Cip1, which inhibits CDK 
activity and may therefore mediate the IFN-induced accumulation of RA FLS in G0/1 
phase. These results indicate that IFN-treatment can negatively modulate the growth 
abnormalities of FLS, suggesting that  therapeutic approaches that selectively 
manipulate STAT-1 may have beneficial effects in RA. 
 
In conclusion, this thesis demonstrates how the progression from a holistic, 
functional genomics approach toward a reductionist approach focusing on a single 
pathway contributes to a better understanding of the pathophysiological mechanisms 
in RA pathology.  
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Van genomics naar STAT-1 in Reumatoïde Artritis 
 
Reumatoïde artritis (RA) is een ernstige, chronische gewrichtsziekte die ongeveer 1% 
van de bevolking treft. De ziekte wordt gekenmerkt door een ontstekingsproces in de 
binnenbekleding van het gewrichtskapsel, het synovium. Deze ontsteking kan leiden 
tot pijnlijke, gezwollen gewrichten en bewegingsbeperking. De oorzaak van RA is tot 
op heden onbekend en ons inzicht in de pathogenese (het ziekteproces) is beperkt. 
Waarschijnlijk spelen zowel immunologische mechanismen als niet-immunologische 
mechanismen een rol bij de pathogenese. Het verloop van RA is bij iedere patiënt 
anders, en kan variëren van een milde vorm die spontaan tot rust komt tot een zelfs 
levensbedreigende ziekte. Het is mogelijk dat RA niet één enkele ziekte is maar 
eenzelfde verschijningsvorm van verschillende, op elkaar gelijkende ziekten. Kortom, 
er zijn nog vele vragen onbeantwoord. 
 
De snelle ontwikkelingen in de wetenschap in de afgelopen decennia hebben nieuwe 
mogelijkheden gebracht voor biomedisch onderzoek. De complete erfelijke informatie 
van een organisme zoals deze gecodeerd is in het DNA noemt men het genoom; 
dankzij het Human Genome Project is deze informatie in kaart gebracht en voor 
iedereen toegankelijk. Hoewel elke cel van het lichaam het complete genoom bevat, is 
de activiteit van de 30.000 genen verschillend van cel tot cel. De combinatie van 
actieve genen, d.w.z. alle genen die tot expressie worden gebracht in de vorm van 
mRNA, is bepalend voor de biologische processen die plaatsvinden in een cel. Tijdens 
een ziekteproces verandert de genexpressie t.o.v. de gezonde situatie; andere genen 
worden actief en de mate van expressie kan veranderen. Sinds de ontwikkeling van de 
microarray of DNA-chip technologie is het mogelijk om de activiteit van duizenden 
genen tegelijkertijd te meten. Met behulp van microarrays wordt als het ware een 
soort “foto” gemaakt van de mate van activiteit van alle genen in een bepaalde cel of 
weefsel in een bepaalde situatie. Op deze manier kan een patroon van genactiviteit, 
een zgn. genexpressieprofiel, verkregen worden, dat inzicht biedt in de biologische 
processen die zich afspelen.  
 
In Hoofdstuk 2 beschrijven wij de toepassingen van microarrays in fundamenteel 
en klinisch immunologisch onderzoek. Met behulp van cDNA microarrays is het 
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genexpressieprofiel in specifieke immuun-cellen onder verschillende condities 
bepaald. Een beter begrip van de processen die een rol spelen bij de immuunrespons  
in de gezonde situatie vormt de basis voor het begrip van het ontsporen van deze 
processen tijdens ziekten waarbij het immuunsysteem betrokken is. Bovendien kan 
de analyse van genexpressieprofielen van cellen en weefsels die door een ziekte zijn 
aangetast inzicht bieden in de moleculaire processen die betrokken zijn bij de 
pathogenese, wat kan leiden tot verbeterde methoden voor diagnostiek, prognose en 
behandeling. 
 
In Hoofdstuk 3 hebben wij het genexpressieprofiel bepaald van aangetast synoviaal 
weefsel van RA-patiënten en patiënten met osteoartrose (OA). Hiervoor hebben wij 
cDNA microarrays gebruikt die een selectie van ~18,000 genen bevatten die 
betrokken zijn bij immunologische processen. De genexpressieprofielen lieten 
aanzienlijke verschillen zien, op basis waarvan wij minimaal twee typen RA- 
patiënten konden onderscheiden. Bij één type RA-patiënten vertoonde het synovium 
tekenen van een toename in ontstekingscellen en immuunactivatie. Op cellulair 
niveau worden processen gereguleerd door zgn. cellulaire signaaltransductieroutes, 
die een extracellulair signaal vertalen naar genexpressie. Gedetailleerde analyse van 
het genexpressieprofiel van het eerste type RA-patiënten suggereerde de 
betrokkenheid van de STAT-1 (Signal Transducer and Activator of Transcription 1) 
signaaltransductieroute. STAT-1 is een transcriptiefactor die na activatie door een 
extracellulair signaal bepaalde genen kan activeren. De betrokkenheid van STAT-1 
bleek in het genexpressieprofiel uit verhoogde expressie van typische STAT-1-
geïnduceerde genen en van enkele genen die coderen voor receptoren die STAT-1 
kunnen activeren. Bij het andere type RA-patiënten vertoonde het synovium geen 
tekenen van ontsteking, maar een verhoogde expressie van genen die betrokken zijn 
bij de omzetting van extracellulaire matrixmoleculen. Het genexpressieprofiel van het 
weefsel van dit type RA-patiënten vertoonde een grote gelijkenis met dat van de OA-
patiënten. Deze data laten zien dat RA-patiënten gesubclassificeerd kunnen worden 
op basis van moleculaire verschillen en suggereren dat STAT-1 een rol speelt in de 
synoviale weefsels van een subgroep van RA-patiënten. 
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In Hoofdstuk 4 hebben wij het genexpressieprofiel bepaald van fibroblastachtige 
cellen die uit het synovium van RA-patiënten kunnen worden opgekweekt, de zgn. 
fibroblast-like synoviocytes (FLS).  Op basis van de genexpressieprofielen van FLS 
konden wederom verschillende typen RA-patiënten onderscheiden worden, en deze 
subclassificatie was identiek aan die op basis van het gehele synoviale weefsel van 
deze patiënten zoals beschreven in Hoofdstuk 3. Het eerste type FLS, dat is 
opgekweekt uit synoviale weefsels met een genexpressieprofiel dat duidt op een  
toename in ontstekingscellen en immuunactivatie,  vertoont een genexpressieprofiel 
dat lijkt op dat van de myofibroblast, een celtype dat is betrokken bij wondgenezing. 
Daarentegen vertoonde het tweede type FLS, dat is opgekweekt uit synoviale weefsels 
met een verhoogde expressie van genen die betrokken zijn bij de omzetting van 
extracellulaire matrixmoleculen, verhoogde expressie van groeifactoren. Deze 
resultaten suggereren dat er een verband bestaat tussen ontsteking van het synovium 
en een toename in het aantal myofibroblast-achtige FLS in de gekweekte FLS 
populatie. Tevens blijken deze cellen ook aanwezig te zijn in het synovium van RA-
patiënten, zoals wij door middel van immunohistochemie konden aantonen. Deze 
resultaten laten zien dat het heterogene karakter van RA niet alleen zichtbaar is in de 
moleculaire kenmerken van synovium, maar tevens zichtbaar is in het 
genexpressieprofiel van FLS. Dit laatste suggereert dat er permanente veranderingen 
in het fenotype van FLS kunnen bestaan die gerelateerd zijn aan de mate van 
ontsteking in het synovium.  
 
Voortbordurend op de resultaten van Hoofdstuk 3 hebben wij in Hoofdstuk 5 de 
expressie en activatie van STAT-1 in het synovium van RA-patiënten bestudeerd. Met 
behulp van immunohistochemische technieken en digitale beeldanalyse hebben wij 
STAT-1 eiwitexpressie en zowel STAT-1 Tyrosine- als Serine-phosphorylatie 
kwantitatief geanalyseerd  in synovium van RA- en controlepatiënten. Gemiddeld was 
de expressie van STAT-1 significant verhoogd in de RA-patiëntengroep vergeleken 
met de controlegroep en de expressie van STAT-1 was met name hoog in de synoviale 
lining, de binnenste laag van het synovium. Er was echter een grote mate van variatie 
in STAT-1 expressie binnen de RA-patiënten, wat in overeenstemming is met onze 
genexpressiedata. Fenotypering van de synoviale cellen toonde aan dat STAT-1 
aanwezig was in T- en B-cellen. De grote hoeveelheid STAT-1 in de synoviale lining 
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bleek met name het gevolg te zijn van expressie door FLS, terwijl STAT-1 expressie in 
macrofagen laag was. Verhoogde STAT-1 expressie was ook zichtbaar in gekweekte 
FLS, wat suggereert dat dit een intrinsiek kenmerk is van FLS van RA-patiënten. 
STAT-1 phosphorylatie bleef niet behouden in kweek, wat aangeeft dat STAT-1 
phosphorylatie een actief proces is dat geïnduceerd wordt door factoren in het 
synovium. Deze resultaten sluiten mooi aan bij de genexpressiedata uit Hoofdstuk 3, 
die verhoogde expressie van typische STAT-1 geïnduceerde genen lieten zien, en 
geven daarom aanvullend bewijs voor de betrokkenheid van de STAT-1 
signaaltransductieroute in het synovium van een subgroep van RA-patiënten.  
 
Om inzicht te krijgen in de biologische effecten van STAT-1 activatie in FLS en de rol 
daarvan in de pathogenese van RA hebben wij in Hoofdstuk 6 het effect van 
interferon (IFN)-geïnduceerde STAT-1 activatie op de overleving en groei van FLS 
van RA-patiënten (RA FLS) onderzocht. Behandeling van RA FLS met IFNα, IFNβ of 
IFNγ induceerde STAT-1 phosphorylatie en een STAT-1-specifieke transcriptionele 
respons, wat aangeeft dat de IFN-respons functioneel is in RA FLS. Meting van de 
DNA synthese gaf aan dat IFNα, IFNβ en IFNγ de proliferatie van RA FLS remden en 
daarbij het stimulerende effect van TNFα overheersten. Na behandeling van RA FLS 
met IFNα, IFNβ of IFNγ was geen significant verschil zichtbaar in het aantal 
apoptotische cellen vergeleken met ongestimuleerde cellen, wat aangeeft dat het 
groeiremmende effect van IFN niet het gevolg is van de inductie van apoptose. 
Analyse van de celcyclusdistributie toonde aan dat IFNα, IFNβ en IFNγ de celcyclus 
remden en ophoping van cellen in de G0/1 fase induceerden, terwijl TNFα juist zoals 
verwacht progressie naar de G2/M fase induceerde. Het remmende effect van IFNα, 
IFNβ en IFNγ op de celcyclus correleerde met de inductie van de Cyclin Dependent 
Kinase Inhibitor (CDKI) p21Waf1/Cip1, een eiwit dat CDK activiteit remt en daardoor de 
ophoping van cellen in de G0/1 fase zou kunnen induceren. Deze resultaten tonen 
aan dat IFNα, IFNβ en IFNγ de abnormale groei van FLS die optreedt in RA zouden 
kunnen remmen en suggereren dat therapeutische interventie die selectief STAT-1 
activatie beïnvloedt daarom mogelijk een beschermend effect zou kunnen hebben in 
RA.  
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Samenvattend hebben wij in dit proefschrift aangetoond hoe een holistische, 
genoom-wijde benadering aangevuld met een meer reductionistische aanpak die 
focust op een enkele signaaltransductieroute inzicht kan geven in de pathogenese van 
RA. 
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Paul-Peter, bedankt voor de mogelijkheid om in je lab te werken. Het was een 
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samengewerkt en heel veel van je geleerd! 
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bijzondere vriendschap en ik wens jou en Nathasja alle geluk toe in jullie nieuwe 
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